
<html lang="en"     class="pb-page"  data-request-id="0e2f9930-6f04-47e1-9968-5dbe51d0a063"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2012.55.issue-10;article:article:10.1021/jm201550q;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase" /></meta><meta name="dc.Creator" content="Diane E.  Gingrich" /></meta><meta name="dc.Creator" content="Joseph G.  Lisko" /></meta><meta name="dc.Creator" content="Matthew A.  Curry" /></meta><meta name="dc.Creator" content="Mangeng  Cheng" /></meta><meta name="dc.Creator" content="Matthew  Quail" /></meta><meta name="dc.Creator" content="Lihui  Lu" /></meta><meta name="dc.Creator" content="Weihua  Wan" /></meta><meta name="dc.Creator" content="Mark S.  Albom" /></meta><meta name="dc.Creator" content="Thelma S.  Angeles" /></meta><meta name="dc.Creator" content="Lisa D.  Aimone" /></meta><meta name="dc.Creator" content="R. Curtis  Haltiwanger" /></meta><meta name="dc.Creator" content="Kevin  Wells-Knecht" /></meta><meta name="dc.Creator" content="Gregory R.  Ott" /></meta><meta name="dc.Creator" content="Arup K.  Ghose" /></meta><meta name="dc.Creator" content="Mark A.  Ator" /></meta><meta name="dc.Creator" content="Bruce  Ruggeri" /></meta><meta name="dc.Creator" content="Bruce D.  Dorsey" /></meta><meta name="dc.Description" content="Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years a..." /></meta><meta name="Description" content="Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years a..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 7, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm201550q" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm201550q" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm201550q" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm201550q" /></link>
        
    
    

<title>Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm201550q" /></meta><meta property="og:title" content="Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0006.jpeg" /></meta><meta property="og:description" content="Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years and culminating in the recent FDA approval of the ALK inhibitor crizotinib. Through a series of targeted modifications on an ALK inhibitor diaminopyrimidine scaffold, our research group has driven improvements in ALK potency, kinase selectivity, and overall pharmaceutical properties. Optimization of this scaffold has led to the identification of a potent and efficacious inhibitor of ALK, 25b. A striking feature of 25b over previously described ALK inhibitors is its &gt;600-fold selectivity over insulin receptor (IR), a closely related kinase family member. Most importantly, 25b exhibited dose proportional escalation in rat compared to compound 3 which suffered dose limiting absorption preventing further advancement. Compound 25b exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-positive ALCL tumor xenograft model in SCID mice, warranting further assessment in advanced preclinical models." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm201550q"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm201550q">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm201550q&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm201550q&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm201550q&amp;href=/doi/10.1021/jm201550q" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 10</span><span class="cit-fg-pageRange">, 4580-4593</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/10" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm201416p" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm2017094" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Diane+E.++Gingrich">Diane E. Gingrich</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph+G.++Lisko">Joseph G. Lisko</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew+A.++Curry">Matthew A. Curry</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mangeng++Cheng">Mangeng Cheng</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Quail">Matthew Quail</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lihui++Lu">Lihui Lu</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Weihua++Wan">Weihua Wan</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+S.++Albom">Mark S. Albom</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thelma+S.++Angeles">Thelma S. Angeles</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lisa+D.++Aimone">Lisa D. Aimone</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=R.+Curtis++Haltiwanger">R. Curtis Haltiwanger</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Wells-Knecht">Kevin Wells-Knecht</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gregory+R.++Ott">Gregory R. Ott</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arup+K.++Ghose">Arup K. Ghose</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+A.++Ator">Mark A. Ator</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce++Ruggeri">Bruce Ruggeri</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+D.++Dorsey">Bruce D. Dorsey</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Worldwide Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#8febeae8e6e1e8fde6ece7bebdcfe8e2eee6e3a1ece0e2"><span class="__cf_email__" data-cfemail="472322202e2920352e242f767507202a262e2b6924282a">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm201550q&amp;href=/doi/10.1021%2Fjm201550q" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 10</span><span class="cit-pageRange">, 4580–4593</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 7, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>16 November 2011</li><li><span class="item_label"><b>Published</b> online</span>7 May 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 May 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm201550q" title="DOI URL">https://doi.org/10.1021/jm201550q</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D4580%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DDiane%2BE.%2BGingrich%252C%2BJoseph%2BG.%2BLisko%252C%2BMatthew%2BA.%2BCurry%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D10%26contentID%3Djm201550q%26title%3DDiscovery%2Bof%2Ban%2BOrally%2BEfficacious%2BInhibitor%2Bof%2BAnaplastic%2BLymphoma%2BKinase%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D4593%26publicationDate%3DMay%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm201550q"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2956</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">25</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm201550q" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Diane&quot;,&quot;last_name&quot;:&quot;E. Gingrich&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;G. Lisko&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;A. Curry&quot;},{&quot;first_name&quot;:&quot;Mangeng&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Quail&quot;},{&quot;first_name&quot;:&quot;Lihui&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Weihua&quot;,&quot;last_name&quot;:&quot;Wan&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;S. Albom&quot;},{&quot;first_name&quot;:&quot;Thelma&quot;,&quot;last_name&quot;:&quot;S. Angeles&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;D. Aimone&quot;},{&quot;first_name&quot;:&quot;R.&quot;,&quot;last_name&quot;:&quot;Curtis Haltiwanger&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Wells-Knecht&quot;},{&quot;first_name&quot;:&quot;Gregory&quot;,&quot;last_name&quot;:&quot;R. Ott&quot;},{&quot;first_name&quot;:&quot;Arup&quot;,&quot;last_name&quot;:&quot;K. Ghose&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;A. Ator&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;Ruggeri&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;D. Dorsey&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;10&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;4580-4593&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm201550q&quot;},&quot;abstract&quot;:&quot;Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years and culminating in the recent FDA approval of the ALK inhibitor crizotinib. Through a series of targeted modifications on an ALK inhibitor diaminopyrimidine scaffold, our research group has driven improvements in ALK potency, kinase selectivity, and overall pharmaceutical properties. Optimization of this scaffold has led to the identification of a potent and efficacious inhibitor of ALK, 25b. A striking feature of 25b over previously described ALK inhibitors is its &gt;600-fold selectivity over insulin receptor (IR), a closely related kinase family member. Most importantly, 25b exhibited dose proportional escalation in rat compared to compound 3 which suffered dose limiting absorption preventing further advancement. Compound 25b exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-positive ALCL t&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201550q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201550q" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201550q&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201550q" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm201550q&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201550q" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm201550q&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm201550q&amp;href=/doi/10.1021/jm201550q" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm201550q" /></input><a href="/doi/pdf/10.1021/jm201550q" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm201550q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm201550q%26sid%3Dliteratum%253Aachs%26pmid%3D22564207%26genre%3Darticle%26aulast%3DGingrich%26date%3D2012%26atitle%3DDiscovery%2Bof%2Ban%2BOrally%2BEfficacious%2BInhibitor%2Bof%2BAnaplastic%2BLymphoma%2BKinase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D10%26spage%3D4580%26epage%3D4593%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292153" title="Tumors">Tumors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/10" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jmcmar.2012.55.issue-10/production/jmcmar.2012.55.issue-10.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years and culminating in the recent FDA approval of the ALK inhibitor crizotinib. Through a series of targeted modifications on an ALK inhibitor diaminopyrimidine scaffold, our research group has driven improvements in ALK potency, kinase selectivity, and overall pharmaceutical properties. Optimization of this scaffold has led to the identification of a potent and efficacious inhibitor of ALK, <b>25b</b>. A striking feature of <b>25b</b> over previously described ALK inhibitors is its >600-fold selectivity over insulin receptor (IR), a closely related kinase family member. Most importantly, <b>25b</b> exhibited dose proportional escalation in rat compared to compound <b>3</b> which suffered dose limiting absorption preventing further advancement. Compound <b>25b</b> exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-positive ALCL tumor xenograft model in SCID mice, warranting further assessment in advanced preclinical models.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74324" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74324" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Despite progress made in the past decade, lung cancer continues to be the most frequent cause of cancer-related deaths among men and women worldwide with greater than 200 000 new cases estimated this year in the United States alone.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> One area of great promise in the treatment of lung and other cancers has been the advent of targeted kinase therapies.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The identification of genetic modifications resulting in tumor development has provided an opportunity to target specific kinases with the goal of providing more beneficial chemotherapeutic agents.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> One kinase that has garnered increasing attention as a therapeutic target is anaplastic lymphoma kinase (ALK) as illustrated by its growing pharmaceutical interest<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and its role in non-small-cell lung cancer (NSCLC).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> ALK is a receptor tyrosine kinase (RTK) member of the insulin receptor (IR) superfamily, originally identified as part of the NPM-ALK fusion gene in anaplastic large cell lymphoma (ALCL) with a t(2;5) chromosomal translocation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> While the physiological role of ALK receptor has not been well-defined, involvement of ALK in the oncogenesis of various human cancers has been well documented and characterized. Besides NPM-ALK, various other ALK fusion genes were subsequently detected in ALCLs, inflammatory myofibroblastic tumor, diffuse large B-cell lymphoma, systemic histiocytosis, and most notably, NSCLC, resulting in the generation of oncogenic ALK fusion proteins with constitutive phosphorylation/activation of ALK.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The constitutive kinase activity associated with ALK fusions appears to play an essential role in proliferation and survival of human cancer cells.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Recently, it has also been reported that germline mutations in ALK are the cause of most hereditary neuroblastoma cases, and ALK activation by mutation and/or gene amplification is functionally relevant in high-risk sporadic neuroblastoma.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> The dysregulated signaling resulting from these rearrangements or mutations/gene amplification has led to a state of “oncogenic addiction”, providing an opportunity for intervention with small molecule inhibitors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Crystal structures have been solved for the unphosphorylated catalytic domain of ALK complexed with two ATP-competitive inhibitors.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> This structural information can be parlayed into the design of additional ALK inhibitors and also provides insight into the basis for activation of ALK by the active site mutations observed in neuroblastoma. Pfizer’s PF-02341066 (crizotinib, <b>1</b>),<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> a dual ALK/cMET inhibitor, was the first ALK inhibitor advanced into clinical trials and more recently received FDA approval for treatment of patients with locally advanced or metastatic ALK-positive NSCLC.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Other pharmaceutical companies have also been active in the ALK arena exploring an array of varied scaffolds. Novartis specifically has published patent applications around a diaminopyrimidine scaffold, as well as describing extensive pharmacology associated with a lead compound NVP-TAE684 (<b>2</b>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> In addition, several groups have reported tyrosine kinase inhibitors which overcome crizotinib resistance.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0008.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Small molecule ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Our research efforts have focused on developing potent and selective inhibitors of ALK with modifications to the diaminopyrimidine scaffold, focusing on two major regions of the molecule designated as the A- and C-rings (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). Previously published research from our group identified a bicyclo[2.2.1]hept-5-ene ring system of compound <b>3</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) as an alternative C-ring fragment impacting selectivity toward IR.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Our earlier report also highlighted that minor modifications to the A-ring fragment can impact IR/ALK selectivity. The combination of an A-ring methoxy selectivity determinant combined with the [2.2.1] C-ring system provided improved kinase selectivity observed with <b>3</b> versus other published inhibitors. Selectivity toward IR is of particular interest because of the involvement of IR in the regulation of glucose transport and glycogen and fat biosynthesis.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a> Avoiding potential complications from this activity was a major objective in designing second generation molecules with improved IR/ALK selectivity over initial lead compound <b>3</b>. While compound <b>3</b> provided a balanced profile consisting of ALK potency and global kinase selectivity, the modest IR/ALK selectivity led the team to optimize the diaminopyrimidine series further in an effort to improve selectivity toward IR (enzymatic IR/ALK IC<sub>50</sub> ratio of >100). In addition, compound <b>3</b> lacked the ability to be dose escalated in preclinical toxicological species, precluding its further development (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0009.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Optimization strategy and areas of modification on the diaminopyrimidine core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>4</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) was also previously identified by our group as an analogue with potent in vitro ALK activity but with a potential hERG liability, as indicated by an in vitro IC<sub>50</sub> of 3.9 μM for hERG in a patch clamp assay (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). The 2,3,4,5-tetrahydro-1<i>H</i>-benzo[<i>d</i>]azepine A-ring motif of <b>4</b> resulted in potent ALK inhibition while providing a site for functional group manipulation to balance potency with favorable physicochemical properties. A variety of substituents incorporated on the azepine nitrogen yielded changes in both the enzyme and cell inhibition, depending on the nature of the substituent. In an attempt to further modulate the potency and selectivity differences observed with the azepine analogues, the basic nitrogen was moved outside the seven-membered ring, resulting in an aminobenzocycloheptene motif (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>). The resulting strategy was to identify suitable azepine or azepinone A-ring replacements to combine with the previously established bicyclo[2.2.1]hept-5-ene ring system, which would provide potent ALK inhibition, improved selectivity against the IR receptor and dose proportional increases in preclinical toxicology species. A focused medicinal chemistry effort evaluating modifications to the aminobenzocycloheptene ring system was therefore initiated.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Two differentially substituted methoxy A-ring fragments were prepared to assess the impact of the methoxy group at the C1 versus C3 position of the A-ring on ALK potency and selectivity for ALK versus IR. The initial synthesis of 1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamines (<b>14a</b>–<b>c</b>) outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> involved bromination of 1-methoxy-2,3-dimethylbenzene with <i>N</i>-bromosuccinimide (NBS) in carbon tetrachloride using either 2,2′-azo-bis-isobutyronitrile, benzoyl peroxide, or ultraviolet light as the initiator to give initial intermediate <b>6</b>. Conversion of <b>6</b> to the seven-membered ring <b>8</b> was accomplished using 3-oxopentanedioic acid diethyl ester in a biphasic reaction of methylene chloride and 0.6 M aqueous sodium bicarbonate with tetra-<i>n</i>-butylammonium iodide as a phase transfer catalyst. The resultant product was carried on without further purification and treated with potassium hydroxide in refluxing ethanol for 3 h to effect ester hydrolysis and decarboxylation. Nitration of <b>8</b> was achieved with potassium nitrate, trifluoroacetic anhydride in acetonitrile to give two nitration products, <b>10</b> and <b>12</b>, in a 1.3:1 ratio, which were separable with normal phase chromatography. Compounds <b>10</b> and <b>12</b> were versatile intermediates that allowed the introduction of chemical diversity through reductive amination chemistry. Compounds possessing the 2-amino-1-methoxy-5,6,8,9-tetrahydro-7-aminobenzocycloheptene fragment, as illustrated by compound <b>10</b>, provided better ALK inhibition compared to the corresponding regiomeric 1-amino-4-methoxy-5,6,8,9-tetrahydro-7-aminobenzocycloheptenane, <b>12</b>. As a result, only reductive alkylation products with 2-amino-1-methoxy A-ring substitution were pursued. The aminated products <b>13a</b>–<b>c</b> were subjected to hydrogenation conditions to provide the respective anilines in good yield.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 7-Aminosubstituted 1-Methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NBS [2 equiv (X = H); 3 equiv (X = Br)], AIBN, CCl<sub>4</sub>, 80–99%; (b) (i) 3-oxopentanedioic acid diethyl ester, 0.6 M sodium bicarbonate, tetra-<i>n</i>-butylammonium iodide, methylene chloride, 24 h; (ii) 1 M KOH, EtOH, reflux 3 h; 33% over two steps; (c) KNO<sub>3</sub>, (CF<sub>3</sub>CO)<sub>2</sub>O, CH<sub>3</sub>CN, 53% (d) NaBH(OAc)<sub>3</sub>, amine, acetic acid, CH<sub>2</sub>Cl<sub>2</sub>, 44–70%; (e) H<sub>2</sub>, Pd/C wet, ethanol, 93%.</p></p></figure><div class="NLM_p">A potential liability with the previously described synthetic pathway was the poor selectivity observed under the nitration conditions. To improve the overall yield of the desired nitration product, the C-6 position was temporarily blocked with bromine as outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> (X = Br). Treatment of <b>5</b> with 3 equiv of NBS yielded the tribrominated product <b>7</b>. Ring annulation proceeded as previously described, and with the position para to the methoxy group blocked, nitration occurred ortho to the methoxy group to provide isomer <b>11</b> in good yield. Desired reductive aminations then yielded nitro intermediates <b>13a</b>–<b>c</b>, whose nitro groups were subsequently reduced to their corresponding anilines under standard Pd/C hydrogenation conditions, with concomitant reduction of the bromide to give <b>14a</b>–<b>c</b>.</div><div class="NLM_p">As illustrated in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>, the regiomeric methoxy A-ring, 3-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene-2,7-diamine, was prepared starting with 4-methoxyphthalic acid dimethyl ester (<b>15</b>). Bromination using phosphorus tribromide in methylene chloride provided <b>16</b>. The 6/7-fused ring system was formed in the same manner as previously outlined. Nitration of <b>17</b> yielded two nitrated products, <b>18</b> and <b>19</b>, in roughly a 1:1.6 ratio, respectively, which were separated on silica gel. Ketone <b>19</b> was subjected to reductive alkylation conditions with a select number of amines followed by hydrogenation to reduce the nitro group to the corresponding anilines (<b>20a</b>–<b>c</b>). A small number of analogues were prepared with the A-ring derived from compound <b>18</b> to evaluate potential potency differences between the A-ring methoxy regiomers. A 100-fold loss of ALK potency was observed with analogues resulting from <b>18</b> compared to regiomer <b>19</b>. As a result, efforts were focused on elaborating compound <b>19</b> with a diverse set of substituents.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 7-Aminosubstituted 3-Methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) LiAlH<sub>4</sub>, THF, 0 °C, 65–97%; (ii) PBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 62–94%; (b) (i) 3-oxopentanedioic acid diethyl ester, 0.6 M sodium bicarbonate, tetra-<i>n</i>-butylammonium iodide, CH<sub>2</sub>Cl<sub>2</sub>, 24 h; (ii) 1 M KOH, EtOH, reflux 3 h, 50% over two steps (c) KNO<sub>3</sub>, CH<sub>3</sub>CN, 53–83%; (d) NaBH(OAc)<sub>3</sub>, amine, acetic acid, CH<sub>2</sub>Cl<sub>2</sub>, 65–90%; (e) H<sub>2</sub>, Pd/C wet, ethanol, 85–95%.</p></p></figure><div class="NLM_p">The target analogues were assembled using our previously published chemistry involving tandom nucleophilic aromatic substitution reactions as shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acid amide fragment is installed first on the 2,4,5-trichloropyrimidine. The appropriately substituted aminobenzocycloheptene ring fragment was subsequently incorporated to afford the fully assembled diaminopyrimidine scaffold. Noteworthy, analogues <b>23</b>–<b>28</b> were generated as diastereomeric pairs from racemic anilines <b>14</b> and <b>20</b>. Fortunately, the diasteromeric pairs were easily separated via preparative reverse phase HPLC.</div><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. A- and C-Ring Coupling Sequence<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acid amide, DMF; (b) HCl, 2-methoxyethanol, substituted aminobenzocycloheptene A-ring fragment, 130 °C.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65887" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65887" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">ALK enzyme and cellular inhibition data, as well as IR enzyme inhibition data, were obtained for the above-described diasteriomeric pairs of targets as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Several trends were identified when evaluating the diastereomeric pairs comprised of two methoxy regiomers (X or Y = OCH<sub>3</sub>). The slower eluting 1-methoxy substituted diastereomer on reverse phase HPLC chromatography, in general, appeared to be the more active of the two diastereomers, exemplified when comparing <b>23a</b>/<b>b</b>, <b>25a</b>/<b>b</b>, and <b>27a/b</b>. Each of the diastereomers, <b>24a</b>/<b>24b</b>, <b>26a</b>/<b>26b</b>, and <b>28a</b>/<b>28b</b>, with 3-methoxy substitution appeared comparable in terms of ALK enzyme and cellular potency (within 3-fold). All four analogues possessing the flexible methoxyethylamino A-ring moiety displayed comparable enzyme and cellular potency, regardless of the position of the methoxy substituent. However, the isomers <b>25b</b> and <b>27b</b>, possessing the more space constrained morpholino and methylpiperazinyl fragments, were 5- to 10-fold more potent ALK enzyme inhibitors compared to their match diasteriomers, <b>25a</b> and <b>27a</b>. This translated into increase cellular activity with <b>25b</b> and <b>27b</b> being the most potent in the Karpas-299 cell assay. Another striking difference observed between methoxy substituted analogues matched pairs was the difference in ALK selectivity over IR (expressed as IR/ALK enzyme IC<sub>50</sub> ratio). The 1-methoxy substituted analogues had higher IR/ALK IC<sub>50</sub> ratios compared to the ratios observed with the corresponding 3-methoxy substituted analogues. Of all of the compounds evaluated, <b>25b</b> displayed the highest IR/ALK enzyme IC<sub>50</sub> ratio of 662, a 15-fold improvement over <b>3</b>. As a result, this compound was profiled more extensively.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. ALK Inhibition Data for Select Diaminopyrimidine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0005.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center">ALK IC<sub>50</sub>, nM<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Karpas-299 cell IC<sub>50</sub>, nM</th><th class="colsep0 rowsep0" align="center">IR/ALK enzyme IC<sub>50</sub> ratio</th><th class="colsep0 rowsep0" align="center"><i>S</i>(90)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">14 ± 3</td><td class="colsep0 rowsep0" align="left">45</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4 ± 1</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">345</td><td class="colsep0 rowsep0" align="left">0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="left">MeO(CH<sub>2</sub>)<sub>2</sub>NH-</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">21 ± 11</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">103</td><td class="colsep0 rowsep0" align="left">0.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="left">MeO(CH<sub>2</sub>)<sub>2</sub>NH-</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">9 ± 1</td><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="left">>333</td><td class="colsep0 rowsep0" align="left">0.31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24a</b></td><td class="colsep0 rowsep0" align="left">MeO(CH<sub>2</sub>)<sub>2</sub>NH-</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">4 ± 2</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">0.23</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24b</b></td><td class="colsep0 rowsep0" align="left">MeO(CH<sub>2</sub>)<sub>2</sub>NH-</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">11 ± 3</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">67</td><td class="colsep0 rowsep0" align="left">0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25a</b></td><td class="colsep0 rowsep0" align="left">morpholino-</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">35 ± 11</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">>29</td><td class="colsep0 rowsep0" align="left">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="left">morpholino-</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">1.9 ± 0.5</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">662</td><td class="colsep0 rowsep0" align="left">0.14</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26a</b></td><td class="colsep0 rowsep0" align="left">morpholino-</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">6 ± 1</td><td class="colsep0 rowsep0" align="left">40</td><td class="colsep0 rowsep0" align="left">88</td><td class="colsep0 rowsep0" align="left">0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26b</b></td><td class="colsep0 rowsep0" align="left">morpholino-</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">16 ± 5</td><td class="colsep0 rowsep0" align="left">120</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">0.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27a</b></td><td class="colsep0 rowsep0" align="left">4-methylpiperazinyl-</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">16.2 ± 0.8</td><td class="colsep0 rowsep0" align="left">200</td><td class="colsep0 rowsep0" align="left">151</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27b</b></td><td class="colsep0 rowsep0" align="left">4-methylpiperazinyl-</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">3.1 ± 0.3</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">>320</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28a</b></td><td class="colsep0 rowsep0" align="left">4-methylpiperazinyl-</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">17 ± 5</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">>59</td><td class="colsep0 rowsep0" align="left">0.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28b</b></td><td class="colsep0 rowsep0" align="left">4-methylpiperazinyl-</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">15 ± 6</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">>67</td><td class="colsep0 rowsep0" align="left">0.03</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Compounds designated “a” are the first eluting diastereomer and those designated “b” are the second eluting diastereomer from a reverse phase preparative HPLC column.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Average ± standard deviation of four or more determinations</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">NT, not tested.</p></div></div></div><div class="NLM_p">To help rationalize the observed improved selectivity for the 1-methoxy substituted analogues, both <b>25b</b> and <b>3</b> were computationally modeled in the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a> (ALK) and the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKK">3EKK</a> (IRK) X-ray structures as illustrated in Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>. Both analogues docked into the active site with the expected bidentate binding mode. This binding mode was consistent with several kinase bound 2,4-dianilinopyrimidine structures available in the Protein Data Bank.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Similar binding modes were also observed for IR; however, the docking scores generated computationally when modeling these structures were considerably and consistently higher (worse) for both ligands, in agreement with the observed activity. Comparison of the active site showed several critical residue differences between ALK and IR (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). The gatekeeper residue (Leu) in ALK has been replaced by Met-1076 in IR.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Interaction of the chloro substituent on the pyrimidine with the Leu-1196 in ALK provides a more favorable interaction compared to the more polarized Met-1076 in IR. The hydrophobic residue Leu-1256 in ALK coming from the β-sheet underneath the hinge region has been replaced by Met-1076. IR is the first kinase where the DFG-out structure was observed in the apo-form with the conformation of the activation loop differing considerably in different structures. All of these factors have affected the binding of a large ligand like <b>25b</b>, since several other IR structures failed to dock such ligands. However, the lack of activity of one of the stereoisomers of this type of ligand was resulting from the conformation difference in the loop region after the D-helix. Unlike ALK, this loop region in IR consistently folds back toward the ATP binding pocket. With structures such as <b>25b</b>, the loop had bad steric overlap with Asn-1097 in the binding mode (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>), resulting in poor IR inhibition and thus providing a possible hypothesis for the increase IR/ALK selectivity observed with <b>25b</b> compared to <b>3</b>.</div><figure id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0010.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of <b>25b</b> with ALK, as derived by Glide/XP docking program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0011.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode of <b>25b</b> with IR (brown ribbon), as derived by Glide/XP docking program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Kinase selectivity for compounds in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> was evaluated using Ambit’s KINOMEScan panel of binding assays and expressed as an <i>S</i>(90) value reflecting the fraction of kinases inhibited of >90% when screened at 1 μM across a panel of >353 kinases.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The compounds displayed in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> range in <i>S</i>(90) values from 0.03 to 0.31 with <b>25b</b> exemplifying broad kinase specificity as measured by the <i>S</i>(90) value of 0.147. In addition, <b>25b</b> was evaluated in Millipore’s KinaseProfiler panel of activity assays for 259 kinases, with IC<sub>50</sub> values determined for 15 kinases inhibited by ≥90% at 1 μM (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Except for Rsk2, -3, and -4 (IC<sub>50</sub> values range of 7–19 nM), the IC<sub>50</sub> for any other kinase tested is at least 10-fold higher than that for ALK (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), supporting that <b>25b</b> is a highly potent and selective ALK inhibitor. Off-target kinase activities in cells could provide a more relevant assessment of kinase selectivity of <b>25b</b>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Millipore KinaseProfiler IC<sub>50</sub> Values for <b>25b</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub>, nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ACK1 (h)</td><td class="colsep0 rowsep0" align="left">41 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ARK5 (h)</td><td class="colsep0 rowsep0" align="left">26 ± 3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRK (h)</td><td class="colsep0 rowsep0" align="left">73 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CHK2 (h)</td><td class="colsep0 rowsep0" align="left">29 ± 7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FAK (h)</td><td class="colsep0 rowsep0" align="left">133 ± 15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fer (h)</td><td class="colsep0 rowsep0" align="left">85 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Fes (h)</td><td class="colsep0 rowsep0" align="left">99 ± 36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt3 (h)</td><td class="colsep0 rowsep0" align="left">88 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Flt4 (h)</td><td class="colsep0 rowsep0" align="left">48 ± 11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GCK (h)</td><td class="colsep0 rowsep0" align="left">60 ± 9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">JNK1a1 (h)</td><td class="colsep0 rowsep0" align="left">112 ± 17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rsk1 (h)</td><td class="colsep0 rowsep0" align="left">61 ± 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rsk2 (h)</td><td class="colsep0 rowsep0" align="left">13 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rsk3 (h)</td><td class="colsep0 rowsep0" align="left">7 ± 1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Rsk4 (h)</td><td class="colsep0 rowsep0" align="left">19 ± 11</td></tr></tbody></table></div></div><div class="NLM_p">In order to define the absolute stereochemistry of the 7-aminosubstituted 1-methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene amine A-ring fragment, efforts to crystallize <b>25a</b> or <b>25b</b> were undertaken. A crystal of suitable quality was achieved with <b>25a</b> (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). The solution of the X-ray analysis confirmed the <i>R</i>-stereochemistry of <b>25a</b>, thus conferring <i>S</i>-stereochemistry at the morpholino carbon juncture for compound <b>25b</b>.</div><div class="NLM_p">Compound <b>25b</b> was advanced for in vivo evaluation based on the ALK cell potency, IR selectivity, and overall kinase selectivity. The pharmacokinetic properties of <b>25b</b> were evaluated in several species as highlighted in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>. Differences in exposure of <b>25b</b> were observed between the two mouse strains SCID and CD-1, with lower clearance and volume of distribution terms and higher AUC obtained in SCID compared to CD-1 mice. Oral exposure was demonstrated in all species with bioavailability <i>F</i> ranging from 16% in cynomolgus monkeys to 71% in SCID mouse.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Pharmacokinetic Parameters of <b>25b</b> in Mice, Sprague–Dawley Rat, Beagle Dog, and Cynomolgus Monkey</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">PK parameter</th><th class="colsep0 rowsep0" align="center">SCID mouse</th><th class="colsep0 rowsep0" align="center">CD-1 mouse</th><th class="colsep0 rowsep0" align="center">rat</th><th class="colsep0 rowsep0" align="center">dog</th><th class="colsep0 rowsep0" align="center">monkey</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">iv<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">0.7</td><td class="colsep0 rowsep0" align="left">0.9 ± 0.2</td><td class="colsep0 rowsep0" align="left">2.4 ± 0.2</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl (mL min<sup>–1</sup> kg<sup>–1</sup>)</td><td class="colsep0 rowsep0" align="left">6</td><td class="colsep0 rowsep0" align="left">29</td><td class="colsep0 rowsep0" align="left">17 ± 2</td><td class="colsep0 rowsep0" align="left">40 ± 1</td><td class="colsep0 rowsep0" align="left">28 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>V</i><sub>d</sub>(L/kg)</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.2</td><td class="colsep0 rowsep0" align="left">8.2 ± 0.5</td><td class="colsep0 rowsep0" align="left">2.9 ± 0.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC (ng·h/mL)</td><td class="colsep0 rowsep0" align="left">3025</td><td class="colsep0 rowsep0" align="left">584</td><td class="colsep0 rowsep0" align="left">989 ± 127</td><td class="colsep0 rowsep0" align="left">409 ± 16</td><td class="colsep0 rowsep0" align="left">615 ± 89</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">po<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="left">2753</td><td class="colsep0 rowsep0" align="left">880</td><td class="colsep0 rowsep0" align="left">599 ± 3</td><td class="colsep0 rowsep0" align="left">427<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">170 ± 51</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">1.3 ± 0.3</td><td class="colsep0 rowsep0" align="left">0.8</td><td class="colsep0 rowsep0" align="left">4.7 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">1.8</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">6.2 ± 1.6</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">1.2 ± 0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">AUC (ng·h/mL)</td><td class="colsep0 rowsep0" align="left">21381</td><td class="colsep0 rowsep0" align="left">2993</td><td class="colsep0 rowsep0" align="left">4833 ± 797</td><td class="colsep0 rowsep0" align="left">2126</td><td class="colsep0 rowsep0" align="left">954 ± 209</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">71</td><td class="colsep0 rowsep0" align="left">51</td><td class="colsep0 rowsep0" align="left">50 ± 8</td><td class="colsep0 rowsep0" align="left">52</td><td class="colsep0 rowsep0" align="left">16 ± 3</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">1 mg/kg dose.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">10 mg/kg dose.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last"><i>n</i> = 2.</p></div></div></div><div class="NLM_p">Compound <b>25b</b> was evaluated in an oral dose escalation study in rat at 10, 30, 55, and 100 mg/kg and is summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. Dose proportional increases in both AUC and <i>C</i><sub>max</sub> were observed with <b>25b</b>, displaying a ∼9-fold increase in <i>C</i><sub>max</sub> and ∼15-fold increase in AUC when comparing the 10 and 100 mg/kg doses. This is in contrast to the <i>C</i><sub>max</sub> and AUC data for <b>3</b> at 10 and 100 mg/kg, where there is only ∼2-fold increase in <i>C</i><sub>max</sub> and AUC despite the 10-fold increase in dose. This comparative data between compounds <b>25b</b> and <b>3</b> highlight the improved PK exposure observed for <b>25b</b>. Efforts to advance <b>3</b> preclinically were terminated and refocused on <b>25b</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Dose Escalation Data Comparison for <b>3</b> and <b>25b</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center">10 mg/kg</th><th class="colsep0 rowsep0" align="center">30 mg/kg</th><th class="colsep0 rowsep0" align="center">55 mg/kg</th><th class="colsep0 rowsep0" align="center">100 mg/kg</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">925 ± 192</td><td class="colsep0 rowsep0" align="left">1360 ± 106</td><td class="colsep0 rowsep0" align="left">1450 ± 115</td><td class="colsep0 rowsep0" align="left">1553 ± 71</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–12</sub>,ng·h/mL</td><td class="colsep0 rowsep0" align="left">6025 ± 1608</td><td class="colsep0 rowsep0" align="left">11804 ± 875</td><td class="colsep0 rowsep0" align="left">13826 ± 1163</td><td class="colsep0 rowsep0" align="left">14011 ± 562</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25b</b></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub></td><td class="colsep0 rowsep0" align="left">349 ± 40</td><td class="colsep0 rowsep0" align="left">1006 ± 92</td><td class="colsep0 rowsep0" align="left">2253 ± 73</td><td class="colsep0 rowsep0" align="left">3053 ± 47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–12</sub>,ng·h/mL</td><td class="colsep0 rowsep0" align="left">2574 ± 243</td><td class="colsep0 rowsep0" align="left">10895 ± 1000</td><td class="colsep0 rowsep0" align="left">24110 ± 1409</td><td class="colsep0 rowsep0" align="left">38187 ± 2474</td></tr></tbody></table></div></div><div class="NLM_p">A single oral dose of <b>25b</b> at 30 mg/kg led to >90% inhibition of NPM-ALK phosphorylation extending to 12 h postadministration in NPM-ALK positive ALCL Karpas-299 tumor xenograft in SCID mouse (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A). The degree of NPM-ALK phosphorylation inhibition was consistent with <b>25b</b> levels in tumor xenografts based on the calculated cellular activity of <b>25b</b> in murine plasma, suggesting that the target inhibition in tumor xenografts was likely due to direct inhibitory effects exerted by <b>25b</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B).</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0012.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacodynamics of <b>25b</b> in Karpas-299 tumor xenografts in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A secondary in vivo study was measurement of the antitumor efficacy of <b>25b</b>, as assessed in a Karpas-299 tumor xenograft model in SCID mouse. Compound <b>25b</b> was administered to SCID mice orally in PEG400 at doses of 10 and 30 mg/kg b.i.d. for the 12-day duration of the study. Dose-dependent antitumor activity was observed at both oral doses of 10 and 30 mg/kg, b.i.d., with essentially complete tumor regressions achieved at the 30 mg/kg oral b.i.d. dose (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>A). This is a significant improvement over <b>3</b>, which only induced tumor stasis of Karpas-299 tumor xenografts when dosed up to 100 mg/kg, b.i.d. (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information S3">Supporting Information S3</a>), consistent with the limited dose-escalation of <b>3</b> observed in rat. Administration of <b>25b</b> was well tolerated with no overt toxicity and no significant body weight loss at both dosing regimens. Dose-related levels of <b>25b</b> were observed in plasma and tumor lysates collected at 2 h after final dosing. Observed levels of <b>25b</b> in tumors were slightly less at the 10 mg/kg dose and 7-fold higher at the 30 mg/kg dose over the plasma adjusted ALK cell IC<sub>90</sub> of 1500 nM (∼750 ng/mL), as measured in the presence of murine plasma (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>B), further supporting the notion that sustained complete target inhibition in tumor is required to achieve regression in NPM-ALK-positive ALCL tumor xenografts.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0013.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of <b>25b</b> on Karpas-299 tumor xenografts in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Dose-dependent antitumor activity was also observed in other NPM-ALK-positive ALCL tumor xenografts and EML4-ALK-positive NSCLC tumor xenografts in mice administered with <b>25b</b> orally, showing complete/near complete tumor regressions following treatment at doses of 30 mg/kg b.i.d. or higher.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a>In addition, <b>25b</b> induced growth inhibition and cytotoxicity of neuroblastoma cell lines harboring ALK activating mutants (F1174L in NB-1643 cells and R1275Q in SH-SY5Y cells, respectively) but not in the ones containing ALK WT without gene amplification (SKNAS cells) (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), indicating that <b>25b</b> is active against the two ALK activating mutants most commonly observed in human neuroblastoma.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0001.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Growth inhibition of <b>25b</b> on neuroblastoma cell lines harboring ALK activating mutations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Optimization of the diaminopyrimidine chemotype has resulted in the identification of a potent, selective, and orally bioavailable ALK inhibitor, <b>25b</b>. This diaminopyrimidine analogue possessed marked improved selectivity versus IR compared to compound <b>3</b>. Further optimization of the diaminopyrimidine core by fixing the C-ring as the [2.2.1] fragment and reoptimizing the A-ring fragment from an azepinone ring to a substituted aminobenzocycloheptene ring has led to substantial improvements in IR/ALK selectivity over those observed for <b>3</b> and improved hERG inhibition versus <b>4</b> (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). Molecular modeling suggests that the improvement in IR/ALK selectivity observed for <b>25b</b> may be due to unfavorable interactions with the Met1139 located underneath the hinge region. In addition to improved IR/ALK selectivity, <b>25b</b> displayed dose proportional increases in rat exposure, providing a clear advantage over compound <b>3</b>. Therefore, further preclinical development of <b>3</b> was discontinued in favor of <b>25b</b>.</div><div class="NLM_p last">Additional studies analyzing the impact of <b>25b</b> and other potent, selective, and orally bioavailable ALK inhibitors with newly identified mutants will be necessary to provide improved ALK inhibitors to treat NSCLC.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(25)</a> Compound <b>25b</b> demonstrated potent inhibitory activity against ALK phosphorylation both in vitro and in vivo and robust antitumor efficacy (tumor regressions) in Karpas-299 tumor xenografts in mice. Combining with its overall favorable pharmaceutical properties, <b>25b</b> was identified as a preclinical development candidate and was further examined in additional biological and pharmaceutical assessments. Efficacy results from more advanced preclinical models will be presented in subsequent publications.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35448" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35448" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Chemistry</h3><div class="NLM_p last">All reagents and anhydrous solvents were obtained from commercial sources and used as received. <sup>1</sup>H and <sup>13</sup>C NMR were obtained on a Bruker 400 MHz instrument in the solvent indicated with tetramethylsilane as an internal standard. Coupling constants (<i>J</i>) are in hertz (Hz). Analytical HPLC was run using a Zorbax RX-C8, 5 mm × 150 mm column, eluting with a mixture of acetonitrile and water containing 0.1% trifluoroacetic acid with a gradient of 10–100% over 6 min, monitoring at wavelengths 254, 290, and 215 nm. LCMS analysis was either performed on a Waters Aquity Ultra Performance LC with a 2.1 mm × 50 mm Waters Aquity UPLC BEH C18 1.7 μm column or Agilent 1100 with a 2.1 mm × 30 mm 3.5 μm Eclipse XDB-C8 column and a solvent system of 10–100% acetonitrile–water with 0.1% formic acid. The mass spectrometry data were acquired on a Micromass LC-ZQ 2000 quadrapole mass spectrometer (Waters Aquity) or a Bruker Esquire 200 ion trap (Agilent 1100) instrument. High resolution mass spectrometry was performed on a Waters Synapt G2 Q-TOF mass spectrometer by positive ion electrospray using leucine¬enkephalin as a lock-mass standard. Column chromatography was typically performed using automation on an ISCO CombiFlash Companion using silica gel. Additional purification was accomplished using a Gilson preparative HPLC system and reverse phase silica gel and trilution LC software. Melting points were taken on a Mel-Temp apparatus and are uncorrected. Purity of described compounds was assessed by HPLC and shown to be >95% pure unless otherwise noted.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Preparation of 1,2-Bis-bromomethyl-3-methoxybenzene (<b>6</b>)<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(26)</a></h3><div class="NLM_p last">1-Methoxy-2,3-dimethyl-benzene (40 g, 0.29 mol), <i>N</i>-bromosuccinimide (104.6 g, 0.5877 mol), and 2,2′-azo-bis-isobutyronitrile (2 g, 0.01 mol) were dissolved in carbon tetrachloride (800 mL). The mixture was heated to reflux and was allowed to stir overnight. The reaction mixture was cooled, and the solids were collected by filtration. The filtrate was then washed with saturated sodium bicarbonate and extracted with dichloromethane. Combined organic layers were dried over sodium sulfate, filtered, and concentrated under vacuum to give the desired product (86 g, 99% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.23 (t, 1H, <i>J</i> = 8.05 Hz), 6.96 (d, 1H, <i>J</i> = 7.64 Hz), 6.86 (d, 1 H, <i>J</i> = 8.36 Hz), 4.77 (s, 2H), 4.61 (s, 2H), 3.89 (s, 3H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Preparation of 1-Methoxy-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<b>8</b>)<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(27)</a></h3><div class="NLM_p">(i) To a 5 L flask was added tetra-<i>n</i>-butylammonium iodide (30 g, 0.09 mol) in 0.6 M of sodium bicarbonate in water (1250 mL) and methylene chloride (500 mL). The reaction mixture was cooled to 0 °C, and a solution of 1,2-bis-bromomethyl-3-methoxybenzene (43.0 g, 0.146 mol) and 3-oxopentanedioic acid, diethyl ester (34.6 mL, 0.190 mol) in methylene chloride (120 mL) was added slowly dropwise to the reaction mixture via addition funnel. Following complete addition, the reaction mixture was vigorously stirred at room temperature overnight. The mixture was transferred in batches to a separatory funnel where the layers were separated. The aqueous layer was washed with additional methylene chloride, and the combined organic extracts were dried over magnesium sulfate, filtered, and concentrated under vacuum to a dark oil. The oil was triturated with diethyl ether, and the tetrabutylammonium salts precipitated out of solution and were collected by filtration. The filtrate was concentrated under vacuum to a dark oil which was carried directly on to the next step without purification.</div><div class="NLM_p last">(ii) A stirred solution of 1-methoxy-7-oxo-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene-6,8-dicarboxylic acid diethyl ester (80 g, 0.2 mol) in ethanol (1500 mL, 26 mol) and aqueous potassium hydroxide solution (1 M, 950 mL) was heated to reflux for 3 h. After 3 h, the mixture was cooled to room temperature and carefully quenched with 1 N HCl. The reaction mixture was concentrated under vacuum to remove ethanol and then extracted with methylene chloride. The organic layer was dried over magnesium sulfate, filtered, and concentrated under vacuum to provide a dark brown-black oil. Purification was accomplished using ISCO chromatography on silica gel with hexane–ethyl acetate as the eluant. Fractions corresponding to product were combined and concentrated under vacuum, during which time product crystallized as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.16 (t, 1H, <i>J</i> = 7.58 Hz), 6.83 (dd, 2H), 3.83 (s, 3H), 3.01 (m, 2H), 2.91 (m, 2H), 2.59 (m, 4H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Preparation of 1-Methoxy-2-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<b>10</b>)</h3><div class="NLM_p last">A flask containing 1-methoxy-5,6,8,9-tetrahydrobenzocyclohepten-7-one (5.76 g, 30.3 mmol) in acetonitrile (142.3 mL) was cooled to 0 °C, and the mixture was stirred for 5 min. Potassium nitrate (3.06 g, 30.3 mmol) was added in one portion, and the mixture was stirred for 5–10 min at 0 °C and then warmed to room temperature. Changes in color from light yellow to a deeper orange were observed over 2 h at room temperature. After 2 h, the reaction mixture was poured into saturated sodium bicarbonate. Solid bicarbonate was also added to adjust the pH between 4.5 and 6.0. The reaction mixture was extracted with methylene chloride (3 × 100 mL). The organic extracts were combined and dried over magnesium sulfate, filtered, and concentrated under vacuum to give the product as an orange waxy solid (7.55 g). Purification was accomplished on silica gel using ISCO chromatography and ethyl acetate–hexanes (0–50%) as the eluant (2.10 g, 29.5%). Additional material was isolated by subjecting the filtrate to chromatography. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.71 (d, 1H, <i>J</i> = 7.92 Hz), 7.11 (d, 1H, <i>J</i> = 8.29 Hz), 3.90 (s, 3H), 3.05 (m, 2H), 2.99 (m, 2H), 2.63 (m, 4H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Preparation of 1-Bromo-2,3-bis-bromomethyl-4-methoxybenzene (<b>7</b>)<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(28)</a></h3><div class="NLM_p last">To a stirred solution of 1-methoxy-2,3-dimethylbenzene (<b>1</b>) (10.00 g, 0.073 mol) in carbon tetrachloride (100 mL, 1 mol) was added <i>N</i>-bromosuccinimide (39.2 g, 0.22 mol) and benzoyl peroxide (0.2 g, 0.7 mmol). The reaction mixture was heated to reflux overnight. Additional NBS (1 equiv) and benzoyl peroxide (0.1 equiv) were added, and the mixture continued to be heated at reflux. The reaction mixture was cooled to room temperature and succinimide removed by filtration. The filtrate was concentrated under vacuum to give product. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.66 (d, 1H, <i>J</i> = 8.84 Hz), 1.06 (d, 1H, <i>J</i> = 8.84 Hz), 4.81 (s, 2H), 4.77 (s, 2H), 3.88 (s, 3H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Preparation of 1-Bromo-4-methoxy-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<b>9</b>)</h3><div class="NLM_p">(i)To a stirred suspension of tetra-<i>n</i>-butylammonium iodide (1.2 g, 0.0032 mol) in 0.6 M of sodium bicarbonate in water (43 mL) and methylene chloride (5 mL, 0.08 mol) was added a solution of 3-oxopentanedioic acid, diethyl ester (1.3 mL, 0.0070 mol) and 1-bromo-2,3-bis-bromomethyl-4-methoxybenzene (2.01 g, 0.00539 mol) in methylene chloride (5 mL) dropwise. The biphasic reaction mixture was stirred vigorously overnight, during which time the mixture changed color from pale yellow to orange. The reaction mixture was quenched with ammonium chloride and extracted with methylene chloride (3 × 30 mL). The organic extracts were dried over magnesium sulfate, filtered, and concentrated under vacuum. The diastereomeric mixture was taken on without purification to the next step.</div><div class="NLM_p last">(ii) A stirred solution of 1-bromo-4-methoxy-7-oxo-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene-6,8-dicarboxylic acid diethyl ester (102 g, 0.247 mol) in ethanol (2000 mL) and 1 M aqueous potassium hydroxide (1300 mL) was heated to reflux for 2 h. The reaction mixture was cooled to room temperature. HCl (1 N) was added to quench the reaction and the product extracted with methylene chloride, washed with water and brine, dried over magnesium sulfate, filtered, and concentrated under vacuum to give a light orange-tan solid. The material was purified by ISCO chromatography using ethyl acetate–hexane (25–50%) to give the desired product as a pale orange-tan solid (58 g, 87% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.44 (d, 1H, <i>J</i> = 8.84 Hz), 6.70 (d, 1H, <i>J</i> = 9.09 Hz), 3.82 (s, 3H), 3.18 (m, 2H), 3.08 (m, 2H), 2.57 (m, 4H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Preparation of 4-Bromo-1-methoxy-2-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<b>11</b>)</h3><div class="NLM_p last">To a stirred solution of 1-bromo-4-methoxy-5,6,8,9-tetrahydrobenzocyclohepten-7-one (20.0 g, 0.074 mol) in sulfuric acid (200 mL) at 0 °C under an atmosphere of nitrogen was added potassium nitrate (7.89 g, 0.078 mol) in portions. After being stirred for 15 min, the reaction mixture was poured over ice–water. A gummy solid formed which was dissolved in methylene chloride, transferred to a separatory funnel and the water layer removed. The organic phase was washed with saturated aqueous bicarbonate and water, dried over magnesium sulfate, filtered, and concentrated under vacuum to an orange solid. Product was purified by ISCO chromatography on silica gel (350 g column) using ethyl acetate–hexane (10–100%). Fractions corresponding to product were combined and concentrated under vacuum to give product as an orange solid (18 g, 77% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.04 (s, 1H), 3.90 (s, 3H), 3.25 (m, 2H), 3.15 (m, 2H), 2.64 (m, 4H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Preparation of ((4-Bromo-1-methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)-(2-methoxyethyl)amine (<b>13a</b>)</h3><div class="NLM_p last">To a stirred solution of 4-bromo-1-methoxy-2-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (2.2 g, 7 mmol) in methylene chloride (150 mL) was added 2-methoxyethylamine (6.1 mL, 70.4 mmol), powdered 4 Å molecular sieves, and acetic acid (4 mL, 70.4 mmol). The reaction mixture was heated to reflux overnight and then cooled to room temperature. Sodium triacetoxyborohydride (4.5 g, 21 mmol) was added in one portion, and the mixture was stirred for 2 h. The reaction solids were removed by filtration, and the filtrate was neutralized with 33% aqueous sodium hydroxide, adjusting the pH between 8 and 10. The product was extracted with methylene chloride (3 × 30 mL). The organic extract was dried over magnesium sulfate, filtered, and concentrated under vacuum. Purification was accomplished on silica gel using methanol–methylene chloride (10%) as the eluant to give the product as a red oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.93 (s, 1H), 3.85 (s, 3H), 3.51 (t, 2H, <i>J</i> = 6.3 Hz), 3.39 (m, 2H), 3.37 (s, 3H), 2.83 (m, 4H), 2.62 (t, 1H, <i>J</i> = 12 Hz), 2.08 (m, 2H), 1.33 (m, 2H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Preparation of 4-(4-Bromo-1-methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)morpholine (<b>13b</b>)</h3><div class="NLM_p last">The product was isolated as a brown oil (17.8 g, 79% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.92 (s, 1H), 3.86 (s, 3H), 3.70 (t, 4H, <i>J</i> = 4.5 Hz), 3.43 (m, 1H), 2.90 (t, 2H, <i>J</i> = 4.5 Hz), 2.68 (m, 2H), 2.55 (t, 2H, <i>J</i> = 4.5 Hz), 2.47 (m, 2H), 2.13 (m, 2H), 1.42 (q, 2H, <i>J</i> = 10 Hz).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Preparation of 1-(4-Bromo-1-methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)-4-methylpiperazine (<b>13c</b>)</h3><div class="NLM_p last">The product was isolated as a brown oil (1.87 g, 72% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.96 (s, 1H), 3.96 (s, 3H), 3.72 (t, 4H, <i>J</i> = 4.5 Hz), 3.43 (m, 1H), 2.90 (t, 2H, <i>J</i> = 4.5 Hz), 2.68 (m, 2H), 2.55 (m, 2H), 2.47 (m, 2H), 2.26 (s, 3H), 2.06 (m, 2H), 1.74 (m, 2H).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Preparation of (2-Methoxyethyl)-(2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)amine (<b>14a</b>)</h3><div class="NLM_p last">4-Bromo-1-methoxy-2-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)-(2-methoxyethyl)amine (2.4 g, 6.4 mmol) was dissolved in ethanol (50 mL) in a 500 mL Parr flask. Palladium on carbon, 10% (90:10 carbon black/palladium, 250 mg, 19 mmol), was added to the flask and the material subjected to hydrogen at 50 psi for 16 h. The catalyst was removed by filtration through Celite and the resulting filtrate concentrated under vacuum to provide the desired product as a red oil (HBr salt). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.68 (d, 1H, <i>J</i> = 8.1 Hz), 6.52 (d, 1H, <i>J</i> = 8.1 Hz), 3.77 (m, 4H), 3.68 (s, 3H), 3.40 (s, 3H), 3.07 (m, 4H), 2.75 (m, 1H), 2.39 (m, 2H), 1.55 (m, 2H).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Preparation of 1-Methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamine (<b>14b</b>)</h3><div class="NLM_p last">The product was isolated as an HBr salt (11 g, 79% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.72 (d, 1H, <i>J</i> = 7.83 Hz), 6.55 (d, 1H, <i>J</i> = 7.83 Hz), 4.15 (broad s, 4H), 3.70 (s, 3H), 3.47 (m, 1H), 3.35 (broad s, 1H), 3.10 (broad s, 4H), 2.59–2.86 (m, 4H), 2.37 (m, 1H), 1.48 (m, 3H).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Preparation of 1-Methoxy-7-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamine (<b>14c</b>)</h3><div class="NLM_p last">The product was isolated as a dark brown oil HBr salt (1.5 g, 89%). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 6.91 (d, 1H, <i>J</i> = 8.84 Hz), 6.49 (s, 1H), 6.44 (d, 1H, <i>J</i> = 8.84 Hz), 3.63 (m, 1H), 2.54–2.75 (m, 6H), 2.31–2.45 (m, 5H), 2.31 (s, 3H), 2.05 (m, 2H), 1.61 (m, 1H), 1.37 (m, 2H).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> Preparation of 1,2-Bis-bromomethyl-4-methoxybenzene (<b>16</b>)<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(29)</a></h3><div class="NLM_p">(i) To a stirred suspension of lithium tetrahydroaluminate (16.6 g, 0.44 mol) in tetrahydrofuran (300 mL) at 0 °C under nitrogen was added dropwise a solution of 4-methoxyphthalic acid dimethyl ester (24.46 g, 0.11 mol) in tetrahydrofuran (100 mL). The mixture was stirred at 0 °C for 1 h and then warmed to room temperature overnight. The mixture was recooled at 0 °C and the reaction quenched with addition of water (125 mL) carefully dropwise, followed by 1 N NaOH (100 mL) and additional water (125 mL). Evolution of gas was observed upon initial quenching with water. Aluminum salts precipitated out of solution and were removed by filtration following complete quenching of the reaction mixture. The filtrate was diluted with ethyl acetate, washed with water, dried over magnesium sulfate, filtered, and concentrated under vacuum to provide (2-hydroxymethyl-4-methoxyphenyl)methanol as a colorless oil (17.8 g, 97% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.24 (d, 1H, <i>J</i> = 8.2 Hz), 6.91 (s, 1H), 6.80 (d, 1H, <i>J</i> = 8.2 Hz), 4.63 (d, 4H, <i>J</i> = 6.3 Hz), 3.8 (s, 3H), 3.44 (broad s, 1H), 3.16 (broad s, 1H).</div><div class="NLM_p last">(ii) (2-Hydroxymethyl-4-methoxyphenyl)methanol (17.8 g, 0.11 mol) was dissolved in chloroform (200 mL, 2 mol) and treated with phosphorus tribromide (60.2 g, 0.222 mol) dropwise over 6 h. After being stirred overnight at room temperature, the mixture was cooled at 0 °C and treated with water (50 mL). The reaction mixture was poured over saturated sodium bicarbonate and extracted with dichloromethane. Combined organics were dried over sodium sulfate, filtered, and concentrated under vacuum to give the product (16.0 g, 51% yield) which was used without further purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.29 (d, 1H, <i>J</i> = 8.4 Hz), 6.9 (s, 1H), 6.83 (d, 1H, <i>J</i> = 8.4 Hz), 4.66 (s, 2H), 4.62 (s, 2H), 3.82 (s, 3H).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Preparation of 2-Methoxy-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<b>17</b>)</h3><div class="NLM_p">(i) To a stirred solution of tetra-<i>n</i>-butylammonium iodide (12.1 g, 0.033 mol) in 0.6 M of sodium bicarbonate in water (300 mL) and methylene chloride (130 mL, 2.1 mol) was added a solution of 1,2-bis-bromomethyl-4-methoxybenzene (16.00 g, 0.054 mol) and 3-oxopentanedioic acid, diethyl ester (14.31 g, 0.071 mol) in methylene chloride (40 mL, 0.6 mol). The solution was stirred vigorously at room temperature for ∼20 h. Saturated ammonium chloride solution was added to the reaction mixture. The product was extracted with ethyl acetate (3 × 100 mL). The ethyl acetate extracts were washed with water and brine, then dried over magnesium sulfate, filtered, and concentrated under vacuum to give a yellow oil. The oil was triturated with ether, and a solid precipitated out of solution and was removed by filtration (tetrabutylammonium salts). The filtrate was concentrated to an oil (20.0 g, 100%) that was carried on to the next step without purification.</div><div class="NLM_p last">(ii) 2-Methoxy-7-oxo-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene-6,8-dicarboxylic acid diethyl ester (18.2 g, 0.0544 mol) was dissolved in ethanol, and the solution was treated with potassium hydroxide (24.4 g, 0.435 mol) in water (140 g, 7.6 mol). The mixture was then refluxed until HPLC showed consumption of starting material (∼5 h). The mixture was then acidified with 1 N HCl, and the product was extracted with dichloromethane. Organic extracts were dried over sodium sulfate, filtered, and concentrated under vacuum. The crude mixture was filtered through a plug of silica, rinsing with dichloromethane before purification. The filtrate was concentrated under vacuum and purified by ISCO flash column chromatography (hexane–ethyl acetate). Combined fractions were reduced under vacuum to afford 2-methoxy-5,6,8,9-tetrahydrobenzocyclohepten-7-one (6.0 g, 58% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.14 (d, 1H, <i>J</i> = 8.8 Hz), 6.79 (s, 1H), 6.75 (d, 1H, <i>J</i> = 8.8 Hz), 3.81 (s, 3H), 2.86 (m, 4H), 2.56 (m, 4H).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Preparation of 2-Methoxy-1-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<b>18</b>) and 2-Methoxy-3-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<b>19</b>)</h3><div class="NLM_p last">2-Methoxy-5,6,8,9-tetrahydrobenzocyclohepten-7-one (6.00 g, 0.0315 mol) was dissolved in acetonitrile (280 mL) and was added to a mixture of trifluoroacetic anhydride (13.4 mL, 0.095 mol) in acetonitrile (60 mL) at 0 °C. Potassium nitrate (3.19 g, 0.032 mol) was then added and the mixture allowed to warm to room temperature. Following complete consumption of starting material, the mixture was poured over saturated sodium bicarbonate, and organics were extracted with ethyl acetate–dichloromethane. Combined organics were dried over sodium sulfate, filtered, and reduced under vacuum. The crude mixture was purified by ISCO flash column chromatography using hexane–ethyl acetate (0–50%). Combined fractions were reduced under vacuum to afford 2-methoxy-1-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (1.80 g, 25% yield) (<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.30 (d, 1H, <i>J</i> = 8.6 Hz), 6.90 (d, 1H, <i>J</i> = 8.6 Hz), 3.89 (s, 3H), 2.93 (m, 2H), 2.77 (m, 2H), 2.60–2.65 (m, 4H)) and 3.62 g (49%) of 2-methoxy-3-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.78 (s, 1H), 6.96 (s, 1H), 3.97 (s, 3H), 2.94 (m, 4H), 2.64 (m, 4H)).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Preparation of 3-Methoxy-<i>N</i>*7*-(2-methoxyethyl)-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene-2,7-diamine (<b>20a</b>)</h3><div class="NLM_p">(i) To a stirred solution of 2-methoxy-3-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (0.81 g, 0.0034 mol) in 1,2-dichloroethane (12 mL) under nitrogen at room temperature were added 2-methoxyethylamine (0,31 g, 0.004 mol) and acetic acid (0.24 mL, 0.004 mol). The reaction mixture was stirred at room temperature for 3 h. The mixture was then cooled to 0 °C, and sodium triacetoxyborohydride (2.2 g, 0.01 mol) was added to the reaction mixture in one portion. The reaction mixture was stirred at 0 °C for 30 min and then warmed to room temperature for 4 h. The reaction mixture was quenched with water and pH adjusted to 8–10 with 10 N NaOH solution. The mixture was extracted with methylene chloride, dried over magnesium sulfate, and concentrated under vacuum. Purification was accomplished on silica gel using ISCO chromatography with methylene chloride–methanol with ammonium hydroxide. The product was isolated as a brown film.<sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.42 (s, 1H), 8.16 (s, 1H), 3.87 (s, 3H), 3.67 (m, 2H), 3.38 (m, 5H), 3.22 (m, 2H), 2.62–2.88 (m, 5H), 2.36 (m, 2H).</div><div class="NLM_p last">(ii) 2-Methoxyethyl-(2-methoxy-3-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)amine (2.50 g, 0.0085 mol) in ethanol (45 mL) was added to a Parr vessel containing palladium on carbon, 10% (90:10 carbon black/palladium, 0.5 g, 0.038 mol), under nitrogen. The vessel was placed on a Parr shaker and subjected to hydrogen at 50 psi for 2 h. Catalyst was removed by filtration and the product used without purification. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.67 (s, 1H), 6.83 (s, 1H), 3.94 (s, 3H), 3.53 (t, 1H, <i>J</i> = 14 Hz), 3.37 (s, 6H), 2.83–2.92 (m, 5H), 2.71 (m, 2H), 2.12 (m, 2H), 1.39 (m, 2H).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Preparation of 3-Methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamine (<b>20b</b>)</h3><div class="NLM_p">(i) 2-Methoxy-3-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (4.94 g, 0.021 mol) in methylene chloride (100 mL) was treated with morpholine (18.30 g, 0.21 mol) followed by acetic acid (12.61 g, 0.21 mol). Powdered 4 Å molecular sieves (2 mass equiv) was added and the mixture heated to reflux for 4 h. The solution was then cooled to room temperature, and sodium triacetoxyborohydride (8.90 g, 0.042 mol) was added. The reaction mixture was poured over saturated sodium bicarbonate, and organics were extracted with ethyl acetate–dichloromethane. Combined organics were dried over sodium sulfate, filtered, and concentrated under vacuum. The crude mixture was purified by ISCO flash column chromatography (methylene chloride–methanol). Combined fractions were reduced under vacuum to afford 4-(2-methoxy-3-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)morpholine (5.4 g, 84% yield).</div><div class="NLM_p last">(ii) 4-(2-Methoxy-3-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)morpholine (5.40 g, 0.018 mol) was dissolved in ethanol (100 mL) and the reaction mixture carefully added to 10% palladium on carbon (0.75 g) under nitrogen in a Parr vessel. The mixture was then placed on a Parr shaker until uptake of hydrogen had ceased (5 h). Catalyst was removed by filtration and the filtrate concentrated under vacuum to afford 3-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamine (4.1 g, 84% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.56 (s, 1H), 6.40 (s, 1H), 4.39 (m, 2H), 3.17 (s, 3H), 3.53 (m, 4H), 3.34 (m, 2H), 2.62 (m, 1H), 2.44 (m, 4H), 1.91 (m, 2H), 1.24 (q, 2H, <i>J</i> = 12 Hz).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> Preparation of 3-Methoxy-7-(4-methyl-piperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamine (<b>20c</b>)</h3><div class="NLM_p">(i) 2-Methoxy-3-nitro-5,6,8,9-tetrahydrobenzocyclohepten-7-one (1.5 g, 6.38 mmol) and 1-methylpiperazine (6.4 g, 63.8 mmol) were dissolved in methylene chloride (150 mL) and treated with acetic acid (3.8 g, 63.8 mmol). The mixture was then heated to reflux for 4 h. When the mixture cooled to room temperature, sodium triacetoxyborohydride (2.7 g, 12.8 mmol) was added in one portion. The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured over saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic phase was dried over sodium sulfate, filtered, and concentrated under vacuum. The crude reaction mixture was purified on silica gel using ISCO chromatography with hexane–ethyl acetate as the eluant. Fractions corresponding to product were dried to provide the desired product which was carried on without purification.</div><div class="NLM_p last">(ii) 1-(2-Methoxy-3-nitro-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-7-yl)-4-methylpiperazine (1.89 g 5.92 mmol) was dissolved in ethanol (40 mL). Palladium on carbon, 10% (90:10 carbon black/palladium, 0.5 g, 37.5 mmol), was added to the reaction mixture, and the contents were placed under hydrogen (50 psi) for 2 h. The catalyst was removed by filtration through Celite and the filtrate concentrated under vacuum to give product. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 6.56 (s, 1H), 3.7 (s, 3H), 3.48 (m, 4H), 3.34 (m, 4H), 2.6 (m, 1H), 2.45 (m, 2H), 2.27 (m, 2H), 1.91 (m, 2H), 1.24 (q, 2H, <i>J</i> = 12 Hz).</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Preparation of (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-(2,5-Dichloropyrimidin-4-ylamino)bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>22</b>)</h3><div class="NLM_p last">A mixture of (2-exo,3-exo)3-aminobicyclo[2.2.1]hept-5-ene-2-carboxamide (250 mg, 1.64 mmol), 2,4,5-trichloropyrimidine (<b>19</b>) (366 mg, 1.99 mmol), and sodium bicarbonate (280 mg, 3.33 mmol) in methanol (4 mL) and water (2 mL) was stirred at room temperature for 69 h. The mixture was diluted with water (10 mL) and extracted with ethyl acetate (2 × 25 mL). The combined organic extracts were washed successively with water and brine. After drying over magnesium sulfate, the reaction mixture was filtered and concentrated under vacuum. The product was triturated with diethyl ether, filtered, and washed with additional diethyl ether. The product (2-exo,3-exo)-3-(2,5-dichloropyrimidin-4-ylamino)bicyclo[2.2.1]hept-5-ene-2-carboxamide was isolated as a white solid (276 mg, 56% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.61 (d, 1H, <i>J</i> = 7.32 Hz), 8.20 (s, 1H), 7.86 (s, 1H), 7.32 (s, 1H), 6.33 (br s, 1H), 6.30 (br s, 1H), 3.99 (m, 1H), 2.88 (s, 1H), 2.75 (s, 1H), 2.04 (d, 1H, <i>J</i> = 8.84 Hz), 1.40 (d, 1H, <i>J</i> = 8.84 Hz); LCMS (<i>m</i>/<i>e</i>) 299, 300 (M + H).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedure for Coupling Reactions: Preparation of (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[5-Chloro-2-((<i>S</i>)-1-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino)pyrimidin-4-ylamino]bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>23a</b>) and (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[5-Chloro-2-((<i>R</i>)-1-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino)pyrimidin-4-ylamino]bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>23b</b>)</h3><div class="NLM_p last">To a microwave vial containing methoxy-7-morphoin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamine (56 mg, 0.2 mmol) and (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-(2,5-dichloropyrimidin-4-ylamino)bicycle[2.2.1]hept-5-ene-2-carboxylic acid amide (50 mg, 0.2 mmol) in isopropyl alcohol (4 mL) was added 4 M HCl in 1,4-dixoane (40 μL) dropwise. The reaction mixture was subjected to microwaves at 140 °C for 50 min. The mixture was concentrated under vacuum to remove solvent and purified by reverse phase preparative HPLC with acetonitrile–water containing 0.1% TFA (5–50% over 17 min) as the eluant. Two diastereomers were isolated, redissolved in methanol (3 mL), and treated separately with MP-carbonate (solid support). The MP-carbonate beads were removed by filtration and the respective filtrates concentrated under vacuum.</div></div><div id="secyy" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[5-Chloro-2-((<i>R</i>)-1-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino)pyrimidin-4-ylamino]bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>25a</b>)</h3><div class="NLM_p last">The product was isolated as tan solid (35.6 mg, 33% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.02 (d, 1H, <i>J</i> = 8.3 Hz), 7.81 (s, 1H), 6.88 (d, 1H, <i>J</i> = 8.3 Hz), 6.31 (m, 1H), 6.25 (m, 1H), 5.85 (s, 1H), 5.55 (s, 1H), 4.19 (t, 1H, <i>J</i> = 7.3 Hz), 3.01 (s, 4H), 3.72 (s, 3H), 3.49 (m, 2H), 3.07–3.15 (m, 4H), 2.91 (m, 2H), 2.76 (m, 1H), 2.38–2.47 (m, 3H), 2.18 (d, 1H, <i>J</i> = 9.6 Hz), 1.61 (d, 1H, <i>J</i> = 9.3 Hz), 1.48 (m, 2H). <sup>13</sup>C (NMR) δ 176.01, 157.99, 156.38, 152.82, 146.59, 139.08, 137.47, 136.43, 134.74, 130.79, 123.79, 117.48, 103.77, 66.65, 65.74, 61.01, 52.12, 48.66, 47.58, 46.95, 43.55, 43.43, 31.64, 29.53, 29.36, 22.82. LCMS (<i>m</i>/<i>e</i>) 539 (M + H). HRMS: calcd for C<sub>28</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 539.2537, found 539.2542.</div></div><div id="seczz" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[5-Chloro-2-((<i>S</i>)-1-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino)pyrimidin-4-ylamino]bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>25b</b>)</h3><div class="NLM_p last">The product was isolated as an off-white solid (42.8 mg, 39% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.16 (d, 1H, <i>J</i> = 7.5 Hz), 7.86 (s, 2H), 7.41 (broad s, 1H), 6.88 (d, 1H, <i>J</i> = 7.5 Hz), 6.31 (s, 2H), 5.81 (s, 1H), 5.62 (s, 1H), 4.28 (m, 1H), 3.97 (s, 4H), 3.73 (s, 3H), 3.39–3.54 (m, 2H), 3.09 (m, 4H), 2.90 (m, 2H), 2.75 (m, 1H), 2.36–2.5 (m, 4H), 2.20 (d, 1H, <i>J</i> = 9 Hz), 1.61 (d, 1H, <i>J</i> = 9 Hz), 1.48 (m, 2H), 1.26 (m, 1H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 175.99, 157.98, 156.36, 152.83, 146.71, 139.09, 137.57, 136.42, 134.80, 130.76, 123.77, 117.54, 103.72, 67.04, 66.71, 61.00, 52.09, 48.67, 47.56, 46.92, 43.53, 43.42, 31.66, 29.56, 29.43, 22.85. LCMS (<i>m</i>/<i>e</i>) 539 (M + H). HRMS: calcd for C<sub>28</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 539.2537, found 539.2533.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[1-methoxy-7-(2-methoxy-ethylamino)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>23a</b>)</h3><div class="NLM_p last">The product was isolated as the beige foam (58.2 mg, 27% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.17 (d, <i>J</i> = 8.3 Hz, 1H), 7.88 (s, 1H), 7.39 (s, 1H), 6.94 (m, 1H), 6.86 (d, <i>J</i> = 8.4 Hz, 1H), 6.37 (m, 1H), 6.31 (m, 1H), 5.61 (br s, 1H), 5.36 (br s, 1H), 4.37 (m, 1H), 3.72 (s, 3H), 3.51 (m, 2H), 3.26 (s, 3H), 3.23 (m, 1H), 3.06 (s, 1H), 2.94 (s, 1H), 2.85–2.70 (m, 6H), 2.49 (d, <i>J</i> = 8.4 Hz, 2H), 2.24 (d, <i>J</i> = 8.9 Hz, 1H), 2.09 (m, 2H), 1.63 (m, 2H), 1.26 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>): δ 175.99, 157.99, 156.37, 152.83, 146.62, 139.08, 137.73, 136.44, 134.94, 130.68, 123.72, 117.43, 103.71, 71.91, 60.96, 57.85, 52.09, 47.57, 46.91, 45.74, 43.54, 43.43, 34.09, 33.55, 30.74, 21.85. HPLC purity: >90%. LCMS (<i>m</i>/<i>e</i>) 527 (M + H). HRMS: calcd for C<sub>27</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 527.2537, found 539.2538.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[1-methoxy-7-(2-methoxyethylamino)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>23b</b>)</h3><div class="NLM_p last">The product was isolated as a beige foam (45.27 mg, 23% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 8.17 (d, <i>J</i> = 8.3 Hz, 1H), 7.88 (s, 1H), 7.39 (s, 1H), 6.94 (m, 1H), 6.86 (d, <i>J</i> = 8.4 Hz, 1H), 6.37 (m, 1H), 6.31 (m, 1H), 5.61 (br s, 1H), 5.36 (br s, 1H), 4.37 (m, 1H), 3.72 (s, 3H), 3.51 (m, 2H), 3.26 (s, 3H), 3.23 (m, 1H), 3.06 (s, 1H), 2.94 (s, 1H), 2.85 – 2.70 (m, 6H), 2.49 (d, <i>J</i> = 8.4 Hz, 2H), 2.24 (d, <i>J</i> = 8.9 Hz, 1H), 2.09 (m, 2H), 1.63 (m, 2H), 1.26 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.00, 157.97, 156.35, 152.83, 146.65, 139.09, 137.73, 136.43, 134.95, 130.69, 123.73, 117.4, 103.69, 71.90, 60.96, 57.85, 52.08, 47.56, 46.91, 45.74, 43.53, 43.41, 34.10, 33.57, 30.73, 28.91, 21.99. LCMS (<i>m</i>/<i>e</i>) 527 (M + H). HRMS: calcd for C<sub>27</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 527.2537, found 539.2531.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[3-methoxy-7-(2-methoxyethylamino)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>24a</b>)</h3><div class="NLM_p last">The product was isolated as a white trifluoroacetic acid salt (20.5 mg, 20% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.63 (broad s, 1H), 9.38 (broad s, 1H), 8.99 (d, 1H, <i>J</i> = 8.08 Hz), 8.45 (broad s, 1H), 7.63 (s, 1H), 7.22 (s, 1H), 6.71 (s, 1H), 6.53 (s, 1H), 6.29 (s, 1H), 5.94 (s, 1H), 5.47 (s, 1H), 3.83 (s, 4H), 3.72 (m, 2H), 3.41 (s, 3H), 3.35 (m, 1H), 3.25 (m, 2H), 3.01 (s, 1H), 2.69–2.85 (m, 5H), 2.54 (d, 1H, <i>J</i> = 7.58 Hz), 2.38 (m, 2H), 2.06 (d, 1H, <i>J</i> = 9.09 Hz), 1.63 (m, 3H), 1.52 (d, 1H, <i>J</i> = 9.09 Hz). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 174.84, 157.80, 156.39, 152.85, 146.29, 139.19, 136.39, 136.09, 133.79, 126.06, 120.17, 111.60, 103.57, 73.78, 71.79, 59.90, 57.91, 57.85, 55.73, 51.82, 47.62, 46.72, 45.68, 43.77, 34.27, 34.00,31.05. LCMS (<i>m</i>/<i>e</i>) 527 (M + H). HRMS: calcd for C<sub>27</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 527.2537, found 527.2554.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[3-methoxy-7-(2-methoxyethylamino)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>24b</b>)</h3><div class="NLM_p last">The product was isolated as a white trifluoroacetic acid salt (18.9 mg, 18% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.23 (broad s, 1H), 9.37 (broad s, 1H), 8.82 (s, 1H), 8.54 (s, 1H), 7.67 (s, 1H), 7.52 (s, 1H), 6.80 (s, 1H), 6.68 (s, 1H), 6.35 (s, 1H), 6.12 (s, 1H), 5.54 (s, 1H), 4.18 (m, 1H), 3.84 (s, 3H), 3.71 (m, 2H), 3.40 (m, 4H), 3.23 (m, 2H), 3.05 (s,1H), 2.63–2.83 (m, 4H), 2.36 (m, 2H), 2.17 (d, 2H, <i>J</i> = 8.59 Hz), 1.60 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 175.83, 157.83, 156.38, 152.83, 146.41, 139.17, 136.43, 136.16, 133.77, 126.00, 120.42, 111.60, 103.60, 73.78, 71.63, 59.89, 57.85, 55.70, 51.78, 47.63, 46.69, 45.63, 43.81, 43.75, 34.00, 33.75, 30.94. LCMS (<i>m</i>/<i>e</i>) 527 (M + H). HRMS: calcd for C<sub>27</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 527.2537, found 527.2536.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[5-Chloro-2-(3-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino)pyrimidin-4-ylamino]bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>26a</b>)</h3><div class="NLM_p last">The product was isolated as an off-white powder (439 mg, 26% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.60 (m, 1H), 8.12 (s, 1H), 7.90 (s, 1H), 7.79 (m, 1H), 7.39 (s, 1H), 6.98 (s, 1H), 6.36 (m, 1H), 6.16 (m, 1H), 4.00 (m, 3H), 3.83 (s, 3H), 3.30 (m, 5H), 2.74 – 2.90 (m, 6H), 2.39 (m, 3H), 1.94 (d, 1H, <i>J</i> = 4.80 Hz), 1.44 (m, 3H), 1.28 (m, 1H), 1.04 (s, 1H), 0.74 (s, 1H). <sup>13</sup>C NMR (DMS0-<i>d</i><sub>6</sub>) δ 175.84, 157.82, 156.38, 152.86, 146.39, 139.18, 136.39, 135.99, 133.67, 126.12, 120.30, 111.62, 103.57, 67.29, 66.71, 55.74, 51.80, 48.60, 47.63, 46.72, 43.76, 32.08, 32.03, 29.97, 29.66, 15.06. LCMS (<i>m</i>/<i>e</i>) 539. HRMS: calcd for C<sub>28</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 539.2537, found 539.2534.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-[5-Chloro-2-(3-methoxy-7-morpholin-4-yl-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino)pyrimidin-4-ylamino]bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>26b</b>)</h3><div class="NLM_p last">The product was was isolated as a single diastereomer as an off-white solid (422 mg, 25% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 9.56 (m, 1H), 8.05 (s, 1H), 7.81 (m, 2H), 7.35 (s, 1H), 6.89 (s, 1H), 6.35 (m, 1H), 6.16 (m, 1H), 4.04 (m, 4H), 3.83 (s, 3H), 3.71 (m, 4H), 2.90 (m, 3H), 2.76 (m, 5H), 2.32 (m, 3H), 2.13 (m, 1H), 1.41 (m, 4H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 175.83, 157.85, 156.39, 152.82, 146.52, 139.12, 136.46, 136.07, 133.68, 126.08, 120.54, 111.63, 103.64, 67.09, 66.71, 63.37, 55.73, 51.80, 48.66, 47.63, 46.70, 43.81, 31.94, 30.05, 29.87, 29.75. LCMS (<i>m</i>/<i>e</i>) 539. HRMS: calcd for C<sub>28</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub> (M + H)<sup>+</sup> 539.2537, found 539.2560.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[1-methoxy-7-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>27a</b>)</h3><div class="NLM_p last">The product was was isolated as an off-white solid (21.7 mg, 7% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 11.74 (s, 1H), 9.13 (d, 1H, <i>J</i> = 8.08 Hz), 7.71 (s, 1H), 7.62 (d, 1H, <i>J</i> = 8.34), 6.90 (d, 1H, <i>J</i> = 8.34 Hz), 6.30 (m, 1H), 6.10 (m, 1H), 5.91 (s, 1H), 5.53 (s, 1H), 4.00 (t, 1H, <i>J</i> = 7.32 Hz), 3.72 (s, 3H), 3.42–3.58 (m, 8H), 3.08 (s, 1H), 2.90 (m, 1H), 2.88 (s, 1H), 2.83 (s, 3H), 2.75 (m, 2H), 2.35–2.45 (m, 6H), 2.10 (d, 1H, <i>J</i> = 10 Hz), 1.59 (d, 1H, <i>J</i> = 8.33 Hz), 1.49 (m, 2H). <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 176.42, 156.88, 154.09, 147.86, 139.46, 138.5, 136.11, 134.46, 129.48, 124.28, 119.39, 118.2, 115.5, 104.27, 67.42, 61.46, 52.96, 51.18, 47.73, 47.56, 45.19, 43.58, 42.77, 42.33, 30.86, 27.95, 22.22. LCMS (<i>m</i>/<i>e</i>) 552 (M + H). LCMS (<i>m</i>/<i>e</i>) 539. HRMS: calcd for C<sub>29</sub>H<sub>38</sub>ClN<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 552.2854, found 552.2866.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[1-methoxy-7-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>27b</b>)</h3><div class="NLM_p last">The product was was isolated as an off-white solid (12.6 mg, 4% yield). <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 10.98 (s, 1H), 9.26 (d, 1H, <i>J</i> = 7.07 Hz), 7.68 (s, 1H), 7.43 (d, 1H, <i>J</i> = 8.09 Hz), 6.92 (d, 1H, <i>J</i> = 8.08 Hz), 6.58 (s, 1H), 6.20 (m, 1H), 5.91 (m, 1H), 5.52 (s, 1H), 3.80 (m, 1H), 3.70 (s, 3H), 3.39–3.62 (m, *H), 3.03 (s, 1H), 2.93 (m, 2H), 2.85 (s, 3H), 2.77 (m, 2H), 2.38 (m, 5H), 1.53 (d, 1H, <i>J</i> = 9.34 Hz), 1.45 (d, 1H, <i>J</i> = 12.4 Hz), 1.27 (m, 2H). LCMS (<i>m</i>/<i>e</i>) 552 (M + H). HRMS: calcd for C<sub>29</sub>H<sub>38</sub>ClN<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 552.2854, found 552.2866.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[3-methoxy-7-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>28a</b>)</h3><div class="NLM_p last">The product was was isolated as a light brown powder (19.5 mg, 12% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12 (s, 1H), 7.89 (s, 1H), 7.78 (m, 1H), 7.38 (s, 1H), 6.96 (s, 1H), 6.35 (m, 1H), 6.14 (m, 1H), 4.02 (m, 2H), 3.82 (s, 3H), 3.50 (m, 4H), 3.30 (m, 3H), 3.14 (m, 2H), 2.78 (s, 3H), 2.71–2.92 (m, 6H), 2.16 (m, 2H), 2.05 (m, 2H), 1.43 (m, 4H). LCMS (<i>m</i>/<i>e</i>) 552 (M + H). HRMS: calcd for C<sub>29</sub>H<sub>38</sub>ClN<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 552.2854, found 552.285.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-{5-Chloro-2-[3-methoxy-7-(4-methylpiperazin-1-yl)-6,7,8,9-tetrahydro-5<i>H</i>-benzocyclohepten-2-ylamino]pyrimidin-4-ylamino}bicyclo[2.2.1]hept-5-ene-2-carboxylic Acid Amide (<b>28b</b>)</h3><div class="NLM_p last">The product was isolated as a light brown powder (23.8 mg, 14% yield). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 8.12 (s, 1H), 7.89 (s, 1H), 7.78 (m, 1H), 7.38 (s, 1H), 6.96 (s, 1H), 6.35 (m, 1H), 6.14 (m, 1H), 4.02 (m, 2H), 3.82 (s, 3H), 3.50 (m, 4H), 3.30 (m, 3H), 3.14 (m, 2H), 2.78 (s, 3H), 2.71–2.92 (m, 6H), 2.16 (m, 2H), 2.05 (m, 2H), 1.43 (m, 4H). HPLC purity: >86%. LCMS (<i>m</i>/<i>e</i>) 552 (M + H). HRMS: calcd for C<sub>29</sub>H<sub>38</sub>ClN<sub>7</sub>O<sub>2</sub> (M + H)<sup>+</sup> 552.2854, found 552.2861.</div></div><div id="sec5_1_30_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Anaplastic Lymphoma Kinase (ALK) Assay</h3><div class="NLM_p last">Compounds were tested for their ability to inhibit the kinase activity of baculovirus-expressed human ALK cytoplasmic domain using a modification of the assay protocol reported for trkA.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(30)</a> Phosphorylation of the substrate, phospholipase C-γ (PLC-γ) generated as a fusion protein with glutathione <i>S</i>-transferase (GST),<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(31)</a> was detected with a europium-labeled antiphosphotyrosine antibody and measured by time-resolved fluorescence (TRF). Briefly, each 96-well plate was coated with 100 μL/well of 10 μg/mL substrate solution (recombinant GST-PLCγ) in Tris-buffered saline (TBS). The ALK assay mixture (total volume of 100 μL/well) consisting of 20 mM HEPES (pH 7.2), 1 μM ATP, 5 mM MnCl<sub>2</sub>, 0.1% BSA, and test compound (diluted in DMSO, 2.5% DMSO final in assay) was then added to the assay plate. Enzyme (50 ng/mL ALK) was added, and the reaction was allowed to proceed at 37 °C for 15 min. Detection of the phosphorylated product was performed by adding 100 μL/well of Eu-N1 labeled PT66 antibody diluted 1:5000 in 0.25% BSA in TBS containing 0.1% Tween-20 (TBS-T). Incubation at 37 °C then proceeded for 1 h, followed by addition of 100 μL of enhancement solution. The plate was gently agitated, and after 30 min, the fluorescence of the resulting solution was measured using the PerkinElmer EnVision 2102 (or 2104) multilabel plate reader (PerkinElmer, Waltham, MA). Data analysis was performed using ActivityBase (IDBS, Guilford, U.K.). IC<sub>50</sub> values were calculated by plotting percent inhibition versus log<sub>10</sub> of the concentration of compound and fitting to the nonlinear regression sigmoidal dose–response (variable slope) equation in XLFit (IDBS, Guilford, U.K.).</div></div><div id="sec5_1_30_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Insulin Receptor (IR) Kinase Assay</h3><div class="NLM_p last">The IR kinase assay was performed using the TRF assay as described above for ALK. The nucleotide substrate ATP was used at 20 μM, and recombinant human baculovirus-expressed IR cytoplasmic domain was added to the assay at a final concentration of 20 ng/mL. In place of Eu-N1 labeled PT66 antibody, Eu-N1 labeled PY100 antibody (diluted 1:10000 in antibody dilution buffer) was utilized for detection.</div></div><div id="sec5_1_30_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Cellular NPM-ALK Phosphorylation Assay</h3><div class="NLM_p last">The cellular NPM-ALK tyrosine phosphorylation assay was carried out as described previously.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> To calculate the cellular IC<sub>90</sub> values in murine plasma, the Karpas-299 cells were incubated with different concentrations of CEP-28122 in murine plasma for about 2 h, and the cells were then processed for NPM-ALK phosphorylation assay as described.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div></div><div id="sec5_1_30_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> X-ray Crystallography</h3><div class="NLM_p last">The X-ray intensity data were measured on a Bruker CCD area detector system (Cu Kα, 2631 frames, 0.5° in ω for 30 s): orthorhombic, <i>P</i>2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>, <i>a</i> = 5.1493(6) Å, <i>b</i> = 18.930(2) Å, <i>c</i> = 27.837(3) Å, <i>Z</i> = 4, C<sub>28</sub>H<sub>35</sub>ClN<sub>6</sub>O<sub>3</sub>. Solved and refined using SHELXTL (Bruker, version 6.1), the final anisotropic full-matrix least-squares refinement on <i>F</i><sup>2</sup> (4110 reflections, 345 variables) converged at R1 = 9.25% for the observed data and wR2 = 24.22% for all data. The absolute stereochemistry can be assigned at a 99.5% reliability level with a Flack parameter of 0.08(5) for the stereochemistry as shown and 0.91(5) for the inverted model. The expected value is 0 for the correct absolute configuration and 1 for the inverted stereochemistry. The Hamilton <i>R</i>-factor ratio is 0.234/0.220 = 1.054, indicating greater than 99.5% reliability in the determination of the difference between the two models.</div></div><div id="sec5_1_30_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Pharmacokinetics</h3><div class="NLM_p last">Adult female SCID mice, male CD-1 mice, male Sprague–Dawley rat (Charles River, Kingston, NY), male beagle dogs (Cephalon, Inc., Maisons Alfort, France), and male cynomolgus monkeys (Covance Laboratories, Alice, TX) were used in the experiments. All animal usage was approved by the Cephalon IACUC. Mice were dosed via the lateral tail vein for iv administration (3% DMSO, 30% Solutol, 67% phosphate buffered saline) or via oral gavage (100% PEG400) using a dose volume of 100 μL. Trunk blood was collected from three mice per time point over a 6 h period. Rats were also dosed via the lateral tail vein for iv administration (1 mL/kg, vehicle as described above) or via oral gavage (5 mL/kg in 40% HPβCD). Serial blood samples were collected from the lateral tail vein into heparinized collection tubes over a 6 h period. In dogs and primate iv administration (0.5 mL/kg in 40% HPβCD) was via the saphenous vein. Dogs received a 1 mL/kg oral dose via gavage, while monkeys were dosed via nasogastric tube (2 mL/kg). Serial blood samples were collected from the femoral vein into heparinized collection tubes over a 24 h period. All animals were fasted overnight prior to oral administration. The plasma was separated by centrifugation, and the sample was prepared for analysis by protein precipitation with acetonitrile. The plasma samples were analyzed for drug and internal standard via LCMS/MS protocol. The pharmacokinetic parameters were calculated by a noncompartmental method using WinNonlin software (Professional, version 4.1, Pharsight Corporation, Palo Alto, CA, 1997). Parameters were calculated using plasma concentration time data for individual animals (rat, dog, and monkey, <i>n</i> = 3), and these data are presented as the mean ± SEM. Mouse data are presented as the composite mean.</div></div><div id="sec5_1_30_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Pharmacodynamics</h3><div class="NLM_p last">Scid mice bearing Karpas-299 sc tumor xenografts were administered <b>25b</b> at 30 mg/kg, po. P-NPM-ALK and total NPM-ALK in tumor samples were detected by immunoblotting, and relative NPM-ALK phosphorylation was calculated as described previously<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and presented as the mean ± standard error of mean (SEM). The compound levels in plasma and tumor lysates were measured by LCMS/MS and presented as the mean ± standard error of mean.</div></div><div id="sec5_1_30_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Antitumor Efficacy Studies in Karpas-299 sc Tumor Xenografts in Mice</h3><div class="NLM_p last">SCID/beige mice (6- to 8-week-old female) were maintained 5/cage in microisolator units on a standard laboratory diet (Teklad Labchow, Harlan Teklad, Madison, WI) and housed under humidity- and temperature-controlled conditions, and the light/dark cycle was set at 12 h intervals. Exponentially growing cells were implanted subcutaneously to the left flank of each mouse. The mice were monitored. When the tumor xenograft volumes reached approximately 600 mm<sup>3</sup>, the tumor-bearing mice were randomized into different treatment groups (8–10 mice/group) and were administered orally with either vehicle (PEG-400) or compound <b>20b</b> formulated in vehicle at indicated doses and with indicated dosing frequency, with 100 μL per dosing volume. The length (<i>L</i>) and width (<i>W</i>) of each tumor was measured with a vernier caliper, and the mouse body weight was determined every 2–3 days. The tumor volumes were then calculated with the formula 0.5236<i>LW</i>(<i>L</i> + <i>W</i>)/2. Statistical analyses of tumor volumes and mouse body weight were carried out using the Mann–Whitney rank sum test. Plasma and tumor samples were obtained at 2 h after final dose, and the compound levels in plasma and tumor lysates were measured by LCMS/MS.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Docking Study</h3><div class="NLM_p last">The computational work was done using Schrodinger/Maestro molecular modeling package (Maestro, version 9.1.107, Schrodinger, LLC, New York, NY). The essential steps in the current docking experiment included preparation of representative ALK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>) and IRK (PDB code <a href="https://" class="ext-link">3EKK</a>) structures from the Protein Data Bank using Maestro protein preparation workflow. These structures had similar ligands and were expected to give the best docking results. The procedure involved (1) grid generation around the ligand, (2) preparation of ligands (<b>25b</b> and <b>3</b>) using the LigPrep module, (3) use of Glide/XP docking to keep the top 10 binding poses for each compound, and (4) selection of the binding mode using our knowledge based approach.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(32)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54"><a href="/doi/suppl/10.1021/jm201550q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04560" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04560" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Structure of compound <b>25a</b>, hERG inhibition data for select inhibitors, and antitumor efficacy of compound <b>3</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201550q/suppl_file/jm201550q_si_001.pdf">jm201550q_si_001.pdf (184.22 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm201550q" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Diane E. Gingrich</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#61050406080f0613080209505321060c00080d4f020e0c"><span class="__cf_email__" data-cfemail="452120222c2b22372c262d7477052228242c296b262a28">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph G. Lisko</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew A. Curry</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mangeng Cheng</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Quail</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lihui Lu</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Weihua Wan</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark S. Albom</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thelma S. Angeles</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa D. Aimone</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">R. Curtis Haltiwanger</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Wells-Knecht</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gregory R. Ott</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arup K. Ghose</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark A. Ator</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce Ruggeri</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce D. Dorsey</span> - <span class="hlFld-Affiliation affiliation">Worldwide
Discovery Research, Cephalon, Inc., 145
Brandywine Parkway, West Chester, Pennsylvania 19380, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d3032e3574-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80748" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80748" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors gratefully acknowledge the scientific contributions of James Haley and Renee Roemmele for the preparation of key intermediates. Special thanks are given to Damaris Rolon-Steele, Kelli Zeigler, Christine LoSardo, and Rebecca Brown for their efforts with the pharmacokinetic data generation and analysis. The authors also thank Edward Hellriegel and Mehran Yazdanian for their contributions regarding the dog and monkey pharmacokinetic studies, Dr. Yael Mosse of Children Hospital of Philadelphia, PA, for kindly providing the neuroblastoma cell lines (SKNAS, SH-SY5Y, and NB-1643), and Henry Breslin for scientific discussion contributions.</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15785" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15785" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 32 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <span class="citation_source-book">Cancer Facts and Figures 2011</span>; <span class="NLM_publisher-name">American Cancer Society</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cancer+Facts+and+Figures+2011%3B+American+Cancer+Society%3A+Atlanta%2C+GA%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DCancer%2520Facts%2520and%2520Figures%25202011%26pub%3DAmerican%2520Cancer%2520Society%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Translating cancer research into targeted therapeutics</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fnature09339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20882008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=543-549&author=J.+S.+De+Bonoauthor=A.+Ashworth&title=Translating+cancer+research+into+targeted+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Translating cancer research into targeted therapeutics</span></div><div class="casAuthors">de Bono, J. S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">543-549</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and less side effects.  Nevertheless, despite some successes drug development remains painfully slow.  Here, we highlight the issues involved and suggest ways in which this process can be improved and expedited.  We envision an increasing shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clin. trials.  The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biol. of the patient and their cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNF4iuzr3HvbVg90H21EOLACvtfcHk0lgMwUsQfohl1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O&md5=1e65763ba1cddeef17e5b68e56a96452</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fnature09339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09339%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTranslating%2520cancer%2520research%2520into%2520targeted%2520therapeutics%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D543%26epage%3D549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Stegmeier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, M.</span><span> </span><span class="NLM_article-title">Targeted cancer therapies in the the twenty-first century: lessons from imatinib</span> <span class="citation_source-journal">Clin. Pharm. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fclpt.2009.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20237469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFCntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=543-552&issue=5&author=F.+Stegmeierauthor=M.+Warmuthauthor=W.+R.+Sellersauthor=M.+Dorsch&title=Targeted+cancer+therapies+in+the+the+twenty-first+century%3A+lessons+from+imatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib</span></div><div class="casAuthors">Stegmeier, F.; Warmuth, M.; Sellers, W. R.; Dorsch, M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-552</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An increased understanding of the mol. etiol. of cancer has enabled the development of novel therapies that are collectively referred to as mol. targeted agents.  Unlike the drugs used in conventional chemotherapy, these agents are designed to specifically interfere with key mol. events that are responsible for the malignant phenotype.  They hold great promise for widening the therapeutic window, which would provide more effective treatment options as compared with cytotoxic therapies.  In addn., the targeted approach that is characteristic of these drugs provides unique opportunities for combination therapies with other anticancer agents that have non-overlapping toxicities.  Targeted agents are therefore primed to become invaluable therapeutic tools in the multimodal treatment of cancer.  The challenges assocd. with these novel targeted therapies are distinct from those faced in conventional chemotherapy.  These unique challenges include the need to select appropriate pharmacodynamic markers to guide dose and schedule and to identify biomarkers that enable selection of patient populations that are most likely to benefit from the treatment.  In addn., although the emergence of resistance to targeted therapies is a problem frequently faced in the clinic, the mol. characterization of resistance mechanisms provides the opportunity to design second-generation therapies or combination therapies aimed at preventing resistance or restoring response.  The development of the tyrosine kinase inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia (CML).  In this article, we discuss the lessons learned from the application of imatinib and other targeted agents in clin. practice and discuss how these insights may guide the development of novel targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKsbivdzh2E7Vg90H21EOLACvtfcHk0lgMwUsQfohl1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFCntb8%253D&md5=e4000908114d67870d536efeb91f17e1</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.297%26sid%3Dliteratum%253Aachs%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DDorsch%26aufirst%3DM.%26atitle%3DTargeted%2520cancer%2520therapies%2520in%2520the%2520the%2520twenty-first%2520century%253A%2520lessons%2520from%2520imatinib%26jtitle%3DClin.%2520Pharm.%2520Ther.%26date%3D2010%26volume%3D87%26issue%3D5%26spage%3D543%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Targeted inhibition of kinases in cancer therapy</span> <span class="citation_source-journal">Mt. Sinai J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1002%2Fmsj.20220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21105121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A280%3ADC%252BC3cbptlGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2010&pages=573-586&author=S.+J.+Bakerauthor=E.+P.+Reddy&title=Targeted+inhibition+of+kinases+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted inhibition of kinases in cancer therapy</span></div><div class="casAuthors">Baker Stacey J; Reddy E Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">The Mount Sinai journal of medicine, New York</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">573-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">With an understanding of the molecular changes that accompany cell transformation, cancer drug discovery has undergone a dramatic change in the past few years.  Whereas most of the emphasis in the past has been placed on developing drugs that induce cell death based on mechanisms that do not discriminate between normal and tumor cells, recent strategies have emphasized targeting specific mechanisms that have gone awry in tumor cells.  However, the identification of cancer-associated mutations in oncogenes and their amplification in tumors has suggested that inhibitors against such proteins might represent attractive substrates for targeted therapy.  In the clinic, the success of imatinib (Gleevec®, STI571) and trastuzumab (Herceptin®), both firsts of their kind, spurred further development of new, second-generation drugs that target kinases in cancer.  This review highlights a few important examples each of these types of therapies, along with some newer agents that are in various stages of development.  Second-generation kinase inhibitors aimed at overriding emerging resistance to these therapies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAYkuL3ykcubBItaL1WaVAfW6udTcc2ebWSSNtCJ1bILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbptlGqtA%253D%253D&md5=8e60c189f8d5447ac34e40121e64b577</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmsj.20220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmsj.20220%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DTargeted%2520inhibition%2520of%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DMt.%2520Sinai%2520J.%2520Med.%26date%3D2010%26volume%3D77%26spage%3D573%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Milkiewicz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Inhibitors of anaplastic lymphoma kinase: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1653</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1517%2F13543776.2010.527332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20961208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1653-1681&issue=12&author=K.+L.+Milkiewiczauthor=G.+R.+Ott&title=Inhibitors+of+anaplastic+lymphoma+kinase%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of anaplastic lymphoma kinase: a patent review</span></div><div class="casAuthors">Milkiewicz, Karen L.; Ott, Gregory R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1653-1681</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that belongs to the insulin receptor superfamily.  Aberrant ALK activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large B-cell lymphoma, systemic histiocytosis and NSCLC or through mutations in the full length protein in hereditary familial neuroblastoma.  Thus, abrogation of ALK signaling through direct kinase inhibition has become an attractive therapeutic intervention point for a subset of genetically defined human cancers.  Areas covered in this review: This manuscript provides a comprehensive review of the patent literature pertaining to ALK inhibitors and outlines their potential as anticancer therapeutic agents.  What the reader will gain: The reader will gain an understanding of the major structural classes of ALK inhibitors and insights into the future of this class of drugs.  Take home message: Multiple small-mol. ALK inhibitors have been reported with diverse chem. architecture, potency, kinase selectivity profiles and activity against potential resistance.  The breadth of inhibitors combined with the recent discoveries of the involvement of ALK in lung, breast and colorectal cancers has kept the field advancing at a rapid pace.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocXB5-B6Du8LVg90H21EOLACvtfcHk0livr8jnkcDzhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7bF&md5=32d9d90cf43bba8dfef6385e6494cc0a</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.527332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.527332%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DInhibitors%2520of%2520anaplastic%2520lymphoma%2520kinase%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26issue%3D12%26spage%3D1653%26epage%3D1681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1016%2Fj.canlet.2010.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20934803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2010&pages=81-94&author=E.+Ardiniauthor=P.+Magnaghiauthor=P.+Orsiniauthor=M.+Menichincheri&title=Anaplastic+lymphoma+kinase%3A+role+in+specific+tumours%2C+and+development+of+small+molecule+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy</span></div><div class="casAuthors">Ardini, E.; Magnaghi, P.; Orsini, P.; Galvani, A.; Menichincheri, M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-94</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase first identified as the product of a gene rearrangement in Anaplastic Large Cell Lymphoma.  ALK has subsequently been found to be rearranged, mutated, or amplified in a further series of tumors including neuroblastoma, and Non-Small Cell Lung Cancer.  There is strong preclin. evidence that ALK is a driving force for oncogenesis in these cases, and that inhibition of ALK kinase activity results in anti-tumoral efficacy.  These observations have sparked the development of small mol. kinase inhibitors, the most advanced of which is currently in clin. testing and which has shown promising preliminary activity in the subset of lung cancer patients whose tumors harbor activated ALK.  In this review, we describe the various oncogenic forms of ALK, relevant clin. settings, and give a detailed overview of current drug discovery efforts in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw80IgX8jf7rVg90H21EOLACvtfcHk0livr8jnkcDzhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7vF&md5=9b72a030b1c4e3c90c0e570ce0c48f38</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2010.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2010.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DMenichincheri%26aufirst%3DM.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520specific%2520tumours%252C%2520and%2520development%2520of%2520small%2520molecule%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Lett.%26date%3D2010%26volume%3D299%26spage%3D81%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gerber, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">548</span><span class="NLM_x">–</span> <span class="NLM_lpage">551</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=548-551&author=D.+E.+Gerberauthor=J.+D.+Minna&title=ALK+inhibition+for+non-small+cell+lung+cancer%3A+from+discovery+to+therapy+in+record+time"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DALK%2520inhibition%2520for%2520non-small%2520cell%2520lung%2520cancer%253A%2520from%2520discovery%2520to%2520therapy%2520in%2520record%2520time%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D548%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Goldstraw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jett, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Chvalier, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Non-small-cell lung cancer</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=1727-1740&author=P.+Goldstrawauthor=D.+Ballauthor=J.+R.+Jettauthor=T.+Le+Chvalierauthor=E.+Lumauthor=A.+G.+Nicholsonauthor=F.+A.+Shepherd&title=Non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstraw%26aufirst%3DP.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DJett%26aufirst%3DJ.%2BR.%26aulast%3DLe%2BChvalier%26aufirst%3DT.%26aulast%3DLum%26aufirst%3DE.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DNon-small-cell%2520lung%2520cancer%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D1727%26epage%3D1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neruoblastoma</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=236-249&author=M.+Chengauthor=G.+R.+Ott&title=Anaplastic+lymphoma+kinase+as+a+therapeutic+target+in+anaplastic+large+cell+lymphoma%2C+non-small+cell+lung+cancer+and+neruoblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520anaplastic%2520large%2520cell%2520lymphoma%252C%2520non-small%2520cell%2520lung%2520cancer%2520and%2520neruoblastoma%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D236%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentine&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chiarle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lh-amo84FFv9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rentrop, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+lymphoma+kinase%3A+role+in+cancer+pathogenesis+and+small-molecule+inhibitor+development+for+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0lh-amo84FFv9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520cancer%2520pathogenesis%2520and%2520small-molecule%2520inhibitor%2520development%2520for%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Grande, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arriola, E.</span><span> </span><span class="NLM_article-title">Targeting oncogenic ALK: A promising strategy for cancer treatment</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1535-7163.MCT-10-0615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21474455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=569-571&issue=4&author=E.+Grandeauthor=M.+Bolosauthor=E.+Arriola&title=Targeting+oncogenic+ALK%3A+A+promising+strategy+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment</span></div><div class="casAuthors">Grande, Enrique; Bolos, Maria-Victoria; Arriola, Edurne</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-579</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematol. tumors.  Novel drugs targeting this tyrosine kinase receptor are under development, and early clin. trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors.  Here, we review the structure and function of the ALK receptor, the mechanisms assocd. with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK.  Mol Cancer Ther; 10(4); 569-79.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-I5KwiK8uaLVg90H21EOLACvtfcHk0lh-amo84FFv9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSrtrc%253D&md5=3b008d05e772f4eae0edb83d750afdb4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0615%26sid%3Dliteratum%253Aachs%26aulast%3DGrande%26aufirst%3DE.%26aulast%3DBolos%26aufirst%3DM.%26aulast%3DArriola%26aufirst%3DE.%26atitle%3DTargeting%2520oncogenic%2520ALK%253A%2520A%2520promising%2520strategy%2520for%2520cancer%2520treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D569%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-936&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=M.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DM.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugières, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugi%C3%A8resauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0liRTl9xHrVSaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugi%25C3%25A8res%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=L.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fröhling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provide a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Fr%C3%B6hlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provide+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provide%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Eng, C.</span><span> </span><span class="NLM_article-title">A ringleader identified</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=883-884&author=C.+Eng&title=A+ringleader+identified"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DC.%26atitle%3DA%2520ringleader%2520identified%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D883%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Targeting anaplastic lymphoma kinase in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+anaplastic+lymphoma+kinase+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0liRTl9xHrVSaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mosse, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Inhibition of ALK signaling for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5608</span><span class="NLM_x">–</span> <span class="NLM_lpage">5614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1078-0432.CCR-08-2762" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5608-5614&author=Y.+P.+Mosseauthor=A.+Woodauthor=J.+M.+Maris&title=Inhibition+of+ALK+signaling+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2762%26sid%3Dliteratum%253Aachs%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DInhibition%2520of%2520ALK%2520signaling%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5608%26epage%3D5614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardi Borgia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structures of analplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">–</span> <span class="NLM_lpage">6825</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=M.+Avanziauthor=A.+Lombardi+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+analplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DM.%26aulast%3DLombardi%2BBorgia%26aufirst%3DA.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520analplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambing, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesley, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span> </span><span class="NLM_article-title">Crystal structure of ALK (anaplastic lymphoma kinase) catalytic domain</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">430</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">437</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=425-437&author=C.+C.+Leeauthor=Y.+Jiaauthor=N.+Liauthor=X.+Sunauthor=K.+Ngauthor=E.+Ambingauthor=M.+Gaoauthor=S.+Huaauthor=C.+Chenauthor=S.+Kimauthor=P.+Michellysauthor=S.+A.+Lesleyauthor=J.+L.+Harrisauthor=G.+Spraggon&title=Crystal+structure+of+ALK+%28anaplastic+lymphoma+kinase%29+catalytic+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DAmbing%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%26aulast%3DLesley%26aufirst%3DS.%2BA.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DSpraggon%26aufirst%3DG.%26atitle%3DCrystal%2520structure%2520of%2520ALK%2520%2528anaplastic%2520lymphoma%2520kinase%2529%2520catalytic%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D425%26epage%3D437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+Kungauthor=M.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lh-5ImDua7w4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-703&author=E.+L.+Kwakauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=B.+Solomonauthor=R.+G.+Makiauthor=S.+H.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.+H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0lh-5ImDua7w4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span>Pfizer Press Release, August 29,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Press+Release%2C+August+29%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a potent, selective and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Li&title=Identification+of+NVP-TAE684%2C+a+potent%2C+selective+and+efficacious+inhibitor+of+NPM-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520potent%252C%2520selective%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engleman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Sharespeareauthor=A.+J.+Iafrateauthor=J.+A.+Englemanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DSharespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngleman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deStanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4920</span><span class="NLM_x">–</span> <span class="NLM_lpage">4931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F0008-5472.CAN-10-3879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21613408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4920-4931&author=C.+M.+Lovlyauthor=J.+M.+Heuckmannauthor=E.+deStanchinaauthor=H.+Chenauthor=R.+K.+Thomasauthor=C.+Liangauthor=W.+Pao&title=Insights+into+ALK-driven+cancers+revealed+through+development+of+novel+ALK+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Lovly, Christine M.; Heuckmann, Johannes M.; de Stanchina, Elisa; Chen, Heidi; Thomas, Roman K.; Liang, Chris; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4920-4931</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings.  In this study, we report the identification and biol. characterization of X-376 and X-396, two potent and highly specific ALK small mol. tyrosine kinase inhibitors (TKIs).  In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clin. trials.  Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles.  Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein.  Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations assocd. with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant.  Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin.  Our findings offer preclin. proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.  Cancer Res; 71(14); 4920-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCEJra8njI7Vg90H21EOLACvtfcHk0ljYZZcxbe1xyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D&md5=000cbd1295c9d9fa6a43027f08c31247</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-3879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-3879%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DdeStanchina%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DInsights%2520into%2520ALK-driven%2520cancers%2520revealed%2520through%2520development%2520of%2520novel%2520ALK%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4920%26epage%3D4931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HcHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of anaplastic lymophoma kinase with in vivo antitumor activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+HcHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+potent+inhibitor+of+anaplastic+lymophoma+kinase+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DHcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520anaplastic%2520lymophoma%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Espinal, J.</span><span> </span><span class="NLM_article-title">What is the role of the insulin receptor tyrosine kinase?</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1988&pages=367-368&author=J.+Espinal&title=What+is+the+role+of+the+insulin+receptor+tyrosine+kinase%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEspinal%26aufirst%3DJ.%26atitle%3DWhat%2520is%2520the%2520role%2520of%2520the%2520insulin%2520receptor%2520tyrosine%2520kinase%253F%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1988%26volume%3D13%26spage%3D367%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Saltiel, A. R.</span><span> </span><span class="NLM_article-title">Putting the brakes on insulin signaling</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">2560</span><span class="NLM_x">–</span> <span class="NLM_lpage">2562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1056%2FNEJMcibr031668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=14695419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=2560-2562&author=A.+R.+Saltiel&title=Putting+the+brakes+on+insulin+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Putting the brakes on insulin signaling</span></div><div class="casAuthors">Saltiel, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2560-2562</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkiC1YdrMCvbVg90H21EOLACvtfcHk0lgaQyHW1CtpVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtrjL&md5=c9e6b3470550cd6a9eaafa6395c3498c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMcibr031668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcibr031668%26sid%3Dliteratum%253Aachs%26aulast%3DSaltiel%26aufirst%3DA.%2BR.%26atitle%3DPutting%2520the%2520brakes%2520on%2520insulin%2520signaling%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D2560%26epage%3D2562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becknell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holskin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1617</span><span class="NLM_x">–</span> <span class="NLM_lpage">1623</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=1617-1623&author=W.+Wanauthor=M.+S.+Albomauthor=L.+Luauthor=M.+R.+Quailauthor=N.+C.+Becknellauthor=L.+R.+Weinbergauthor=D.+R.+Reddyauthor=B.+P.+Holskinauthor=T.+S.+Angelesauthor=T.+L.+Underinerauthor=S.+L.+Meyerauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=M.+Cheng&title=Anaplastic+lymphoma+kinase+activity+is+essential+for+the+proliferation+and+survival+of+anaplastic+large-cell+lymphoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DBecknell%26aufirst%3DN.%2BC.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DHolskin%26aufirst%3DB.%2BP.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520activity%2520is%2520essential%2520for%2520the%2520proliferation%2520and%2520survival%2520of%2520anaplastic%2520large-cell%2520lymphoma%2520cells%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D1617%26epage%3D1623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="note"><p class="first last">There were 39 such structures with kinases like aurora kinase (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNZ">3UNZ</a>), ALK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>), insulin receptor (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKN">3EKN</a>), JNK1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ELJ">3ELJ</a>), FAK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK">2JKK</a>), ERk2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z7L">2Z7L</a>), CDK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1H01">1H01</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-<i>f</i>][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6328</span><span class="NLM_x">–</span> <span class="NLM_lpage">6341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&issue=18&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+new+variant+of+an+old+template+and+application+to+the+discovery+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520new%2520variant%2520of%2520an%2520old%2520template%2520and%2520application%2520to%2520the%2520discovery%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D18%26spage%3D6328%26epage%3D6341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span>Selectivity value for 90% inhibition from single point data: <i>S</i>(90) = (no. of kinases ≥ 90% inhibition)/(total no. of kinases tested).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Selectivity+value+for+90%25+inhibition+from+single+point+data%3A+S%2890%29+%3D+%28no.+of+kinases+%E2%89%A5+90%25+inhibition%29%2F%28total+no.+of+kinases+tested%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machiorlatti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">–</span> <span class="NLM_lpage">679</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+highly+potent+and+selective+orally+active+inhibitor+of+anaplastic+lymphoma+kinase+with+antitumor+activity+in+experimental+models+of+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0liMFCpdfE5eGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520highly%2520potent%2520and%2520selective%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520antitumor%2520activity%2520in%2520experimental%2520models%2520of%2520human%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, N.</span><span> </span><span class="NLM_article-title">New driver mutations in non-small cell lung cancer.</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=175-180&author=W.+Paoauthor=N.+Girard&title=New+driver+mutations+in+non-small+cell+lung+cancer."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGirard%26aufirst%3DN.%26atitle%3DNew%2520driver%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer.%26jtitle%3DLancet%26date%3D2011%26volume%3D12%26spage%3D175%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Kraus, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, P. K.</span><span> </span><span class="NLM_article-title">Synthesis of purquinonic acid ethyl ester and deliquinone via a common intermediate</span> <span class="citation_source-journal">J. Org. Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5857</span><span class="NLM_x">–</span> <span class="NLM_lpage">5859</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo020029g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=5857-5859&author=G.+A.+Krausauthor=P.+K.+Choudhury&title=Synthesis+of+purquinonic+acid+ethyl+ester+and+deliquinone+via+a+common+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjo020029g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo020029g%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DChoudhury%26aufirst%3DP.%2BK.%26atitle%3DSynthesis%2520of%2520purquinonic%2520acid%2520ethyl%2520ester%2520and%2520deliquinone%2520via%2520a%2520common%2520intermediate%26jtitle%3DJ.%2520Org.%2520Chem%26date%3D2002%26volume%3D67%26spage%3D5857%26epage%3D5859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Yoshii, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoshi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, H.</span><span> </span><span class="NLM_article-title">Conformational analysis and selection of odor-active conformers: synthesis of molecules for the lily-of-the-vally (muguet)-type odor</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2001&pages=2051-2063&author=F.+Yoshiiauthor=T.+Nakamuraauthor=S.+Hironoauthor=Y.+Shimizuauthor=T.+Hoshiauthor=M.+Andoauthor=H.+Hagiwara&title=Conformational+analysis+and+selection+of+odor-active+conformers%3A+synthesis+of+molecules+for+the+lily-of-the-vally+%28muguet%29-type+odor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshii%26aufirst%3DF.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DHoshi%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DHagiwara%26aufirst%3DH.%26atitle%3DConformational%2520analysis%2520and%2520selection%2520of%2520odor-active%2520conformers%253A%2520synthesis%2520of%2520molecules%2520for%2520the%2520lily-of-the-vally%2520%2528muguet%2529-type%2520odor%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2001%26volume%3D84%26spage%3D2051%26epage%3D2063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Goldberg, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bensimon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alper, H.</span><span> </span><span class="NLM_article-title">Highly regioselective bromination of 2,3-dimethylanisole with <i>N</i>-bromosuccinimide</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6374</span><span class="NLM_x">–</span> <span class="NLM_lpage">6376</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00049a067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=6374-6376&author=Y.+Goldbergauthor=C.+Bensimonauthor=H.+Alper&title=Highly+regioselective+bromination+of+2%2C3-dimethylanisole+with+N-bromosuccinimide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjo00049a067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00049a067%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DY.%26aulast%3DBensimon%26aufirst%3DC.%26aulast%3DAlper%26aufirst%3DH.%26atitle%3DHighly%2520regioselective%2520bromination%2520of%25202%252C3-dimethylanisole%2520with%2520N-bromosuccinimide%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D6374%26epage%3D6376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Tolbert, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haubrich, J. E.</span><span> </span><span class="NLM_article-title">Photoexcited proton transfer from enhanced photoacids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">10593</span><span class="NLM_x">–</span> <span class="NLM_lpage">10600</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00102a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=10593-10600&author=L.+M.+Tolbertauthor=J.+E.+Haubrich&title=Photoexcited+proton+transfer+from+enhanced+photoacids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja00102a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00102a028%26sid%3Dliteratum%253Aachs%26aulast%3DTolbert%26aufirst%3DL.%2BM.%26aulast%3DHaubrich%26aufirst%3DJ.%2BE.%26atitle%3DPhotoexcited%2520proton%2520transfer%2520from%2520enhanced%2520photoacids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D10593%26epage%3D10600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C. A.</span><span> </span><span class="NLM_article-title">Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1996&pages=49-55&author=T.+S.+Angelesauthor=C.+Stefflerauthor=B.+A.+Bartlettauthor=R.+L.+Hudkinsauthor=R.+M.+Stephensauthor=D.+R.+Kaplanauthor=C.+A.+Dionne&title=Enzyme-linked+immunosorbent+assay+for+trkA+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DSteffler%26aufirst%3DC.%26aulast%3DBartlett%26aufirst%3DB.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26atitle%3DEnzyme-linked%2520immunosorbent%2520assay%2520for%2520trkA%2520tyrosine%2520kinase%2520activity%26jtitle%3DAnal.%2520Biochem.%26date%3D1996%26volume%3D236%26spage%3D49%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Rotin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phopholipase Cγ</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1992&pages=559-567&author=D.+Rotinauthor=B.+Margolisauthor=M.+Mohammadiauthor=R.+J.+Dalyauthor=G.+Daumauthor=N.+Liauthor=E.+H.+Fischerauthor=W.+H.+Burgessauthor=A.+Ullrichauthor=J.+Schlessinger&title=SH2+domains+prevent+tyrosine+dephosphorylation+of+the+EGF+receptor%3A+identification+of+Tyr992+as+the+high-affinity+binding+site+for+SH2+domains+of+phopholipase+C%CE%B3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRotin%26aufirst%3DD.%26aulast%3DMargolis%26aufirst%3DB.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DDaum%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DFischer%26aufirst%3DE.%2BH.%26aulast%3DBurgess%26aufirst%3DW.%2BH.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DSH2%2520domains%2520prevent%2520tyrosine%2520dephosphorylation%2520of%2520the%2520EGF%2520receptor%253A%2520identification%2520of%2520Tyr992%2520as%2520the%2520high-affinity%2520binding%2520site%2520for%2520SH2%2520domains%2520of%2520phopholipase%2520C%25CE%25B3%26jtitle%3DEMBO%2520J.%26date%3D1992%26volume%3D11%26spage%3D559%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and national inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+national+inhibitor+design+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520national%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5a','cit5b','cit5c'],'ref6':['cit6'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9a','cit9b','cit9c','cit9d','cit9e'],'ref10':['cit10a','cit10b'],'ref11':['cit11a','cit11b'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16a','cit16b','cit16c'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':[],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref100':['cit100'],'ref101':['cit101'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 25 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Muhammad Faisal, Jae Ho Kim, Kyung Ho Yoo, Eun Joo Roh, Soon Sun Hong, <span class="NLM_string-name hlFld-ContribAuthor">So Ha Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Development and Therapeutic Potential of NUAKs Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 2-25. <a href="https://doi.org/10.1021/acs.jmedchem.0c00533" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00533</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00533%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252BTherapeutic%252BPotential%252Bof%252BNUAKs%252BInhibitors%26aulast%3DFaisal%26aufirst%3DMuhammad%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D01042020%26date%3D24122020%26volume%3D64%26issue%3D1%26spage%3D2%26epage%3D25" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ying Xia, Shusuke Ochi, <span class="NLM_string-name hlFld-ContribAuthor">Guangbin Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Two-Carbon Ring Expansion of 1-Indanones via Insertion of Ethylene into Carbon–Carbon Bonds. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2019,</strong> <em>141 </em>
                                    (33)
                                     , 13038-13042. <a href="https://doi.org/10.1021/jacs.9b07445" title="DOI URL">https://doi.org/10.1021/jacs.9b07445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b07445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b07445%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DTwo-Carbon%252BRing%252BExpansion%252Bof%252B1-Indanones%252Bvia%252BInsertion%252Bof%252BEthylene%252Binto%252BCarbon%2525E2%252580%252593Carbon%252BBonds%26aulast%3DXia%26aufirst%3DYing%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D12072019%26date%3D08082019%26date%3D07082019%26volume%3D141%26issue%3D33%26spage%3D13038%26epage%3D13042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kaori  Fujii</span>, <span class="hlFld-ContribAuthor ">Yoshiro  Yasaka</span>, <span class="hlFld-ContribAuthor ">Masakatsu  Ueno</span>, <span class="hlFld-ContribAuthor ">Yoshinari  Koyanagi</span>, <span class="hlFld-ContribAuthor ">Sora  Kasuga</span>, <span class="hlFld-ContribAuthor ">Yoshihiro  Matano</span>, and <span class="hlFld-ContribAuthor ">Yoshifumi  Kimura</span>  . </span><span class="cited-content_cbyCitation_article-title">Excited-State Proton Transfer of Cyanonaphthols in Protic Ionic Liquids: Appearance of a New Fluorescent Species. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Physical Chemistry B</span><span> <strong>2017,</strong> <em>121 </em>
                                    (24)
                                     , 6042-6049. <a href="https://doi.org/10.1021/acs.jpcb.7b03658" title="DOI URL">https://doi.org/10.1021/acs.jpcb.7b03658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jpcb.7b03658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jpcb.7b03658%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Physical%2520Chemistry%2520B%26atitle%3DExcited-State%252BProton%252BTransfer%252Bof%252BCyanonaphthols%252Bin%252BProtic%252BIonic%252BLiquids%25253A%252BAppearance%252Bof%252Ba%252BNew%252BFluorescent%252BSpecies%26aulast%3DFujii%26aufirst%3DKaori%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D18042017%26date%3D21052017%26date%3D08062017%26date%3D22062017%26volume%3D121%26issue%3D24%26spage%3D6042%26epage%3D6049" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregory R.  Ott</span>, <span class="hlFld-ContribAuthor ">Mangeng  Cheng</span>, <span class="hlFld-ContribAuthor ">Keith S.  Learn</span>, <span class="hlFld-ContribAuthor ">Jason  Wagner</span>, <span class="hlFld-ContribAuthor ">Diane E.  Gingrich</span>, <span class="hlFld-ContribAuthor ">Joseph G.  Lisko</span>, <span class="hlFld-ContribAuthor ">Matthew  Curry</span>, <span class="hlFld-ContribAuthor ">Eugen F.  Mesaros</span>, <span class="hlFld-ContribAuthor ">Arup K.  Ghose</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Quail</span>, <span class="hlFld-ContribAuthor ">Weihua  Wan</span>, <span class="hlFld-ContribAuthor ">Lihui  Lu</span>, <span class="hlFld-ContribAuthor ">Pawel  Dobrzanski</span>, <span class="hlFld-ContribAuthor ">Mark S.  Albom</span>, <span class="hlFld-ContribAuthor ">Thelma S.  Angeles</span>, <span class="hlFld-ContribAuthor ">Kevin  Wells-Knecht</span>, <span class="hlFld-ContribAuthor ">Zeqi  Huang</span>, <span class="hlFld-ContribAuthor ">Lisa D.  Aimone</span>, <span class="hlFld-ContribAuthor ">Elizabeth  Bruckheimer</span>, <span class="hlFld-ContribAuthor ">Nathan  Anderson</span>, <span class="hlFld-ContribAuthor ">Jay  Friedman</span>, <span class="hlFld-ContribAuthor ">Sandra V.  Fernandez</span>, <span class="hlFld-ContribAuthor ">Mark A.  Ator</span>, <span class="hlFld-ContribAuthor ">Bruce A.  Ruggeri</span>, and <span class="hlFld-ContribAuthor ">Bruce D.  Dorsey</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (16)
                                     , 7478-7496. <a href="https://doi.org/10.1021/acs.jmedchem.6b00487" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00487</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00487%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BClinical%252BCandidate%252BCEP-37440%25252C%252Ba%252BSelective%252BInhibitor%252Bof%252BFocal%252BAdhesion%252BKinase%252B%252528FAK%252529%252Band%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DOtt%26aufirst%3DGregory%2BR.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D01042016%26date%3D15082016%26date%3D25082016%26volume%3D59%26issue%3D16%26spage%3D7478%26epage%3D7496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhiqing  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Zilan  Song</span>, <span class="hlFld-ContribAuthor ">Kui  Wu</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Qizheng  Yao</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Yanhong  Yang</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, and <span class="hlFld-ContribAuthor ">Ao  Zhang</span>  . </span><span class="cited-content_cbyCitation_article-title">Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2014,</strong> <em>5 </em>
                                    (4)
                                     , 304-308. <a href="https://doi.org/10.1021/ml400373j" title="DOI URL">https://doi.org/10.1021/ml400373j</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml400373j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml400373j%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252B2%25252C4-Diarylaminopyrimidine%252BAnalogues%252B%252528DAAPalogues%252529%252BShowing%252BPotent%252Bc-Met%25252FALK%252BMultikinase%252BInhibitory%252BActivities%26aulast%3DLiu%26aufirst%3DZhiqing%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D2013%26date%3D18092013%26date%3D08022014%26date%3D11022014%26date%3D10042014%26date%3D08022014%26volume%3D5%26issue%3D4%26spage%3D304%26epage%3D308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bryan K.  Chan</span>, <span class="hlFld-ContribAuthor ">Anthony A.  Estrada</span>, <span class="hlFld-ContribAuthor ">Huifen  Chen</span>, <span class="hlFld-ContribAuthor ">John  Atherall</span>, <span class="hlFld-ContribAuthor ">Charles  Baker-Glenn</span>, <span class="hlFld-ContribAuthor ">Alan  Beresford</span>, <span class="hlFld-ContribAuthor ">Daniel J.  Burdick</span>, <span class="hlFld-ContribAuthor ">Mark  Chambers</span>, <span class="hlFld-ContribAuthor ">Sara L.  Dominguez</span>, <span class="hlFld-ContribAuthor ">Jason  Drummond</span>, <span class="hlFld-ContribAuthor ">Andrew  Gill</span>, <span class="hlFld-ContribAuthor ">Tracy  Kleinheinz</span>, <span class="hlFld-ContribAuthor ">Claire E.  Le Pichon</span>, <span class="hlFld-ContribAuthor ">Andrew D.  Medhurst</span>, <span class="hlFld-ContribAuthor ">Xingrong  Liu</span>, <span class="hlFld-ContribAuthor ">John G.  Moffat</span>, <span class="hlFld-ContribAuthor ">Kevin  Nash</span>, <span class="hlFld-ContribAuthor ">Kimberly  Scearce-Levie</span>, <span class="hlFld-ContribAuthor ">Zejuan  Sheng</span>, <span class="hlFld-ContribAuthor ">Daniel G.  Shore</span>, <span class="hlFld-ContribAuthor ">Hervé  Van de Poël</span>, <span class="hlFld-ContribAuthor ">Shuo  Zhang</span>, <span class="hlFld-ContribAuthor ">Haitao  Zhu</span>, and <span class="hlFld-ContribAuthor ">Zachary K.  Sweeney</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>4 </em>
                                    (1)
                                     , 85-90. <a href="https://doi.org/10.1021/ml3003007" title="DOI URL">https://doi.org/10.1021/ml3003007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml3003007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml3003007%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BHighly%252BSelective%25252C%252BBrain-Penetrant%252BAminopyrazole%252BLRRK2%252BInhibitor%26aulast%3DChan%26aufirst%3DBryan%2BK.%26date%3D2013%26date%3D2012%26date%3D2012%26date%3D2012%26date%3D24092012%26date%3D23112012%26date%3D29112012%26date%3D10012013%26date%3D23112012%26volume%3D4%26issue%3D1%26spage%3D85%26epage%3D90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrej  Jancarik</span>, <span class="hlFld-ContribAuthor ">Nguyen  Khanh Hung</span>, <span class="hlFld-ContribAuthor ">Dmitry  Skidin</span>, <span class="hlFld-ContribAuthor ">Francesca  Moresco</span>, <span class="hlFld-ContribAuthor ">Andre  Gourdon</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation of Tetrabenzo[4.4.2]undecastarphene by On‐Surface Synthesis. </span><span class="cited-content_cbyCitation_journal-name">ChemPlusChem</span><span> <strong>2021,</strong> <em>86 </em>
                                    (7)
                                     , 991-996. <a href="https://doi.org/10.1002/cplu.202100112" title="DOI URL">https://doi.org/10.1002/cplu.202100112</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cplu.202100112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcplu.202100112%26sid%3Dliteratum%253Aachs%26jtitle%3DChemPlusChem%26atitle%3DPreparation%252Bof%252BTetrabenzo%25255B4.4.2%25255Dundecastarphene%252Bby%252BOn%2525E2%252580%252590Surface%252BSynthesis%26aulast%3DJancarik%26aufirst%3DAndrej%26date%3D2021%26date%3D2021%26volume%3D86%26issue%3D7%26spage%3D991%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ying  Xia</span>, <span class="hlFld-ContribAuthor ">Guangbin  Dong</span>. </span><span class="cited-content_cbyCitation_article-title">Temporary or removable directing groups enable activation of unstrained C–C bonds. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Chemistry</span><span> <strong>2020,</strong> <em>4 </em>
                                    (11)
                                     , 600-614. <a href="https://doi.org/10.1038/s41570-020-0218-8" title="DOI URL">https://doi.org/10.1038/s41570-020-0218-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41570-020-0218-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41570-020-0218-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Chemistry%26atitle%3DTemporary%252Bor%252Bremovable%252Bdirecting%252Bgroups%252Benable%252Bactivation%252Bof%252Bunstrained%252BC%2525E2%252580%252593C%252Bbonds%26aulast%3DXia%26aufirst%3DYing%26date%3D2020%26date%3D2020%26volume%3D4%26issue%3D11%26spage%3D600%26epage%3D614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simone  Thum</span>, <span class="hlFld-ContribAuthor ">Dirk  Schepmann</span>, <span class="hlFld-ContribAuthor ">Raquel F.  Reinoso</span>, <span class="hlFld-ContribAuthor ">Inés  Alvarez</span>, <span class="hlFld-ContribAuthor ">Simon M.  Ametamey</span>, <span class="hlFld-ContribAuthor ">Bernhard  Wünsch</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and pharmacological evaluation of fluorinated benzo[7]annulen-7-amines as GluN2B-selective NMDA receptor antagonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Labelled Compounds and Radiopharmaceuticals</span><span> <strong>2019,</strong> <em>62 </em>
                                    (8)
                                     , 354-379. <a href="https://doi.org/10.1002/jlcr.3718" title="DOI URL">https://doi.org/10.1002/jlcr.3718</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jlcr.3718&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjlcr.3718%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Labelled%2520Compounds%2520and%2520Radiopharmaceuticals%26atitle%3DSynthesis%252Band%252Bpharmacological%252Bevaluation%252Bof%252Bfluorinated%252Bbenzo%25255B7%25255Dannulen-7-amines%252Bas%252BGluN2B-selective%252BNMDA%252Breceptor%252Bantagonists%26aulast%3DThum%26aufirst%3DSimone%26date%3D2019%26date%3D2019%26volume%3D62%26issue%3D8%26spage%3D354%26epage%3D379" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ming  Guo</span>, <span class="hlFld-ContribAuthor ">Daiying  Zuo</span>, <span class="hlFld-ContribAuthor ">Junlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Lingyun  Xing</span>, <span class="hlFld-ContribAuthor ">Wenfeng  Gou</span>, <span class="hlFld-ContribAuthor ">Feng  Jiang</span>, <span class="hlFld-ContribAuthor ">Nan  Jiang</span>, <span class="hlFld-ContribAuthor ">Dajun  Zhang</span>, <span class="hlFld-ContribAuthor ">Xin  Zhai</span>. </span><span class="cited-content_cbyCitation_article-title">Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>158 </em>, 322-333. <a href="https://doi.org/10.1016/j.ejmech.2018.09.012" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.09.012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.09.012%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDual%252Bpotent%252BALK%252Band%252BROS1%252Binhibitors%252Bcombating%252Bdrug-resistant%252Bmutants%25253A%252BSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Baminopyridine-containing%252Bdiarylaminopyrimidine%252Bderivatives%26aulast%3DGuo%26aufirst%3DMing%26date%3D2018%26volume%3D158%26spage%3D322%26epage%3D333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">2-Aminopyrimidines. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 237-283. <a href="https://doi.org/10.1002/9781118686263.ch7" title="DOI URL">https://doi.org/10.1002/9781118686263.ch7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118686263.ch7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118686263.ch7%26sid%3Dliteratum%253Aachs%26atitle%3D2-Aminopyrimidines%26date%3D2018%26date%3D2018%26spage%3D237%26epage%3D283%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DPrivileged%252BStructures%252Bin%252BDrug%252BDiscovery%26aulast%3DYet%26aufirst%3DLarry%26date%3D2018%26volume%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Zaman  Ashraf</span>, <span class="hlFld-ContribAuthor ">Sulman  Basit</span>, <span class="hlFld-ContribAuthor ">Abdul  Ghaffar</span>, <span class="hlFld-ContribAuthor ">Muhammad Sohail  Zafar</span>, <span class="hlFld-ContribAuthor ">Aamer  Saeed</span>, <span class="hlFld-ContribAuthor ">Sultan Ayoub  Meo</span>. </span><span class="cited-content_cbyCitation_article-title">Latest perspectives of orally bioavailable 2,4-diarylaminopyrimidine analogues (DAAPalogues) as anaplastic lymphoma kinase inhibitors: discovery and clinical developments. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2018,</strong> <em>8 </em>
                                    (30)
                                     , 16470-16493. <a href="https://doi.org/10.1039/C8RA01934G" title="DOI URL">https://doi.org/10.1039/C8RA01934G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8RA01934G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8RA01934G%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DLatest%252Bperspectives%252Bof%252Borally%252Bbioavailable%252B2%25252C4-diarylaminopyrimidine%252Banalogues%252B%252528DAAPalogues%252529%252Bas%252Banaplastic%252Blymphoma%252Bkinase%252Binhibitors%25253A%252Bdiscovery%252Band%252Bclinical%252Bdevelopments%26aulast%3DLatif%26aufirst%3DMuhammad%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D30%26spage%3D16470%26epage%3D16493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Hatcher</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors of ALK. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 435-467. <a href="https://doi.org/10.1007/7355_2017_18" title="DOI URL">https://doi.org/10.1007/7355_2017_18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2017_18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2017_18%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecule%252BInhibitors%252Bof%252BALK%26aulast%3DHatcher%26aufirst%3DJohn%2BM.%26date%3D2017%26spage%3D435%26epage%3D467%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Zandvliet</span>. </span><span class="cited-content_cbyCitation_article-title">Canine lymphoma: a review. </span><span class="cited-content_cbyCitation_journal-name">Veterinary Quarterly</span><span> <strong>2016,</strong> <em>36 </em>
                                    (2)
                                     , 76-104. <a href="https://doi.org/10.1080/01652176.2016.1152633" title="DOI URL">https://doi.org/10.1080/01652176.2016.1152633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/01652176.2016.1152633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F01652176.2016.1152633%26sid%3Dliteratum%253Aachs%26jtitle%3DVeterinary%2520Quarterly%26atitle%3DCanine%252Blymphoma%25253A%252Ba%252Breview%26aulast%3DZandvliet%26aufirst%3DM.%26date%3D2016%26date%3D2016%26volume%3D36%26issue%3D2%26spage%3D76%26epage%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dawn  Song</span>, <span class="hlFld-ContribAuthor ">Minji  Lee</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Sunjoo  Ahn</span>, <span class="hlFld-ContribAuthor ">Chang Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>26 </em>
                                    (7)
                                     , 1720-1725. <a href="https://doi.org/10.1016/j.bmcl.2016.02.052" title="DOI URL">https://doi.org/10.1016/j.bmcl.2016.02.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2016.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2016.02.052%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252B2%25252C4-diaminopyrimidines%252Bbearing%252Btetrahydronaphthalenyl%252Bmoiety%252Bagainst%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%25253A%252BSynthesis%25252C%252Bin%252Bvitro%25252C%252Bex%252Bvivo%25252C%252Band%252Bin%252Bvivo%252Befficacy%252Bstudies%26aulast%3DSong%26aufirst%3DDawn%26date%3D2016%26volume%3D26%26issue%3D7%26spage%3D1720%26epage%3D1725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ga Ae  Kang</span>, <span class="hlFld-ContribAuthor ">Minji  Lee</span>, <span class="hlFld-ContribAuthor ">Dawn  Song</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Sunjoo  Ahn</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Chang Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Heejung  Jung</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>25 </em>
                                    (18)
                                     , 3992-3998. <a href="https://doi.org/10.1016/j.bmcl.2015.07.004" title="DOI URL">https://doi.org/10.1016/j.bmcl.2015.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2015.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2015.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-diaminopyrimidines%252Bbearing%252Bbicyclic%252Baminobenzazepines%252Bfor%252Banaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitor%26aulast%3DKang%26aufirst%3DGa%2BAe%26date%3D2015%26volume%3D25%26issue%3D18%26spage%3D3992%26epage%3D3998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hyeon Ji  Lee</span>, <span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Hyeonjeong  Choe</span>, <span class="hlFld-ContribAuthor ">Imran  Ali</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Eun Hye  Yang</span>, <span class="hlFld-ContribAuthor ">Jeong In  Yun</span>, <span class="hlFld-ContribAuthor ">Chong Hak  Chae</span>, <span class="hlFld-ContribAuthor ">Jae-Kyung  Jung</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">ALK inhibitors of bis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines and -triazines for cancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2014,</strong> <em>37 </em>
                                    (9)
                                     , 1130-1138. <a href="https://doi.org/10.1007/s12272-013-0323-z" title="DOI URL">https://doi.org/10.1007/s12272-013-0323-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-013-0323-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-013-0323-z%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DALK%252Binhibitors%252Bof%252Bbis-ortho-alkoxy-para-piperazinesubstituted-pyrimidines%252Band%252B-triazines%252Bfor%252Bcancer%252Btreatment%26aulast%3DLee%26aufirst%3DHyeon%2BJi%26date%3D2014%26date%3D2014%26volume%3D37%26issue%3D9%26spage%3D1130%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wei-Feng  Ma</span>, <span class="hlFld-ContribAuthor ">Hai-Kui  Yang</span>, <span class="hlFld-ContribAuthor ">Meng-Jin  Hu</span>, <span class="hlFld-ContribAuthor ">Qian  Li</span>, <span class="hlFld-ContribAuthor ">Tian-Zhu  Ma</span>, <span class="hlFld-ContribAuthor ">Zhong-Zhen  Zhou</span>, <span class="hlFld-ContribAuthor ">Rui-Yuan  Liu</span>, <span class="hlFld-ContribAuthor ">Wen-Wei  You</span>, <span class="hlFld-ContribAuthor ">Pei-Liang  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot synthesis and antiproliferative activity of novel 2,4-diaminopyrimidine derivatives bearing piperidine and piperazine moieties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>84 </em>, 127-134. <a href="https://doi.org/10.1016/j.ejmech.2014.07.017" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.07.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.07.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.07.017%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DOne-pot%252Bsynthesis%252Band%252Bantiproliferative%252Bactivity%252Bof%252Bnovel%252B2%25252C4-diaminopyrimidine%252Bderivatives%252Bbearing%252Bpiperidine%252Band%252Bpiperazine%252Bmoieties%26aulast%3DMa%26aufirst%3DWei-Feng%26date%3D2014%26volume%3D84%26spage%3D127%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jeong In  Yun</span>, <span class="hlFld-ContribAuthor ">Eun Hye  Yang</span>, <span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Hyeon Ji  Lee</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>, <span class="hlFld-ContribAuthor ">Chang-Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Chong Hak  Chae</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Hee Jung  Jung</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>, <span class="hlFld-ContribAuthor ">Sang Un  Choi</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Novel 2,4-dianilino-5-fluoropyrimidine derivatives possessing ALK inhibitory activities. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2014,</strong> <em>37 </em>
                                    (7)
                                     , 873-881. <a href="https://doi.org/10.1007/s12272-013-0247-7" title="DOI URL">https://doi.org/10.1007/s12272-013-0247-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-013-0247-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-013-0247-7%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DNovel%252B2%25252C4-dianilino-5-fluoropyrimidine%252Bderivatives%252Bpossessing%252BALK%252Binhibitory%252Bactivities%26aulast%3DYun%26aufirst%3DJeong%2BIn%26date%3D2014%26date%3D2013%26volume%3D37%26issue%3D7%26spage%3D873%26epage%3D881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugen F  Mesaros</span>, <span class="hlFld-ContribAuthor ">Gregory R  Ott</span>, <span class="hlFld-ContribAuthor ">Bruce D  Dorsey</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2014,</strong> <em>24 </em>
                                    (4)
                                     , 417-442. <a href="https://doi.org/10.1517/13543776.2014.877890" title="DOI URL">https://doi.org/10.1517/13543776.2014.877890</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1517/13543776.2014.877890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1517%2F13543776.2014.877890%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAnaplastic%252Blymphoma%252Bkinase%252Binhibitors%252Bas%252Banticancer%252Btherapeutics%25253A%252Ba%252Bpatent%252Breview%26aulast%3DMesaros%26aufirst%3DEugen%2BF%26date%3D2014%26date%3D2014%26volume%3D24%26issue%3D4%26spage%3D417%26epage%3D442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen-Chieh  Wang</span>, <span class="hlFld-ContribAuthor ">Hui-Yi  Shiao</span>, <span class="hlFld-ContribAuthor ">Chieh-Chien  Lee</span>, <span class="hlFld-ContribAuthor ">Ka-Shu  Fung</span>, <span class="hlFld-ContribAuthor ">Hsing-Pang  Hsieh</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. </span><span class="cited-content_cbyCitation_journal-name">Med. Chem. Commun.</span><span> <strong>2014,</strong> <em>5 </em>
                                    (9)
                                     , 1266-1279. <a href="https://doi.org/10.1039/C4MD00048J" title="DOI URL">https://doi.org/10.1039/C4MD00048J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C4MD00048J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC4MD00048J%26sid%3Dliteratum%253Aachs%26jtitle%3DMed.%2520Chem.%2520Commun.%26atitle%3DAnaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%252Binhibitors%25253A%252Ba%252Breview%252Bof%252Bdesign%252Band%252Bdiscovery%26aulast%3DWang%26aufirst%3DWen-Chieh%26date%3D2014%26date%3D2014%26volume%3D5%26issue%3D9%26spage%3D1266%26epage%3D1279" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chi Hoon  Park</span>, <span class="hlFld-ContribAuthor ">Hyeonjeong  Choe</span>, <span class="hlFld-ContribAuthor ">In-Young  Jang</span>, <span class="hlFld-ContribAuthor ">So Yeong  Kwon</span>, <span class="hlFld-ContribAuthor ">Muhammad  Latif</span>, <span class="hlFld-ContribAuthor ">Heung Kyoung  Lee</span>, <span class="hlFld-ContribAuthor ">Hyeon Ji  Lee</span>, <span class="hlFld-ContribAuthor ">Eun Hye  Yang</span>, <span class="hlFld-ContribAuthor ">Jeong In  Yun</span>, <span class="hlFld-ContribAuthor ">Chong Hak  Chae</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>, <span class="hlFld-ContribAuthor ">Sang Un  Choi</span>, <span class="hlFld-ContribAuthor ">Jae Du  Ha</span>, <span class="hlFld-ContribAuthor ">Heejung  Jung</span>, <span class="hlFld-ContribAuthor ">Hyoung Rae  Kim</span>, <span class="hlFld-ContribAuthor ">Pilho  Kim</span>, <span class="hlFld-ContribAuthor ">Chong Ock  Lee</span>, <span class="hlFld-ContribAuthor ">Chang-Soo  Yun</span>, <span class="hlFld-ContribAuthor ">Kwangho  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (22)
                                     , 6192-6196. <a href="https://doi.org/10.1016/j.bmcl.2013.08.090" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.08.090</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.08.090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.08.090%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DNovel%252Bbis-ortho-alkoxy-para-piperazinesubstituted-2%25252C4-dianilinopyrimidines%252B%252528KRCA-0008%252529%252Bas%252Bpotent%252Band%252Bselective%252BALK%252Binhibitors%252Bfor%252Banticancer%252Btreatment%26aulast%3DPark%26aufirst%3DChi%2BHoon%26date%3D2013%26volume%3D23%26issue%3D22%26spage%3D6192%26epage%3D6196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Catherine  Lai</span>, <span class="hlFld-ContribAuthor ">Kieron  Dunleavy</span>. </span><span class="cited-content_cbyCitation_article-title">NK/T-cell lymphomas in children. </span><span class="cited-content_cbyCitation_journal-name">Best Practice & Research Clinical Haematology</span><span> <strong>2013,</strong> <em>26 </em>
                                    (1)
                                     , 33-41. <a href="https://doi.org/10.1016/j.beha.2013.04.004" title="DOI URL">https://doi.org/10.1016/j.beha.2013.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.beha.2013.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.beha.2013.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBest%2520Practice%2520%2526%2520Research%2520Clinical%2520Haematology%26atitle%3DNK%25252FT-cell%252Blymphomas%252Bin%252Bchildren%26aulast%3DLai%26aufirst%3DCatherine%26date%3D2013%26volume%3D26%26issue%3D1%26spage%3D33%26epage%3D41" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2013,</strong> <em>68 </em>
                                    (1)
                                     , 68-94. <a href="https://doi.org/10.1016/j.phrs.2012.11.007" title="DOI URL">https://doi.org/10.1016/j.phrs.2012.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2012.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2012.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DAnaplastic%252Blymphoma%252Bkinase%252B%252528ALK%252529%25253A%252BStructure%25252C%252Boncogenic%252Bactivation%25252C%252Band%252Bpharmacological%252Binhibition%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2013%26volume%3D68%26issue%3D1%26spage%3D68%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0008.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Small molecule ALK inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0009.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Optimization strategy and areas of modification on the diaminopyrimidine core.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of 7-Aminosubstituted 1-Methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) NBS [2 equiv (X = H); 3 equiv (X = Br)], AIBN, CCl<sub>4</sub>, 80–99%; (b) (i) 3-oxopentanedioic acid diethyl ester, 0.6 M sodium bicarbonate, tetra-<i>n</i>-butylammonium iodide, methylene chloride, 24 h; (ii) 1 M KOH, EtOH, reflux 3 h; 33% over two steps; (c) KNO<sub>3</sub>, (CF<sub>3</sub>CO)<sub>2</sub>O, CH<sub>3</sub>CN, 53% (d) NaBH(OAc)<sub>3</sub>, amine, acetic acid, CH<sub>2</sub>Cl<sub>2</sub>, 44–70%; (e) H<sub>2</sub>, Pd/C wet, ethanol, 93%.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of 7-Aminosubstituted 3-Methoxy-6,7,8,9-tetrahydro-5<i>H</i>-benzocycloheptene Amine Fragments<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (i) LiAlH<sub>4</sub>, THF, 0 °C, 65–97%; (ii) PBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 62–94%; (b) (i) 3-oxopentanedioic acid diethyl ester, 0.6 M sodium bicarbonate, tetra-<i>n</i>-butylammonium iodide, CH<sub>2</sub>Cl<sub>2</sub>, 24 h; (ii) 1 M KOH, EtOH, reflux 3 h, 50% over two steps (c) KNO<sub>3</sub>, CH<sub>3</sub>CN, 53–83%; (d) NaBH(OAc)<sub>3</sub>, amine, acetic acid, CH<sub>2</sub>Cl<sub>2</sub>, 65–90%; (e) H<sub>2</sub>, Pd/C wet, ethanol, 85–95%.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. A- and C-Ring Coupling Sequence<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) K<sub>2</sub>CO<sub>3</sub>, (1<i>S</i>,2<i>S</i>,3<i>R</i>,4<i>R</i>)-3-aminobicyclo[2.2.1]hept-5-ene-2-carboxylic acid amide, DMF; (b) HCl, 2-methoxyethanol, substituted aminobenzocycloheptene A-ring fragment, 130 °C.</p></p></figure><figure data-id="fig3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0010.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Binding mode of <b>25b</b> with ALK, as derived by Glide/XP docking program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0011.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Binding mode of <b>25b</b> with IR (brown ribbon), as derived by Glide/XP docking program.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0012.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacodynamics of <b>25b</b> in Karpas-299 tumor xenografts in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0013.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacy of <b>25b</b> on Karpas-299 tumor xenografts in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/medium/jm-2011-01550q_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0001.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Growth inhibition of <b>25b</b> on neuroblastoma cell lines harboring ALK activating mutations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-10/jm201550q/production/images/large/jm-2011-01550q_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm201550q&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i56">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62016" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62016" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 32 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <span class="citation_source-book">Cancer Facts and Figures 2011</span>; <span class="NLM_publisher-name">American Cancer Society</span>: <span class="NLM_publisher-loc">Atlanta, GA</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cancer+Facts+and+Figures+2011%3B+American+Cancer+Society%3A+Atlanta%2C+GA%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DCancer%2520Facts%2520and%2520Figures%25202011%26pub%3DAmerican%2520Cancer%2520Society%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashworth, A.</span><span> </span><span class="NLM_article-title">Translating cancer research into targeted therapeutics</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">549</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fnature09339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20882008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=543-549&author=J.+S.+De+Bonoauthor=A.+Ashworth&title=Translating+cancer+research+into+targeted+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2aR"><div class="casContent"><span class="casTitleNuber">2a</span><div class="casTitle"><span class="NLM_cas:atitle">Translating cancer research into targeted therapeutics</span></div><div class="casAuthors">de Bono, J. S.; Ashworth, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">543-549</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and less side effects.  Nevertheless, despite some successes drug development remains painfully slow.  Here, we highlight the issues involved and suggest ways in which this process can be improved and expedited.  We envision an increasing shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clin. trials.  The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biol. of the patient and their cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNF4iuzr3HvbVg90H21EOLACvtfcHk0lijxV2fHGZFsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajur7O&md5=1e65763ba1cddeef17e5b68e56a96452</span></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=10.1038%2Fnature09339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09339%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DAshworth%26aufirst%3DA.%26atitle%3DTranslating%2520cancer%2520research%2520into%2520targeted%2520therapeutics%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D543%26epage%3D549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Stegmeier, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warmuth, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sellers, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsch, M.</span><span> </span><span class="NLM_article-title">Targeted cancer therapies in the the twenty-first century: lessons from imatinib</span> <span class="citation_source-journal">Clin. Pharm. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">543</span><span class="NLM_x">–</span> <span class="NLM_lpage">552</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fclpt.2009.297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20237469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFCntb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2010&pages=543-552&issue=5&author=F.+Stegmeierauthor=M.+Warmuthauthor=W.+R.+Sellersauthor=M.+Dorsch&title=Targeted+cancer+therapies+in+the+the+twenty-first+century%3A+lessons+from+imatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Cancer Therapies in the Twenty-First Century: Lessons From Imatinib</span></div><div class="casAuthors">Stegmeier, F.; Warmuth, M.; Sellers, W. R.; Dorsch, M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">543-552</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  An increased understanding of the mol. etiol. of cancer has enabled the development of novel therapies that are collectively referred to as mol. targeted agents.  Unlike the drugs used in conventional chemotherapy, these agents are designed to specifically interfere with key mol. events that are responsible for the malignant phenotype.  They hold great promise for widening the therapeutic window, which would provide more effective treatment options as compared with cytotoxic therapies.  In addn., the targeted approach that is characteristic of these drugs provides unique opportunities for combination therapies with other anticancer agents that have non-overlapping toxicities.  Targeted agents are therefore primed to become invaluable therapeutic tools in the multimodal treatment of cancer.  The challenges assocd. with these novel targeted therapies are distinct from those faced in conventional chemotherapy.  These unique challenges include the need to select appropriate pharmacodynamic markers to guide dose and schedule and to identify biomarkers that enable selection of patient populations that are most likely to benefit from the treatment.  In addn., although the emergence of resistance to targeted therapies is a problem frequently faced in the clinic, the mol. characterization of resistance mechanisms provides the opportunity to design second-generation therapies or combination therapies aimed at preventing resistance or restoring response.  The development of the tyrosine kinase inhibitor imatinib has revolutionized the treatment of chronic myeloid leukemia (CML).  In this article, we discuss the lessons learned from the application of imatinib and other targeted agents in clin. practice and discuss how these insights may guide the development of novel targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKsbivdzh2E7Vg90H21EOLACvtfcHk0lijxV2fHGZFsQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFCntb8%253D&md5=e4000908114d67870d536efeb91f17e1</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2009.297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2009.297%26sid%3Dliteratum%253Aachs%26aulast%3DStegmeier%26aufirst%3DF.%26aulast%3DWarmuth%26aufirst%3DM.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DDorsch%26aufirst%3DM.%26atitle%3DTargeted%2520cancer%2520therapies%2520in%2520the%2520the%2520twenty-first%2520century%253A%2520lessons%2520from%2520imatinib%26jtitle%3DClin.%2520Pharm.%2520Ther.%26date%3D2010%26volume%3D87%26issue%3D5%26spage%3D543%26epage%3D552" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Baker, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, E. P.</span><span> </span><span class="NLM_article-title">Targeted inhibition of kinases in cancer therapy</span> <span class="citation_source-journal">Mt. Sinai J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">77</span><span class="NLM_x">, </span> <span class="NLM_fpage">573</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1002%2Fmsj.20220" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21105121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A280%3ADC%252BC3cbptlGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2010&pages=573-586&author=S.+J.+Bakerauthor=E.+P.+Reddy&title=Targeted+inhibition+of+kinases+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted inhibition of kinases in cancer therapy</span></div><div class="casAuthors">Baker Stacey J; Reddy E Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">The Mount Sinai journal of medicine, New York</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">573-86</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">With an understanding of the molecular changes that accompany cell transformation, cancer drug discovery has undergone a dramatic change in the past few years.  Whereas most of the emphasis in the past has been placed on developing drugs that induce cell death based on mechanisms that do not discriminate between normal and tumor cells, recent strategies have emphasized targeting specific mechanisms that have gone awry in tumor cells.  However, the identification of cancer-associated mutations in oncogenes and their amplification in tumors has suggested that inhibitors against such proteins might represent attractive substrates for targeted therapy.  In the clinic, the success of imatinib (Gleevec®, STI571) and trastuzumab (Herceptin®), both firsts of their kind, spurred further development of new, second-generation drugs that target kinases in cancer.  This review highlights a few important examples each of these types of therapies, along with some newer agents that are in various stages of development.  Second-generation kinase inhibitors aimed at overriding emerging resistance to these therapies are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAYkuL3ykcubBItaL1WaVAfW6udTcc2eYMDpgbXgqecbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbptlGqtA%253D%253D&md5=8e60c189f8d5447ac34e40121e64b577</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fmsj.20220&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmsj.20220%26sid%3Dliteratum%253Aachs%26aulast%3DBaker%26aufirst%3DS.%2BJ.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DTargeted%2520inhibition%2520of%2520kinases%2520in%2520cancer%2520therapy%26jtitle%3DMt.%2520Sinai%2520J.%2520Med.%26date%3D2010%26volume%3D77%26spage%3D573%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Milkiewicz, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Inhibitors of anaplastic lymphoma kinase: a patent review</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1653</span><span class="NLM_x">–</span> <span class="NLM_lpage">1681</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1517%2F13543776.2010.527332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20961208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1653-1681&issue=12&author=K.+L.+Milkiewiczauthor=G.+R.+Ott&title=Inhibitors+of+anaplastic+lymphoma+kinase%3A+a+patent+review"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4aR"><div class="casContent"><span class="casTitleNuber">4a</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of anaplastic lymphoma kinase: a patent review</span></div><div class="casAuthors">Milkiewicz, Karen L.; Ott, Gregory R.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1653-1681</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Importance of the field: Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that belongs to the insulin receptor superfamily.  Aberrant ALK activity has been implicated in the oncogenesis of human cancers as a fusion protein in anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, diffuse large B-cell lymphoma, systemic histiocytosis and NSCLC or through mutations in the full length protein in hereditary familial neuroblastoma.  Thus, abrogation of ALK signaling through direct kinase inhibition has become an attractive therapeutic intervention point for a subset of genetically defined human cancers.  Areas covered in this review: This manuscript provides a comprehensive review of the patent literature pertaining to ALK inhibitors and outlines their potential as anticancer therapeutic agents.  What the reader will gain: The reader will gain an understanding of the major structural classes of ALK inhibitors and insights into the future of this class of drugs.  Take home message: Multiple small-mol. ALK inhibitors have been reported with diverse chem. architecture, potency, kinase selectivity profiles and activity against potential resistance.  The breadth of inhibitors combined with the recent discoveries of the involvement of ALK in lung, breast and colorectal cancers has kept the field advancing at a rapid pace.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocXB5-B6Du8LVg90H21EOLACvtfcHk0lhDLMcYTtdu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVekt7bF&md5=32d9d90cf43bba8dfef6385e6494cc0a</span></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=10.1517%2F13543776.2010.527332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.2010.527332%26sid%3Dliteratum%253Aachs%26aulast%3DMilkiewicz%26aufirst%3DK.%2BL.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DInhibitors%2520of%2520anaplastic%2520lymphoma%2520kinase%253A%2520a%2520patent%2520review%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2010%26volume%3D20%26issue%3D12%26spage%3D1653%26epage%3D1681" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">299</span><span class="NLM_x">, </span> <span class="NLM_fpage">81</span><span class="NLM_x">–</span> <span class="NLM_lpage">94</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1016%2Fj.canlet.2010.09.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20934803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7vF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=299&publication_year=2010&pages=81-94&author=E.+Ardiniauthor=P.+Magnaghiauthor=P.+Orsiniauthor=M.+Menichincheri&title=Anaplastic+lymphoma+kinase%3A+role+in+specific+tumours%2C+and+development+of+small+molecule+inhibitors+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4bR"><div class="casContent"><span class="casTitleNuber">4b</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic Lymphoma Kinase: Role in specific tumours, and development of small molecule inhibitors for cancer therapy</span></div><div class="casAuthors">Ardini, E.; Magnaghi, P.; Orsini, P.; Galvani, A.; Menichincheri, M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">299</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">81-94</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The Anaplastic Lymphoma Kinase (ALK) is a receptor tyrosine kinase first identified as the product of a gene rearrangement in Anaplastic Large Cell Lymphoma.  ALK has subsequently been found to be rearranged, mutated, or amplified in a further series of tumors including neuroblastoma, and Non-Small Cell Lung Cancer.  There is strong preclin. evidence that ALK is a driving force for oncogenesis in these cases, and that inhibition of ALK kinase activity results in anti-tumoral efficacy.  These observations have sparked the development of small mol. kinase inhibitors, the most advanced of which is currently in clin. testing and which has shown promising preliminary activity in the subset of lung cancer patients whose tumors harbor activated ALK.  In this review, we describe the various oncogenic forms of ALK, relevant clin. settings, and give a detailed overview of current drug discovery efforts in the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqw80IgX8jf7rVg90H21EOLACvtfcHk0lhDLMcYTtdu3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKhs7vF&md5=9b72a030b1c4e3c90c0e570ce0c48f38</span></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2010.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2010.09.001%26sid%3Dliteratum%253Aachs%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DMenichincheri%26aufirst%3DM.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520specific%2520tumours%252C%2520and%2520development%2520of%2520small%2520molecule%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Lett.%26date%3D2010%26volume%3D299%26spage%3D81%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gerber, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span> </span><span class="NLM_article-title">ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">548</span><span class="NLM_x">–</span> <span class="NLM_lpage">551</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=548-551&author=D.+E.+Gerberauthor=J.+D.+Minna&title=ALK+inhibition+for+non-small+cell+lung+cancer%3A+from+discovery+to+therapy+in+record+time"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGerber%26aufirst%3DD.%2BE.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26atitle%3DALK%2520inhibition%2520for%2520non-small%2520cell%2520lung%2520cancer%253A%2520from%2520discovery%2520to%2520therapy%2520in%2520record%2520time%26jtitle%3DCancer%2520Cell%26date%3D2010%26volume%3D18%26spage%3D548%26epage%3D551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Goldstraw, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jett, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Chvalier, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lum, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, F. A.</span><span> </span><span class="NLM_article-title">Non-small-cell lung cancer</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">378</span><span class="NLM_x">, </span> <span class="NLM_fpage">1727</span><span class="NLM_x">–</span> <span class="NLM_lpage">1740</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=378&publication_year=2011&pages=1727-1740&author=P.+Goldstrawauthor=D.+Ballauthor=J.+R.+Jettauthor=T.+Le+Chvalierauthor=E.+Lumauthor=A.+G.+Nicholsonauthor=F.+A.+Shepherd&title=Non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGoldstraw%26aufirst%3DP.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DJett%26aufirst%3DJ.%2BR.%26aulast%3DLe%2BChvalier%26aufirst%3DT.%26aulast%3DLum%26aufirst%3DE.%26aulast%3DNicholson%26aufirst%3DA.%2BG.%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26atitle%3DNon-small-cell%2520lung%2520cancer%26jtitle%3DLancet%26date%3D2011%26volume%3D378%26spage%3D1727%26epage%3D1740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit5c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neruoblastoma</span> <span class="citation_source-journal">Anti-Cancer Agents Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">236</span><span class="NLM_x">–</span> <span class="NLM_lpage">249</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=236-249&author=M.+Chengauthor=G.+R.+Ott&title=Anaplastic+lymphoma+kinase+as+a+therapeutic+target+in+anaplastic+large+cell+lymphoma%2C+non-small+cell+lung+cancer+and+neruoblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520as%2520a%2520therapeutic%2520target%2520in%2520anaplastic%2520large%2520cell%2520lymphoma%252C%2520non-small%2520cell%2520lung%2520cancer%2520and%2520neruoblastoma%26jtitle%3DAnti-Cancer%2520Agents%2520Med.%2520Chem.%26date%3D2010%26volume%3D10%26spage%3D236%26epage%3D249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirstein, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valentine, M. B.</span><span class="NLM_etal"></span><span> </span><span class="NLM_article-title">Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">263</span><span class="NLM_x">, </span> <span class="NLM_fpage">1281</span><span class="NLM_x">–</span> <span class="NLM_lpage">1284</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=263&publication_year=1994&pages=1281-1284&author=S.+W.+Morrisauthor=M.+N.+Kirsteinauthor=M.+B.+Valentine&title=Fusion+of+a+kinase+gene%2C+ALK%2C+to+a+nucleolar+protein+gene%2C+NPM%2C+in+non-Hodgkin%E2%80%99s+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DKirstein%26aufirst%3DM.%2BN.%26aulast%3DValentine%26aufirst%3DM.%2BB.%26atitle%3DFusion%2520of%2520a%2520kinase%2520gene%252C%2520ALK%252C%2520to%2520a%2520nucleolar%2520protein%2520gene%252C%2520NPM%252C%2520in%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%26jtitle%3DScience%26date%3D1994%26volume%3D263%26spage%3D1281%26epage%3D1284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Chiarle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voena, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambrogio, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piva, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span> </span><span class="NLM_article-title">The anaplastic lymphoma kinase in the pathogenesis of cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fnrc2291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=18097461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=11-23&author=R.+Chiarleauthor=C.+Voenaauthor=C.+Ambrogioauthor=R.+Pivaauthor=G.+Inghirami&title=The+anaplastic+lymphoma+kinase+in+the+pathogenesis+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">The anaplastic lymphoma kinase in the pathogenesis of cancer</span></div><div class="casAuthors">Chiarle, Roberto; Voena, Claudia; Ambrogio, Chiara; Piva, Roberto; Inghirami, Giorgio</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-23</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The receptor tyrosine kinase anaplastic lymphoma kinase (ALK) was first identified as part of a chromosomal translocation assocd. with some anaplastic large cell lymphomas (ALCLs).  Now data are emerging that indicate that ALK might be a valid therapeutic target in ALCL and that it could also be involved in other cancers.  Tyrosine kinases are involved in the pathogenesis of most cancers.  However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.  The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many mol. mechanisms.  In this review, we will analyze how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacol. tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5HoaZPQUiUrVg90H21EOLACvtfcHk0lj_L-Le-W2lkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVKku73P&md5=a57d7ab61be51664ca9f5b804c3e2910</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1038%2Fnrc2291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2291%26sid%3Dliteratum%253Aachs%26aulast%3DChiarle%26aufirst%3DR.%26aulast%3DVoena%26aufirst%3DC.%26aulast%3DAmbrogio%26aufirst%3DC.%26aulast%3DPiva%26aufirst%3DR.%26aulast%3DInghirami%26aufirst%3DG.%26atitle%3DThe%2520anaplastic%2520lymphoma%2520kinase%2520in%2520the%2520pathogenesis%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2008%26volume%3D8%26spage%3D11%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slavish, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rentrop, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span> <span class="citation_source-journal">Expert Rev. Anticancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">356</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1586%2F14737140.9.3.331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=19275511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=331-356&author=T.+R.+Webbauthor=J.+Slavishauthor=R.+E.+Georgeauthor=A.+T.+Lookauthor=L.+Xueauthor=Q.+Jiangauthor=X.+Cuiauthor=W.+B.+Rentropauthor=S.+W.+Morris&title=Anaplastic+lymphoma+kinase%3A+role+in+cancer+pathogenesis+and+small-molecule+inhibitor+development+for+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy</span></div><div class="casAuthors">Webb, Thomas R.; Slavish, Jake; George, Rani E.; Look, A. Thomas; Xue, Liquan; Jiang, Qin; Cui, Xiaoli; Rentrop, Walter B.; Morris, Stephan W.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Anticancer Therapy</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">331-356</span>CODEN:
                <span class="NLM_cas:coden">ERATBJ</span>;
        ISSN:<span class="NLM_cas:issn">1473-7140</span>.
    
            (<span class="NLM_cas:orgname">Expert Reviews Ltd.</span>)
        </div><div class="casAbstract">A review.  Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.  More recently, genomic DNA amplification and protein overexpression, as well as activating point mutations, of ALK have been described in neuroblastomas.  In addn. to those cancers for which a causative role for aberrant ALK activity is well validated, more circumstantial links implicate the full-length, normal ALK receptor in the genesis of other malignancies - including glioblastoma and breast cancer - via a mechanism of receptor activation involving autocrine and/or paracrine growth loops with the reported ALK ligands, pleiotrophin and midkine.  This review summarizes normal ALK biol., the confirmed and putative roles of ALK in the development of human cancers and efforts to target ALK using small-mol. kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoERzbvlik_c7Vg90H21EOLACvtfcHk0lj_L-Le-W2lkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtFaltrc%253D&md5=a980ef18ac316bd3894b72ddd2748c17</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1586%2F14737140.9.3.331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737140.9.3.331%26sid%3Dliteratum%253Aachs%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DSlavish%26aufirst%3DJ.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DLook%26aufirst%3DA.%2BT.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DQ.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DRentrop%26aufirst%3DW.%2BB.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%253A%2520role%2520in%2520cancer%2520pathogenesis%2520and%2520small-molecule%2520inhibitor%2520development%2520for%2520therapy%26jtitle%3DExpert%2520Rev.%2520Anticancer%2520Ther.%26date%3D2009%26volume%3D9%26spage%3D331%26epage%3D356" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Grande, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolos, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arriola, E.</span><span> </span><span class="NLM_article-title">Targeting oncogenic ALK: A promising strategy for cancer treatment</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">4</span><span class="NLM_x">) </span> <span class="NLM_fpage">569</span><span class="NLM_x">–</span> <span class="NLM_lpage">571</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1535-7163.MCT-10-0615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21474455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=569-571&issue=4&author=E.+Grandeauthor=M.+Bolosauthor=E.+Arriola&title=Targeting+oncogenic+ALK%3A+A+promising+strategy+for+cancer+treatment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment</span></div><div class="casAuthors">Grande, Enrique; Bolos, Maria-Victoria; Arriola, Edurne</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">569-579</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematol. tumors.  Novel drugs targeting this tyrosine kinase receptor are under development, and early clin. trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors.  Here, we review the structure and function of the ALK receptor, the mechanisms assocd. with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK.  Mol Cancer Ther; 10(4); 569-79.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-I5KwiK8uaLVg90H21EOLACvtfcHk0lj_L-Le-W2lkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSrtrc%253D&md5=3b008d05e772f4eae0edb83d750afdb4</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0615%26sid%3Dliteratum%253Aachs%26aulast%3DGrande%26aufirst%3DE.%26aulast%3DBolos%26aufirst%3DM.%26aulast%3DArriola%26aufirst%3DE.%26atitle%3DTargeting%2520oncogenic%2520ALK%253A%2520A%2520promising%2520strategy%2520for%2520cancer%2520treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26issue%3D4%26spage%3D569%26epage%3D571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Mossé, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laureys, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Speleman, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hakonarson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torkamani, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schork, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodeur, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonini, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rappaport, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devoto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Identification of ALK as a major familial neuroblastoma predisposition gene</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">930</span><span class="NLM_x">–</span> <span class="NLM_lpage">936</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=930-936&author=Y.+P.+Moss%C3%A9author=M.+Laudenslagerauthor=L.+Longoauthor=K.+A.+Coleauthor=A.+Woodauthor=E.+F.+Attiyehauthor=M.+J.+Laquagliaauthor=R.+Sennettauthor=J.+E.+Lynchauthor=P.+Perriauthor=G.+Laureysauthor=F.+Spelemanauthor=C.+Kimauthor=C.+Houauthor=H.+Hakonarsonauthor=A.+Torkamaniauthor=M.+J.+Schorkauthor=G.+M.+Brodeurauthor=G.+P.+Toniniauthor=E.+Rappaportauthor=M.+Devotoauthor=J.+M.+Maris&title=Identification+of+ALK+as+a+major+familial+neuroblastoma+predisposition+gene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoss%25C3%25A9%26aufirst%3DY.%2BP.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DLongo%26aufirst%3DL.%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DLaquaglia%26aufirst%3DM.%2BJ.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DLynch%26aufirst%3DJ.%2BE.%26aulast%3DPerri%26aufirst%3DP.%26aulast%3DLaureys%26aufirst%3DG.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DKim%26aufirst%3DC.%26aulast%3DHou%26aufirst%3DC.%26aulast%3DHakonarson%26aufirst%3DH.%26aulast%3DTorkamani%26aufirst%3DA.%26aulast%3DSchork%26aufirst%3DM.%2BJ.%26aulast%3DBrodeur%26aufirst%3DG.%2BM.%26aulast%3DTonini%26aufirst%3DG.%2BP.%26aulast%3DRappaport%26aufirst%3DE.%26aulast%3DDevoto%26aufirst%3DM.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DIdentification%2520of%2520ALK%2520as%2520a%2520major%2520familial%2520neuroblastoma%2520predisposition%2520gene%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D930%26epage%3D936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Janoueix-Lerosey, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lequin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brugières, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribeiro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Pontual, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combaret, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynal, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puisieux, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schleiermacher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierron, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valteau-Couanet, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frebourg, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyonnet, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amiel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delattre, O.</span><span> </span><span class="NLM_article-title">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">967</span><span class="NLM_x">–</span> <span class="NLM_lpage">970</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1038%2Fnature07398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=18923523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9b&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=967-970&author=I.+Janoueix-Leroseyauthor=D.+Lequinauthor=L.+Brugi%C3%A8resauthor=A.+Ribeiroauthor=L.+de+Pontualauthor=V.+Combaretauthor=V.+Raynalauthor=A.+Puisieuxauthor=G.+Schleiermacherauthor=G.+Pierronauthor=D.+Valteau-Couanetauthor=T.+Frebourgauthor=J.+Michonauthor=S.+Lyonnetauthor=J.+Amielauthor=O.+Delattre&title=Somatic+and+germline+activating+mutations+of+the+ALK+kinase+receptor+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9bR"><div class="casContent"><span class="casTitleNuber">9b</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma</span></div><div class="casAuthors">Janoueix-Lerosey, Isabelle; Lequin, Delphine; Brugieres, Laurence; Ribeiro, Agnes; de Pontual, Loic; Combaret, Valerie; Raynal, Virginie; Puisieux, Alain; Schleiermacher, Gudrun; Pierron, Gaelle; Valteau-Couanet, Dominique; Frebourg, Thierry; Michon, Jean; Lyonnet, Stanislas; Amiel, Jeanne; Delattre, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">455</span>
        (<span class="NLM_cas:issue">7215</span>),
    <span class="NLM_cas:pages">967-970</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Neuroblastoma, a tumor derived from the peripheral sympathetic nervous system, is one of the most frequent solid tumors in childhood.  It usually occurs sporadically but familial cases are obsd., with a subset of cases occurring in assocn. with congenital malformations of the neural crest being linked to germline mutations of the PHOX2B gene.  Here the authors conducted genome-wide comparative genomic hybridization anal. on a large series of neuroblastomas.  Copy no. increase at the locus encoding the anaplastic lymphoma kinase (ALK) tyrosine kinase receptor was obsd. recurrently.  One particularly informative case presented a high-level gene amplification that was strictly limited to ALK, indicating that this gene may contribute on its own to neuroblastoma development.  Through subsequent direct sequencing of cell lines and primary tumor DNAs the authors identified somatic mutations of the ALK kinase domain that mainly clustered in two hotspots.  Germline mutations were obsd. in two neuroblastoma families, indicating that ALK is a neuroblastoma predisposition gene.  Mutated ALK proteins were overexpressed, hyperphosphorylated and showed constitutive kinase activity.  The knockdown of ALK expression in ALK-mutated cells, but also in cell lines overexpressing a wild-type ALK, led to a marked decrease of cell proliferation.  Altogether, these data identify ALK as a crit. player in neuroblastoma development that may hence represent a very attractive therapeutic target in this disease that is still frequently fatal with current treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr_O_BMCZk7rVg90H21EOLACvtfcHk0lhZB4UfBH1yOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1GgurrI&md5=7321fe0dc6408f9b5b3c53b8d83478ce</span></div><a href="/servlet/linkout?suffix=cit9b&amp;dbid=16384&amp;doi=10.1038%2Fnature07398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07398%26sid%3Dliteratum%253Aachs%26aulast%3DJanoueix-Lerosey%26aufirst%3DI.%26aulast%3DLequin%26aufirst%3DD.%26aulast%3DBrugi%25C3%25A8res%26aufirst%3DL.%26aulast%3DRibeiro%26aufirst%3DA.%26aulast%3Dde%2BPontual%26aufirst%3DL.%26aulast%3DCombaret%26aufirst%3DV.%26aulast%3DRaynal%26aufirst%3DV.%26aulast%3DPuisieux%26aufirst%3DA.%26aulast%3DSchleiermacher%26aufirst%3DG.%26aulast%3DPierron%26aufirst%3DG.%26aulast%3DValteau-Couanet%26aufirst%3DD.%26aulast%3DFrebourg%26aufirst%3DT.%26aulast%3DMichon%26aufirst%3DJ.%26aulast%3DLyonnet%26aufirst%3DS.%26aulast%3DAmiel%26aufirst%3DJ.%26aulast%3DDelattre%26aufirst%3DO.%26atitle%3DSomatic%2520and%2520germline%2520activating%2520mutations%2520of%2520the%2520ALK%2520kinase%2520receptor%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D967%26epage%3D970" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takita, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kato, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igarashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawara, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayashi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogawa, S.</span><span> </span><span class="NLM_article-title">Oncogenic mutations of ALK kinase in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">974</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=971-974&author=Y.+Chenauthor=J.+Takitaauthor=Y.+L.+Choiauthor=M.+Katoauthor=M.+Ohiraauthor=M.+Sanadaauthor=L.+Wangauthor=M.+Sodaauthor=A.+Kikuchiauthor=T.+Igarashiauthor=A.+Nakagawaraauthor=Y.+Hayashiauthor=H.+Manoauthor=S.+Ogawa&title=Oncogenic+mutations+of+ALK+kinase+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTakita%26aufirst%3DJ.%26aulast%3DChoi%26aufirst%3DY.%2BL.%26aulast%3DKato%26aufirst%3DM.%26aulast%3DOhira%26aufirst%3DM.%26aulast%3DSanada%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSoda%26aufirst%3DM.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIgarashi%26aufirst%3DT.%26aulast%3DNakagawara%26aufirst%3DA.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DMano%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DS.%26atitle%3DOncogenic%2520mutations%2520of%2520ALK%2520kinase%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D971%26epage%3D974" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">George, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fröhling, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luther, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">London, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGrady, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xue, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zozulya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gregor, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilliland, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diller, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, A. T.</span><span> </span><span class="NLM_article-title">Activating mutations in ALK provide a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">975</span><span class="NLM_x">–</span> <span class="NLM_lpage">978</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=975-978&author=R.+E.+Georgeauthor=T.+Sandaauthor=M.+Hannaauthor=S.+Fr%C3%B6hlingauthor=W.+Lutherauthor=J.+Zhangauthor=Y.+Ahnauthor=W.+Zhouauthor=W.+B.+Londonauthor=P.+McGradyauthor=L.+Xueauthor=S.+Zozulyaauthor=V.+E.+Gregorauthor=T.+R.+Webbauthor=N.+S.+Grayauthor=D.+G.+Gillilandauthor=L.+Dillerauthor=H.+Greulichauthor=S.+W.+Morrisauthor=M.+Meyersonauthor=A.+T.+Look&title=Activating+mutations+in+ALK+provide+a+therapeutic+target+in+neuroblastoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hling%26aufirst%3DS.%26aulast%3DLuther%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DAhn%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLondon%26aufirst%3DW.%2BB.%26aulast%3DMcGrady%26aufirst%3DP.%26aulast%3DXue%26aufirst%3DL.%26aulast%3DZozulya%26aufirst%3DS.%26aulast%3DGregor%26aufirst%3DV.%2BE.%26aulast%3DWebb%26aufirst%3DT.%2BR.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGilliland%26aufirst%3DD.%2BG.%26aulast%3DDiller%26aufirst%3DL.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMorris%26aufirst%3DS.%2BW.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DLook%26aufirst%3DA.%2BT.%26atitle%3DActivating%2520mutations%2520in%2520ALK%2520provide%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D975%26epage%3D978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit9e"><span><span class="NLM_label">(e) </span><span class="NLM_contrib-group">Eng, C.</span><span> </span><span class="NLM_article-title">A ringleader identified</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">455</span><span class="NLM_x">, </span> <span class="NLM_fpage">883</span><span class="NLM_x">–</span> <span class="NLM_lpage">884</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=455&publication_year=2008&pages=883-884&author=C.+Eng&title=A+ringleader+identified"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9e&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEng%26aufirst%3DC.%26atitle%3DA%2520ringleader%2520identified%26jtitle%3DNature%26date%3D2008%26volume%3D455%26spage%3D883%26epage%3D884" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span> </span><span class="NLM_article-title">Targeting anaplastic lymphoma kinase in lung cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2081</span><span class="NLM_x">–</span> <span class="NLM_lpage">2086</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1078-0432.CCR-10-1591" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21288922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10a&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=2081-2086&author=A.+T.+Shawauthor=B.+Solomon&title=Targeting+anaplastic+lymphoma+kinase+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10aR"><div class="casContent"><span class="casTitleNuber">10a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Anaplastic Lymphoma Kinase in Lung Cancer</span></div><div class="casAuthors">Shaw, Alice T.; Solomon, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2081-2086</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Several decades of cancer research have revealed a pivotal role for tyrosine kinases as key regulators of signaling pathways, controlling cell growth and differentiation.  Deregulation of tyrosine kinase-mediated signaling occurs frequently in cancer and is believed to drive the initiation and progression of disease.  Chromosomal rearrangements involving the tyrosine kinase anaplastic lymphoma kinase (ALK) occur in a variety of human malignancies including non-small cell lung cancer (NSCLC), anaplastic large cell lymphomas, and inflammatory myofibroblastic tumors.  The aberrant activation of ALK signaling leads to "oncogene addiction" and marked sensitivity to ALK inhibitors such as crizotinib (PF-02341066).  This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.  Current efforts seek to expand the role of ALK kinase inhibition in lung and other cancers and to address the mol. basis for the development of resistance.  Clin Cancer Res; 17(8); 2081-6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCqEzvXv0qJrVg90H21EOLACvtfcHk0ljcIyyWUKSSNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslCgs7k%253D&md5=6d0f5e1174ba934f00c10a877a3b17e1</span></div><a href="/servlet/linkout?suffix=cit10a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-1591&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-1591%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26atitle%3DTargeting%2520anaplastic%2520lymphoma%2520kinase%2520in%2520lung%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D2081%26epage%3D2086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit10b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mosse, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">Inhibition of ALK signaling for cancer therapy</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">5608</span><span class="NLM_x">–</span> <span class="NLM_lpage">5614</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10b&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1078-0432.CCR-08-2762" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=5608-5614&author=Y.+P.+Mosseauthor=A.+Woodauthor=J.+M.+Maris&title=Inhibition+of+ALK+signaling+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10b&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-2762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-2762%26sid%3Dliteratum%253Aachs%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DInhibition%2520of%2520ALK%2520signaling%2520for%2520cancer%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2009%26volume%3D15%26spage%3D5608%26epage%3D5614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bossi, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saccardo, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menichincheri, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusconi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Magnaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orsini, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardi Borgia, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bandiera, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fogliatto, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertrand, J. A.</span><span> </span><span class="NLM_article-title">Crystal structures of analplastic lymphoma kinase in complex with ATP competitive inhibitors</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6813</span><span class="NLM_x">–</span> <span class="NLM_lpage">6825</span></span><div class="citationLinks">[<a href="/doi/10.1021/bi1005514" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6813-6825&author=R.+T.+Bossiauthor=M.+B.+Saccardoauthor=E.+Ardiniauthor=M.+Menichincheriauthor=L.+Rusconiauthor=P.+Magnaghiauthor=P.+Orsiniauthor=M.+Avanziauthor=A.+Lombardi+Borgiaauthor=M.+Nesiauthor=T.+Bandieraauthor=G.+Fogliattoauthor=J.+A.+Bertrand&title=Crystal+structures+of+analplastic+lymphoma+kinase+in+complex+with+ATP+competitive+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11a&amp;dbid=16384&amp;doi=10.1021%2Fbi1005514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi1005514%26sid%3Dliteratum%253Aachs%26aulast%3DBossi%26aufirst%3DR.%2BT.%26aulast%3DSaccardo%26aufirst%3DM.%2BB.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DMenichincheri%26aufirst%3DM.%26aulast%3DRusconi%26aufirst%3DL.%26aulast%3DMagnaghi%26aufirst%3DP.%26aulast%3DOrsini%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DM.%26aulast%3DLombardi%2BBorgia%26aufirst%3DA.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DBandiera%26aufirst%3DT.%26aulast%3DFogliatto%26aufirst%3DG.%26aulast%3DBertrand%26aufirst%3DJ.%2BA.%26atitle%3DCrystal%2520structures%2520of%2520analplastic%2520lymphoma%2520kinase%2520in%2520complex%2520with%2520ATP%2520competitive%2520inhibitors%26jtitle%3DBiochemistry%26date%3D2010%26volume%3D49%26spage%3D6813%26epage%3D6825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit11b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Lee, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ambing, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hua, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michellys, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesley, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spraggon, G.</span><span> </span><span class="NLM_article-title">Crystal structure of ALK (anaplastic lymphoma kinase) catalytic domain</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">430</span><span class="NLM_x">, </span> <span class="NLM_fpage">425</span><span class="NLM_x">–</span> <span class="NLM_lpage">437</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=430&publication_year=2010&pages=425-437&author=C.+C.+Leeauthor=Y.+Jiaauthor=N.+Liauthor=X.+Sunauthor=K.+Ngauthor=E.+Ambingauthor=M.+Gaoauthor=S.+Huaauthor=C.+Chenauthor=S.+Kimauthor=P.+Michellysauthor=S.+A.+Lesleyauthor=J.+L.+Harrisauthor=G.+Spraggon&title=Crystal+structure+of+ALK+%28anaplastic+lymphoma+kinase%29+catalytic+domain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DNg%26aufirst%3DK.%26aulast%3DAmbing%26aufirst%3DE.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DHua%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DMichellys%26aufirst%3DP.%26aulast%3DLesley%26aufirst%3DS.%2BA.%26aulast%3DHarris%26aufirst%3DJ.%2BL.%26aulast%3DSpraggon%26aufirst%3DG.%26atitle%3DCrystal%2520structure%2520of%2520ALK%2520%2528anaplastic%2520lymphoma%2520kinase%2529%2520catalytic%2520domain%26jtitle%3DBiochem.%2520J.%26date%3D2010%26volume%3D430%26spage%3D425%26epage%3D437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+Kungauthor=M.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0ljcIyyWUKSSNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">703</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-703&author=E.+L.+Kwakauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=B.+Solomonauthor=R.+G.+Makiauthor=S.+H.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.+H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0lhbANxe37RQZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D703" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span>Pfizer Press Release, August 29,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Pfizer+Press+Release%2C+August+29%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Galkin, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melnick, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hood, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span> </span><span class="NLM_article-title">Identification of NVP-TAE684, a potent, selective and efficacious inhibitor of NPM-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">275</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=270-275&author=A.+V.+Galkinauthor=J.+S.+Melnickauthor=S.+Kimauthor=T.+L.+Hoodauthor=N.+Liauthor=L.+Li&title=Identification+of+NVP-TAE684%2C+a+potent%2C+selective+and+efficacious+inhibitor+of+NPM-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGalkin%26aufirst%3DA.%2BV.%26aulast%3DMelnick%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DHood%26aufirst%3DT.%2BL.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DIdentification%2520of%2520NVP-TAE684%252C%2520a%2520potent%252C%2520selective%2520and%2520efficacious%2520inhibitor%2520of%2520NPM-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D270%26epage%3D275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Katayama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benes, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharespeare, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engleman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span> </span><span class="NLM_article-title">Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">7535</span><span class="NLM_x">–</span> <span class="NLM_lpage">7540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=7535-7540&author=R.+Katayamaauthor=T.+M.+Khanauthor=C.+Benesauthor=E.+Lifshitsauthor=H.+Ebiauthor=V.+M.+Riveraauthor=W.+C.+Sharespeareauthor=A.+J.+Iafrateauthor=J.+A.+Englemanauthor=A.+T.+Shaw&title=Therapeutic+strategies+to+overcome+crizotinib+resistance+in+non-small+cell+lung+cancers+harboring+the+fusion+oncogene+EML4-ALK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKatayama%26aufirst%3DR.%26aulast%3DKhan%26aufirst%3DT.%2BM.%26aulast%3DBenes%26aufirst%3DC.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DEbi%26aufirst%3DH.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26aulast%3DSharespeare%26aufirst%3DW.%2BC.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DEngleman%26aufirst%3DJ.%2BA.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26atitle%3DTherapeutic%2520strategies%2520to%2520overcome%2520crizotinib%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancers%2520harboring%2520the%2520fusion%2520oncogene%2520EML4-ALK%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D7535%26epage%3D7540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Sakamoto, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukaguchi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hiroshima, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kodama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukami, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oikawa, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsukuda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishii, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aoki, Y.</span><span> </span><span class="NLM_article-title">CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">679</span><span class="NLM_x">–</span> <span class="NLM_lpage">690</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2011&pages=679-690&author=H.+Sakamotoauthor=T.+Tsukaguchiauthor=S.+Hiroshimaauthor=T.+Kodamaauthor=T.+Kobayashiauthor=T.+A.+Fukamiauthor=N.+Oikawaauthor=T.+Tsukudaauthor=N.+Ishiiauthor=Y.+Aoki&title=CH5424802%2C+a+selective+ALK+inhibitor+capable+of+blocking+the+resistant+gatekeeper+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSakamoto%26aufirst%3DH.%26aulast%3DTsukaguchi%26aufirst%3DT.%26aulast%3DHiroshima%26aufirst%3DS.%26aulast%3DKodama%26aufirst%3DT.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DFukami%26aufirst%3DT.%2BA.%26aulast%3DOikawa%26aufirst%3DN.%26aulast%3DTsukuda%26aufirst%3DT.%26aulast%3DIshii%26aufirst%3DN.%26aulast%3DAoki%26aufirst%3DY.%26atitle%3DCH5424802%252C%2520a%2520selective%2520ALK%2520inhibitor%2520capable%2520of%2520blocking%2520the%2520resistant%2520gatekeeper%2520mutant%26jtitle%3DCancer%2520Cell%26date%3D2011%26volume%3D19%26spage%3D679%26epage%3D690" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit16c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">deStanchina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">4920</span><span class="NLM_x">–</span> <span class="NLM_lpage">4931</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F0008-5472.CAN-10-3879" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=21613408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16c&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=4920-4931&author=C.+M.+Lovlyauthor=J.+M.+Heuckmannauthor=E.+deStanchinaauthor=H.+Chenauthor=R.+K.+Thomasauthor=C.+Liangauthor=W.+Pao&title=Insights+into+ALK-driven+cancers+revealed+through+development+of+novel+ALK+tyrosine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16cR"><div class="casContent"><span class="casTitleNuber">16c</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors</span></div><div class="casAuthors">Lovly, Christine M.; Heuckmann, Johannes M.; de Stanchina, Elisa; Chen, Heidi; Thomas, Roman K.; Liang, Chris; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4920-4931</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where ALK represents a rational therapeutic target in these settings.  In this study, we report the identification and biol. characterization of X-376 and X-396, two potent and highly specific ALK small mol. tyrosine kinase inhibitors (TKIs).  In Ambit kinome screens, cell growth inhibition studies, and surrogate kinase assays, X-376 and X-396 were more potent inhibitors of ALK but less potent inhibitors of MET compared to PF-02341066 (PF-1066), an ALK/MET dual TKI currently in clin. trials.  Both X-376 and X-396 displayed potent antitumor activity in vivo with favorable pharmacokinetic and toxicity profiles.  Similar levels of drug sensitivity were displayed by the three most common ALK fusion proteins in lung cancer (EML4-ALK variants E13;A20, E20;A20, and E6b;A20) as well as a KIF5B-ALK fusion protein.  Moreover, X-396 could potently inhibit ALK kinases engineered with two point mutations assocd. with acquired resistance to PF-1066, L1196M, and C1156Y, when engineered into an E13;A20 fusion variant.  Finally, X-396 displayed synergistic growth inhibitory activity when combined with the mTOR inhibitor rapamycin.  Our findings offer preclin. proof-of-concept for use of these novel agents to improve therapeutic outcomes of patients with mutant ALK-driven malignancies.  Cancer Res; 71(14); 4920-31.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCEJra8njI7Vg90H21EOLACvtfcHk0lg-TdKSX7qxHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFartro%253D&md5=000cbd1295c9d9fa6a43027f08c31247</span></div><a href="/servlet/linkout?suffix=cit16c&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-3879&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-3879%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DdeStanchina%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DInsights%2520into%2520ALK-driven%2520cancers%2520revealed%2520through%2520development%2520of%2520novel%2520ALK%2520tyrosine%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D4920%26epage%3D4931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tripathy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">HcHugh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anzalone, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">Discovery of a potent inhibitor of anaplastic lymophoma kinase with in vivo antitumor activity</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">498</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml100158s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=493-498&author=G.+R.+Ottauthor=R.+Tripathyauthor=M.+Chengauthor=R.+HcHughauthor=A.+V.+Anzaloneauthor=T.+L.+Underinerauthor=M.+R.+Quailauthor=L.+Luauthor=W.+Wanauthor=T.+S.+Angelesauthor=M.+S.+Albomauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=Discovery+of+a+potent+inhibitor+of+anaplastic+lymophoma+kinase+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fml100158s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100158s%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DTripathy%26aufirst%3DR.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DHcHugh%26aufirst%3DR.%26aulast%3DAnzalone%26aufirst%3DA.%2BV.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520inhibitor%2520of%2520anaplastic%2520lymophoma%2520kinase%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D493%26epage%3D498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Espinal, J.</span><span> </span><span class="NLM_article-title">What is the role of the insulin receptor tyrosine kinase?</span> <span class="citation_source-journal">Trends Biochem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1988</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">367</span><span class="NLM_x">–</span> <span class="NLM_lpage">368</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1988&pages=367-368&author=J.+Espinal&title=What+is+the+role+of+the+insulin+receptor+tyrosine+kinase%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEspinal%26aufirst%3DJ.%26atitle%3DWhat%2520is%2520the%2520role%2520of%2520the%2520insulin%2520receptor%2520tyrosine%2520kinase%253F%26jtitle%3DTrends%2520Biochem.%2520Sci.%26date%3D1988%26volume%3D13%26spage%3D367%26epage%3D368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Saltiel, A. R.</span><span> </span><span class="NLM_article-title">Putting the brakes on insulin signaling</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">2560</span><span class="NLM_x">–</span> <span class="NLM_lpage">2562</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1056%2FNEJMcibr031668" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=14695419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtrjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2003&pages=2560-2562&author=A.+R.+Saltiel&title=Putting+the+brakes+on+insulin+signaling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Putting the brakes on insulin signaling</span></div><div class="casAuthors">Saltiel, Alan R.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">349</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2560-2562</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkiC1YdrMCvbVg90H21EOLACvtfcHk0lg-TdKSX7qxHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVWhtrjL&md5=c9e6b3470550cd6a9eaafa6395c3498c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1056%2FNEJMcibr031668&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcibr031668%26sid%3Dliteratum%253Aachs%26aulast%3DSaltiel%26aufirst%3DA.%2BR.%26atitle%3DPutting%2520the%2520brakes%2520on%2520insulin%2520signaling%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2003%26volume%3D349%26spage%3D2560%26epage%3D2562" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becknell, N. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinberg, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holskin, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Underiner, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyer, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1617</span><span class="NLM_x">–</span> <span class="NLM_lpage">1623</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2006&pages=1617-1623&author=W.+Wanauthor=M.+S.+Albomauthor=L.+Luauthor=M.+R.+Quailauthor=N.+C.+Becknellauthor=L.+R.+Weinbergauthor=D.+R.+Reddyauthor=B.+P.+Holskinauthor=T.+S.+Angelesauthor=T.+L.+Underinerauthor=S.+L.+Meyerauthor=R.+L.+Hudkinsauthor=B.+D.+Dorseyauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=M.+Cheng&title=Anaplastic+lymphoma+kinase+activity+is+essential+for+the+proliferation+and+survival+of+anaplastic+large-cell+lymphoma+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DBecknell%26aufirst%3DN.%2BC.%26aulast%3DWeinberg%26aufirst%3DL.%2BR.%26aulast%3DReddy%26aufirst%3DD.%2BR.%26aulast%3DHolskin%26aufirst%3DB.%2BP.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DUnderiner%26aufirst%3DT.%2BL.%26aulast%3DMeyer%26aufirst%3DS.%2BL.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DCheng%26aufirst%3DM.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520activity%2520is%2520essential%2520for%2520the%2520proliferation%2520and%2520survival%2520of%2520anaplastic%2520large-cell%2520lymphoma%2520cells%26jtitle%3DBlood%26date%3D2006%26volume%3D107%26spage%3D1617%26epage%3D1623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="note"><p class="first last">There were 39 such structures with kinases like aurora kinase (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNZ">3UNZ</a>), ALK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7">2XB7</a>), insulin receptor (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKN">3EKN</a>), JNK1 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ELJ">3ELJ</a>), FAK (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK">2JKK</a>), ERk2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z7L">2Z7L</a>), CDK2 (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1H01">1H01</a>).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thieu, T. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lisko, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mesaros, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span> </span><span class="NLM_article-title">2,7-Disubstituted-pyrrolo[2,1-<i>f</i>][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">6328</span><span class="NLM_x">–</span> <span class="NLM_lpage">6341</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200758k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6328-6341&issue=18&author=G.+R.+Ottauthor=G.+J.+Wellsauthor=T.+V.+Thieuauthor=M.+R.+Quailauthor=J.+G.+Liskoauthor=E.+F.+Mesarosauthor=D.+E.+Gingrichauthor=A.+K.+Ghoseauthor=W.+Wanauthor=L.+Luauthor=M.+Chengauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=Z.+Huangauthor=L.+D.+Aimoneauthor=M.+A.+Atorauthor=B.+A.+Ruggeriauthor=B.+D.+Dorsey&title=2%2C7-Disubstituted-pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazines%3A+new+variant+of+an+old+template+and+application+to+the+discovery+of+anaplastic+lymphoma+kinase+%28ALK%29+inhibitors+with+in+vivo+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200758k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200758k%26sid%3Dliteratum%253Aachs%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DWells%26aufirst%3DG.%2BJ.%26aulast%3DThieu%26aufirst%3DT.%2BV.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DLisko%26aufirst%3DJ.%2BG.%26aulast%3DMesaros%26aufirst%3DE.%2BF.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26atitle%3D2%252C7-Disubstituted-pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazines%253A%2520new%2520variant%2520of%2520an%2520old%2520template%2520and%2520application%2520to%2520the%2520discovery%2520of%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%2520inhibitors%2520with%2520in%2520vivo%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26issue%3D18%26spage%3D6328%26epage%3D6341" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span>Selectivity value for 90% inhibition from single point data: <i>S</i>(90) = (no. of kinases ≥ 90% inhibition)/(total no. of kinases tested).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Selectivity+value+for+90%25+inhibition+from+single+point+data%3A+S%2890%29+%3D+%28no.+of+kinases+%E2%89%A5+90%25+inhibition%29%2F%28total+no.+of+kinases+tested%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Cheng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quail, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ott, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albom, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aimone, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cristofani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machiorlatti, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abele, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ator, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inghirami, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruggeri, B. A.</span><span> </span><span class="NLM_article-title">CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">670</span><span class="NLM_x">–</span> <span class="NLM_lpage">679</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm201550q&amp;key=10.1158%2F1535-7163.MCT-11-0776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm201550q&amp;key=22203728" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Fjm201550q&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=670-679&author=M.+Chengauthor=M.+R.+Quailauthor=D.+E.+Gingrichauthor=G.+R.+Ottauthor=L.+Luauthor=W.+Wanauthor=M.+S.+Albomauthor=T.+S.+Angelesauthor=L.+D.+Aimoneauthor=F.+Cristofaniauthor=R.+Machiorlattiauthor=C.+Abeleauthor=M.+A.+Atorauthor=B.+D.+Dorseyauthor=G.+Inghiramiauthor=B.+A.+Ruggeri&title=CEP-28122%2C+a+highly+potent+and+selective+orally+active+inhibitor+of+anaplastic+lymphoma+kinase+with+antitumor+activity+in+experimental+models+of+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers</span></div><div class="casAuthors">Cheng, Mangeng; Quail, Matthew R.; Gingrich, Diane E.; Ott, Gregory R.; Lu, Lihui; Wan, Weihua; Albom, Mark S.; Angeles, Thelma S.; Aimone, Lisa D.; Cristofani, Flavio; Machiorlatti, Rodolfo; Abele, Cristina; Ator, Mark A.; Dorsey, Bruce D.; Inghirami, Giorgio; Ruggeri, Bruce A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">670-679</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) is constitutively activated in a no. of human cancer types due to chromosomal translocations, point mutations, and gene amplification and has emerged as an excellent mol. target for cancer therapy.  Here we report the identification and preclin. characterization of CEP-28122, a highly potent and selective orally active ALK inhibitor.  CEP-28122 is a potent inhibitor of recombinant ALK activity and cellular ALK tyrosine phosphorylation.  It induced concn.-dependent growth inhibition/cytotoxicity of ALK-pos. anaplastic large-cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), and neuroblastoma cells, and displayed dose-dependent inhibition of ALK tyrosine phosphorylation in tumor xenografts in mice, with substantial target inhibition (>90%) for more than 12 h following single oral dosing at 30 mg/kg.  Dose-dependent antitumor activity was obsd. in ALK-pos. ALCL, NSCLC, and neuroblastoma tumor xenografts in mice administered CEP-28122 orally, with complete/near complete tumor regressions obsd. following treatment at doses of 30 mg/kg twice daily or higher.  Treatment of mice bearing Sup-M2 tumor xenografts for 4 wk and primary human ALCL tumor grafts for 2 wk at 55 or 100 mg/kg twice daily led to sustained tumor regression in all mice, with no tumor reemergence for more than 60 days postcessation of treatment.  Conversely, CEP-28122 displayed marginal antitumor activity against ALK-neg. human tumor xenografts under the same dosing regimens.  Administration of CEP-28122 was well tolerated in mice and rats.  In summary, CEP-28122 is a highly potent and selective orally active ALK inhibitor with a favorable pharmaceutical and pharmacokinetic profile and robust and selective pharmacol. efficacy against ALK-pos. human cancer cells and tumor xenograft models in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWAF2Kawjc8rVg90H21EOLACvtfcHk0lhm9WnYYldVmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlKisrk%253D&md5=40001fb02de25d0f78bb11a41819651a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0776%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DQuail%26aufirst%3DM.%2BR.%26aulast%3DGingrich%26aufirst%3DD.%2BE.%26aulast%3DOtt%26aufirst%3DG.%2BR.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DWan%26aufirst%3DW.%26aulast%3DAlbom%26aufirst%3DM.%2BS.%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DAimone%26aufirst%3DL.%2BD.%26aulast%3DCristofani%26aufirst%3DF.%26aulast%3DMachiorlatti%26aufirst%3DR.%26aulast%3DAbele%26aufirst%3DC.%26aulast%3DAtor%26aufirst%3DM.%2BA.%26aulast%3DDorsey%26aufirst%3DB.%2BD.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DRuggeri%26aufirst%3DB.%2BA.%26atitle%3DCEP-28122%252C%2520a%2520highly%2520potent%2520and%2520selective%2520orally%2520active%2520inhibitor%2520of%2520anaplastic%2520lymphoma%2520kinase%2520with%2520antitumor%2520activity%2520in%2520experimental%2520models%2520of%2520human%2520cancers%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D670%26epage%3D679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, N.</span><span> </span><span class="NLM_article-title">New driver mutations in non-small cell lung cancer.</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">175</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=175-180&author=W.+Paoauthor=N.+Girard&title=New+driver+mutations+in+non-small+cell+lung+cancer."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DGirard%26aufirst%3DN.%26atitle%3DNew%2520driver%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer.%26jtitle%3DLancet%26date%3D2011%26volume%3D12%26spage%3D175%26epage%3D180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Kraus, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choudhury, P. K.</span><span> </span><span class="NLM_article-title">Synthesis of purquinonic acid ethyl ester and deliquinone via a common intermediate</span> <span class="citation_source-journal">J. Org. Chem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">5857</span><span class="NLM_x">–</span> <span class="NLM_lpage">5859</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo020029g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=5857-5859&author=G.+A.+Krausauthor=P.+K.+Choudhury&title=Synthesis+of+purquinonic+acid+ethyl+ester+and+deliquinone+via+a+common+intermediate"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjo020029g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo020029g%26sid%3Dliteratum%253Aachs%26aulast%3DKraus%26aufirst%3DG.%2BA.%26aulast%3DChoudhury%26aufirst%3DP.%2BK.%26atitle%3DSynthesis%2520of%2520purquinonic%2520acid%2520ethyl%2520ester%2520and%2520deliquinone%2520via%2520a%2520common%2520intermediate%26jtitle%3DJ.%2520Org.%2520Chem%26date%3D2002%26volume%3D67%26spage%3D5857%26epage%3D5859" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Yoshii, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirono, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimizu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoshi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, H.</span><span> </span><span class="NLM_article-title">Conformational analysis and selection of odor-active conformers: synthesis of molecules for the lily-of-the-vally (muguet)-type odor</span> <span class="citation_source-journal">Helv. Chim. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">2051</span><span class="NLM_x">–</span> <span class="NLM_lpage">2063</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2001&pages=2051-2063&author=F.+Yoshiiauthor=T.+Nakamuraauthor=S.+Hironoauthor=Y.+Shimizuauthor=T.+Hoshiauthor=M.+Andoauthor=H.+Hagiwara&title=Conformational+analysis+and+selection+of+odor-active+conformers%3A+synthesis+of+molecules+for+the+lily-of-the-vally+%28muguet%29-type+odor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYoshii%26aufirst%3DF.%26aulast%3DNakamura%26aufirst%3DT.%26aulast%3DHirono%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DY.%26aulast%3DHoshi%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DHagiwara%26aufirst%3DH.%26atitle%3DConformational%2520analysis%2520and%2520selection%2520of%2520odor-active%2520conformers%253A%2520synthesis%2520of%2520molecules%2520for%2520the%2520lily-of-the-vally%2520%2528muguet%2529-type%2520odor%26jtitle%3DHelv.%2520Chim.%2520Acta%26date%3D2001%26volume%3D84%26spage%3D2051%26epage%3D2063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Goldberg, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bensimon, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alper, H.</span><span> </span><span class="NLM_article-title">Highly regioselective bromination of 2,3-dimethylanisole with <i>N</i>-bromosuccinimide</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6374</span><span class="NLM_x">–</span> <span class="NLM_lpage">6376</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo00049a067" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1992&pages=6374-6376&author=Y.+Goldbergauthor=C.+Bensimonauthor=H.+Alper&title=Highly+regioselective+bromination+of+2%2C3-dimethylanisole+with+N-bromosuccinimide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjo00049a067&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00049a067%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DY.%26aulast%3DBensimon%26aufirst%3DC.%26aulast%3DAlper%26aufirst%3DH.%26atitle%3DHighly%2520regioselective%2520bromination%2520of%25202%252C3-dimethylanisole%2520with%2520N-bromosuccinimide%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1992%26volume%3D57%26spage%3D6374%26epage%3D6376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Tolbert, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haubrich, J. E.</span><span> </span><span class="NLM_article-title">Photoexcited proton transfer from enhanced photoacids</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">10593</span><span class="NLM_x">–</span> <span class="NLM_lpage">10600</span></span><div class="citationLinks">[<a href="/doi/10.1021/ja00102a028" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=1994&pages=10593-10600&author=L.+M.+Tolbertauthor=J.+E.+Haubrich&title=Photoexcited+proton+transfer+from+enhanced+photoacids"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fja00102a028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja00102a028%26sid%3Dliteratum%253Aachs%26aulast%3DTolbert%26aufirst%3DL.%2BM.%26aulast%3DHaubrich%26aufirst%3DJ.%2BE.%26atitle%3DPhotoexcited%2520proton%2520transfer%2520from%2520enhanced%2520photoacids%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1994%26volume%3D116%26spage%3D10593%26epage%3D10600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Angeles, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartlett, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudkins, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dionne, C. A.</span><span> </span><span class="NLM_article-title">Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">236</span><span class="NLM_x">, </span> <span class="NLM_fpage">49</span><span class="NLM_x">–</span> <span class="NLM_lpage">55</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=236&publication_year=1996&pages=49-55&author=T.+S.+Angelesauthor=C.+Stefflerauthor=B.+A.+Bartlettauthor=R.+L.+Hudkinsauthor=R.+M.+Stephensauthor=D.+R.+Kaplanauthor=C.+A.+Dionne&title=Enzyme-linked+immunosorbent+assay+for+trkA+tyrosine+kinase+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAngeles%26aufirst%3DT.%2BS.%26aulast%3DSteffler%26aufirst%3DC.%26aulast%3DBartlett%26aufirst%3DB.%2BA.%26aulast%3DHudkins%26aufirst%3DR.%2BL.%26aulast%3DStephens%26aufirst%3DR.%2BM.%26aulast%3DKaplan%26aufirst%3DD.%2BR.%26aulast%3DDionne%26aufirst%3DC.%2BA.%26atitle%3DEnzyme-linked%2520immunosorbent%2520assay%2520for%2520trkA%2520tyrosine%2520kinase%2520activity%26jtitle%3DAnal.%2520Biochem.%26date%3D1996%26volume%3D236%26spage%3D49%26epage%3D55" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Rotin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margolis, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohammadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daly, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daum, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgess, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span> </span><span class="NLM_article-title">SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phopholipase Cγ</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">559</span><span class="NLM_x">–</span> <span class="NLM_lpage">567</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1992&pages=559-567&author=D.+Rotinauthor=B.+Margolisauthor=M.+Mohammadiauthor=R.+J.+Dalyauthor=G.+Daumauthor=N.+Liauthor=E.+H.+Fischerauthor=W.+H.+Burgessauthor=A.+Ullrichauthor=J.+Schlessinger&title=SH2+domains+prevent+tyrosine+dephosphorylation+of+the+EGF+receptor%3A+identification+of+Tyr992+as+the+high-affinity+binding+site+for+SH2+domains+of+phopholipase+C%CE%B3"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRotin%26aufirst%3DD.%26aulast%3DMargolis%26aufirst%3DB.%26aulast%3DMohammadi%26aufirst%3DM.%26aulast%3DDaly%26aufirst%3DR.%2BJ.%26aulast%3DDaum%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DFischer%26aufirst%3DE.%2BH.%26aulast%3DBurgess%26aufirst%3DW.%2BH.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DSchlessinger%26aufirst%3DJ.%26atitle%3DSH2%2520domains%2520prevent%2520tyrosine%2520dephosphorylation%2520of%2520the%2520EGF%2520receptor%253A%2520identification%2520of%2520Tyr992%2520as%2520the%2520high-affinity%2520binding%2520site%2520for%2520SH2%2520domains%2520of%2520phopholipase%2520C%25CE%25B3%26jtitle%3DEMBO%2520J.%26date%3D1992%26volume%3D11%26spage%3D559%26epage%3D567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Ghose, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbertz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pippin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salvino, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mallamo, J. P.</span><span> </span><span class="NLM_article-title">Knowledge based prediction of ligand binding modes and national inhibitor design for kinase drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5149</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800475y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5149&author=A.+K.+Ghoseauthor=T.+Herbertzauthor=D.+A.+Pippinauthor=J.+M.+Salvinoauthor=J.+P.+Mallamo&title=Knowledge+based+prediction+of+ligand+binding+modes+and+national+inhibitor+design+for+kinase+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm800475y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800475y%26sid%3Dliteratum%253Aachs%26aulast%3DGhose%26aufirst%3DA.%2BK.%26aulast%3DHerbertz%26aufirst%3DT.%26aulast%3DPippin%26aufirst%3DD.%2BA.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DMallamo%26aufirst%3DJ.%2BP.%26atitle%3DKnowledge%2520based%2520prediction%2520of%2520ligand%2520binding%2520modes%2520and%2520national%2520inhibitor%2520design%2520for%2520kinase%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XB7','PDB','2XB7'); return false;">PDB: 2XB7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKK','PDB','3EKK'); return false;">PDB: 3EKK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UNZ','PDB','3UNZ'); return false;">PDB: 3UNZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3EKN','PDB','3EKN'); return false;">PDB: 3EKN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ELJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ELJ','PDB','3ELJ'); return false;">PDB: 3ELJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JKK','PDB','2JKK'); return false;">PDB: 2JKK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z7L" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2Z7L','PDB','2Z7L'); return false;">PDB: 2Z7L</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1H01" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1H01','PDB','1H01'); return false;">PDB: 1H01</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i54"><a href="/doi/suppl/10.1021/jm201550q">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_35627"></div></div></div></div></div><hr /></hr><p class="last">Structure of compound <b>25a</b>, hERG inhibition data for select inhibitors, and antitumor efficacy of compound <b>3</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm201550q/suppl_file/jm201550q_si_001.pdf">jm201550q_si_001.pdf (184.22 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm201550q&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-10%3Barticle%3Aarticle%3A10.1021%2Fjm201550q%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm201550q" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798f4ad3dbed1a7","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
